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INTRODUCTION: 
 
Type 2 and Type 1 are the most common forms of Diabetes worldwide.  
However, about 1 to 5 percent of patients who present with diabetes that may be 
secondary to other disorders. Of these, the disorders of the pancreas are the most 
common1. Various Pancreatic disorders can cause diabetes including pancreatic 
infections, inflammation, neoplasms, post pancreatic surgery, cystic fibrosis and 
hemochromatosis. However chronic pancreatitis is the commonest pancreatic 
disorder associated with diabetes.2 Chronic Pancreatitis is a heterogeneous 
disease. From a worldwide perspective, alcoholism is the most common cause of 
chronic pancreatitis.3 However, in many tropical countries akin to India, the 
aetiology frequently includes so-called ‘Tropical Chronic Pancreatitis 4,5 and the 
type of diabetes associated with it has been named as “Fibrocalcific Pancreatic 
Diabetes” (FCPD). 
 
Initially categorized by WHO in 1985 as a subtype of Malnutrition Related 
Diabetes Mellitus (MRDM)6 , FCPD has subsequently been included as a disease 
of the exocrine pancreas under other specific forms of diabetes, as suggested by a 
workshop held at Cuttack (Orissa), India in 19957 . 
 
EPIDEMIOLOGY OF THE DISEASE 
Over the past six decades there have been several publications where pancreatic 
calcification in non alcoholic young individuals from various tropical countries 
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and a majority of cases reported from Southern parts of India. It was Zuidema 
(1959) who originally reported a series of 45 patients of pancreatic calcification 
with diabetes mellitus from Indonesia.8    Following this report there were a series 
of publications of a similar type of patients from various part of Asia (India, 
Bangladesh and Sri Lanka) 9-10, Africa (Uganda, Nigeria, Zambia, Madagascar) 11-
13 and even in Brazil.14 The majority of publications arise from India. 15-22 
 
More recently, a study by Balaji et al. (1994) in 28,567 inhabitants from Quilon 
district of Kerala detected a prevalence of 0.09% .23 A study from Chennai 
showed a similar trend and a reduction in the incidence of FCPD. Initial studies 
during 1991-1995 showed a prevalence of 1.6%.  However subsequent studies 
have shown a prevalence of 0.36% during 2001-2003 & 0.2% during 2006-2010, 
respectively.24-25 Balakrishnan et al (2008) conducted a nationwide prospective 
study on chronic pancreatitis based on clinical and radiological criteria and 
reported a prevalence of FCPD of 3.2%, Idiopathic Pancreatitis (60.2%), while 
Alcoholic Pancreatitis comprised 38.7%. This study has demonstrated the 
presence of a changing profile of chronic pancreatitis in India. 26 Studies from 
different part of India showed variable prevalence and changing hues of FCPD 
patients with changing times.27-28 
 
AETIOPATHOGENESIS: 
The aetiopathogenesis of FCPD is still poorly understood. Several hypotheses 
have been proposed based on epidemiological data.  Preliminary studies have 
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described malnutrition as the main underlying aetiopathological factor of 
FCPD.29-32   However recent studies on FCPD described malnutrition as the effect 
rather than the cause of disease. 33,34. The McMillan and Geevarghese hypothesis 
linked FCPD to the consumption of cassava.35,36 Cassava contains two important 
cyanogenic glycosides linamarin and lotaustralin , which in the setting of 
malnutrition, do not get detoxified  leading to pancreatic damage and thus 
diabetes sets in.37 However, recent epidemiologic and experimental studies have 
questioned the cassava hypothesis.38  Heightened oxidant stress along with 
relative deficiency of antioxidants has also been proposed to be a possible 
pathogenic mechanism for FCPD. Braganza et al had shown that patients with 
chronic pancreatitis including FCPD as associated with a heightened oxidative 
detoxification reaction mediated by cytochrome P450-1.39-40 whilea preliminary 
study on FCPD patients have shown a high level of malondialdehyde and a 
decreased antioxidant level.41 Familial clustering of FCPD has been described by 
several authors and the role of genetic predisposition has been actively pursued. 
Pitchumoni has reported that the familial aggregation of FCPD in 17 families with 
two or more members had evidence of pancreatitis. A study from Chennai has 
shown that 8% of patients with FCPD has evidence of a familial aggregation. 42 
Initial genetic studies on FCPD were conducted to detect an association with the 
HLA complex.  Recent studies have shown alterations in Serum protease inhibitor 
Kazal type 1 (SPINK1), Cationic trypsinogen (PRSS1), Anionic trypsinogen 
(PRSS2), and Chymotrypsinogen C to be associated with FCPD. 
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CLINICAL FEATURES 
The typical clinical presentation and natural history of FCPD includes abdominal 
pain, pancreatic calcification, pancreatic exocrine deficiency (steatorrhea) and 
Diabetes Mellitus. The onset of diabetes is usually between ages 20-30 years. 
Large ductal calcifications, ductal dilatation usually involving the main pancreatic 
duct and marked increase in risk of pancreatic malignancy are the key 
distinguishing features of FCPD. 
 
INSULIN SECRETION AND INSULIN RESISTANCE IN FCPD: 
The unique natures of clinical presentation of the disease and the intriguing 
pathogenetic mechanisms governing it have been areas of research for decades. 
While widespread destruction of the pancreatic β-cells would obviously lead to an 
impaired insulin secretion, the wide fluctuations in blood glucose levels and lack 
of ketosis point to a pathogenesis significantly different from the insulin deficient 
type 1 Diabetes Mellitus. Whether like Type 2 Diabetes Meliitus, there is a role of 
insulin resistance at the level of the liver and peripheral tissues, remains to be 
fully elucidated.  Moreover, the contribution of body fat distribution and energy 
expenditure might also be significant in explaining the onset of diabetes in FCPD. 
We therefore propose a comprehensive study of metabolic and body composition 
parameters in individuals with Fibrocalculous Pancreatic Diabetes. The novelty of 
our study lies in utilizing pancreatic clamps, which is the gold standard, to study 
the physiological variations in insulin sensitivity. This will be further 
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supplemented by the use of advanced MRI and DEXA techniques to estimate the 
body fat and body composition. 
The characterization of insulin mediated glucose fluxes and the possible 
relationship with body composition indices might have significant therapeutic 
ramifications. Diabetes management in these patients remains cumbersome, and 
often the widespread use of insulin leads to fatal hypoglycemias. Especially in 
countries like India, where discrepancies between insulin injection and adequate 
food intake is a major concern, this assumes even greater significance.  Our study 
might help in identifying those individuals in whom alternatives to insulin might 
achieve good glycemic control and thus reduce treatment related morbidity and 
mortality. 
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AIMS AND OBJECTIVES: 
The objectives of the study were : 
1. To assess the hepatic and peripheral insulin sensitivity in individuals with 
Fibrocalculous pancreatic diabetes (FCPD). 
2. To characterize the body composition and hepatic and muscle lipid 
deposition in individuals with Fibrocalculous pancreatic diabetes. 
3. To assess the insulin and glucagon secretory responses to a mixed meal 
challenge in individuals with Fibrocalculous pancreatic diabetes. 
4. To compare these characteristics with that in individuals with Type 1 
Diabetes Mellitus (T1DM), individuals with Type 2 Diabetes Mellitus 
(T2DM) and in non-diabetic healthy controls. 
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REVIEW OF LITERATURE: 
DEFINITION AND TERMINOLOGY : 
Fibrocalculous Pancreatic Diabetes (FCPD) has been defined as a type of diabetes 
that is secondary to chronic non-alcoholic calcific pancreatitis that is seen almost 
exclusively in developing countries of the tropical world. A variety of names have 
been used to identify this entity which exist in literature like Tropical Calcific 
Pancreatitis,Tropical Chronic Pancreatitis, Tropical Pancreatic Diabetes, 
Nutritional Pancreatitis, Endemic Pancreatic Syndrome, which essentially refers 
to the same condition .The term ‘Tropical Calcific Pancreatitis’ is based on 
it’sgeographic distribution and it may seem in part illogical as the disorder has 
been recently reported in developing countries  in immigrants from tropical 
regions.8Fibrocalculous Pancreatic Diabetes is the preferred term used by 
diabetologists and endocrinologists while the term Tropical Calcific Pancreatitis 
has been used by  gastroenterologists.  FCPD and Tropical Calcific Pancreatitis 
(TCP) are considered as two different stages of the same disease. TCP is 
considered as the pre-diabetic stage of FCPD .9,10 Chronic pancreatitis has a 
number of aetiologies of which alcohol consumption accounts for the majority of 
the cases in Western countries and alcoholic pancreatitis(ACP) is also seen in 
India  .3,11 However in many tropical countries like India, the aetiology frequently 
includes the so-called ‘Tropical Chronic Pancreatitis’.  
 
 
 
Review of literature  
 
The differences between the clinical profiles of Tropical and Alcoholic Chronic 
Pancreatitis  are summarized in the table below: 
 
 
 Tropical-calcific 
pancreatitis 
Alcoholic 
pancreatitis 
Demographic   features  
 
Peak age of onset ( years ) 20-30 30-50 
Male :Female  70:30 90:10 
Socioeconomic status  Poor> affluent All groups 
Alcohol abuse  Absent Present 
Pancreatic  morphology 
 
Prevalence of calculi  90% 50-60% 
Features of calculi  Large , in large duct 
 
Small specked, in 
small ducts 
   
Duct dilation  Usually marked 
 
Usually moderate 
Fibrosis  Heavy 
 
Variable 
Risk of pancreatic cancer  Markedly  increased Increased 
Diabetes 
 
Prevalence  >90% 50% 
Time course  Rapid evolution 
 
Slower evolution 
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EPIDEMIOLOGY OF THE DISEASE: 
Over the past six decades there have been several publications where pancreatic 
calcification in non alcoholic young individuals from various tropical countries 
and a majority of cases reported from Southern parts of India. It was Zuidema 
(1959) who originally reported a series of 45 patients of pancreatic calcification 
with diabetes mellitus from Indonesia.14The patients in his study were poor and 
consumed a very low protein and calorie diet. Clinical features were striking in 
that they had gross emaciation, parotidomegaly and hair and skin changes 
resembling that of Kwashiorkor.  Following this report there were a series of 
publications of a similar type of patients from various part of Asia (India, 
Bangladesh and Sri Lanka)15-16, Africa (Uganda, Nigeria, Zambia, Madagascar)17-
19 and even in Brazil.20 The majority of publications are from India. 21-28The first 
case of Pancreatic Calculi from India was reported by Kini in 1938.29In 1954, 
Elizabeth and Stephen reported cases of pancreatic calculi that were observed 
during postmortemstudies at the Christian Medical College, Vellore (Tamil Nadu) 
in Southern India.30The largest series of cases of FCPD initially reported were 
from South Western parts of Kerala. 4,31Dr Geevarghesewho was one of the 
pioneers in the field has reported more than 1700 cases in his monograms, and 
indeed it is one the largest series reported.4,32. He is therefore often referred to as 
“The Father of Pancreatic Diabetes’’. In Kerala, FCPD constituted about 29.3% of 
the total diabetes registered and 1.35 % of the total inpatients in Kottayam 
Medical College in the 1960’s.  However, this figure later dramatically reduced to 
0.03% in 1971 and 0.09% in 1980.4 
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A Population based study by Balajiet al. (1994) in 28,567 inhabitants from Quilon 
district of Kerala detected aprevalence of 0.09% .33This may be partly assisted for 
by the large increase in the prevalence of type 2 diabetes mellitus.Astudy from 
Chennai showed a similartrendand a reduction in the incidence of FCPD. Initial 
studies during 1991-1995 showed a prevalence of 1.6%.  However subsequent 
studies have shown a prevalence of 0.36% during 2001-2003 & 0.2% during 
2006-2010, respectively.34-35Balakrishnanet al (2008) conducted a nationwide 
prospective study on chronic pancreatitis based on clinical and radiological 
criteria and reported a prevalence of  Tropical Chronic Pancreatitis of 3.2%, 
Idiopathic Pancreatitis (60.2%), while Alcoholic Pancreatitis comprised 38.7%. 
which suggests a low prevalence of FCPD. This study has demonstrated the 
presence of a changing profile of chronic pancreatitis in India. 36Studies from 
different part of India showed variable prevalence and changing hues of FCPD 
patients with changing times.37-38 
 
PATHOGENESIS OF FCPD: 
The aetiopathogenesis of FCPD is still poorly understood. Several hypotheses 
have been proposed based on epidemiological data. However these hypotheses 
have never been proven either in well designed case control studies or in 
experimental models. Over the last one decade, studies are focused on identifying 
the susceptible gene linked with FCPD. The aetiological hypothesis of FCPD are 
mentioned below: 
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 1)  Malnutrition.  
 2)  Dietary toxins.  
 3)  Micronutrient deficiency and Oxidative stress. 
 4) Familial aggregation.  
 5) Genetic factors.  
 
1) Malnutrition: 
Fibrocalculous Pancreatitis is more prevalent in tropical and developing countries.  
It is usually seen amongst malnourished young individuals.  Preliminary studies 
have described malnutrition as the main underlying aetiopathological factor of 
FCPD.43-46However recent studies on FCPD described malnutrition as the effect 
rather than the cause of disease.39,47 For example, in a country like Ethiopia,48 
where malnutrition was at one time wide spread, the disease had never been 
detected and on the other hand in states like Kerala (India) had a higher incidence 
of FCPD in spite of high literacy and low infant mortality rates. Moreover, FCPD 
is not seen in Kwashiorkor, a classic form of protein energy malnutrition.  
Similarly, there are recent reports where FCPD have been noticed in obese 
individuals and patients from a higher socioeconomic background. All these facts 
suggest that FCPD is not only solely secondary to protein malnutrition but also 
due to other nutritional factors which may in particular include micronutrient 
deficiencies and may play a contributory role in the pathogenesis.  
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2) Dietary toxins: (Cassava Toxicity) 
Cassava, which is commonly known as tapioca or manihot is consumed as a 
staple food in many developing countries. The McMillan and Geevarghese 
hypothesis links FCPD to the consumption of cassava.49-50This was based on an 
overlap between the geographical distribution of FCPD and the region of 
consumption of cassava (Kerala, India) and some experimental evidence.  
Cassava contains two important cyanogenic glycosides linamarin and lotaustralin. 
These glycosides get detoxified in the body by conversion into thiocyantes, which 
is non toxic. This conversion requires sulfur containing amino acids like 
methionine and cystine. In the setting of malnutrition, deficiency of these amino 
acids results in a lack of detoxification leading to pancreatic damage and thus 
diabetes sets in.51Studies in experimental rats have shown that the ingestion of 
cyanide can lead to transient hyperglycemia but not permanent diabetes. 52-53 
Moreover, the rats were given potassium cyanide and not cassava. Indeed, recent 
epidemiologic and experimental studies have questioned the cassava hypothesis.54 
FCPD is even prevalent in many parts of India where no cassava is grown or 
consumed.  FCPD has not been reported in West Africans who regularly consume 
cassava.55 Thus, it is unlikely that cassava ingestion can explain the majority of 
cases of FCPD seen worldwide and the current thinking is that cyanogen toxicity 
is not a relevant factor in its aetiopathogenesis. 
Other dietary factors:- 
In non cassava areas, foods like Sorgam, Ragi, Jowar and a variety of peas 
contain cyanide, which require sulfur containing amino acids for detoxification. 
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Other toxins such as ergot-like toxins from plants and indigenous medicines, 
serotonin from bananas, trace heavy metals like thorium and cerium from the soil 
has been implicated for their possible role in FCPD.56,57However no experimental 
proof available. Balakrishnan et al conducted an enquiry on the dietary pattern in 
FCPD patients and it was found that there was no difference in protein 
(53gm/day) and calorie intake as compared to control subjects. However, fat 
intakes in both groups were low (27gm/day). It is known that both low and high 
fat intake can predispose to alcoholic pancreatitis.58,59 In an animal experiment, 
rats that were fed on low protein diet during foetal and the early stage of life 
showed a poor pancreatic development, reduced Beta cell size, reduced islet 
volume, and altered islet vascularization.60On the contrary, an experimental study 
on Bonnet Monkeys fed on low protein and high carbohydrate diet developed 
inflammatory and vascular changes in the pancreas and heart. The experimental 
diet used in this study is somewhat identical to the diet consumed by the poor in 
tropical countries. The lesions in the pancreas are similar to that of finding seen in 
FCPD patients. However, pancreatic calculi were not observed in this study. 61-62 
3) Micronutrient Deficiency and Oxidative Stress: 
Heightened oxidant stress along with relative deficiency of antioxidants has been 
proposedto be a possible pathogenic mechanism for FCPD. Braganza et al had 
shown that patients with chronic pancreatitis including FCPD as associated with a 
heightened oxidative detoxification reaction mediated by cytochrome P450-1.63-64 
There are several factors that induce cytochrome P 450 -1 activity of which 
xenobiotics (cigarettes, alcohol, occupationalchemicals, corn oil etc) are 
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important.Bioactivation of Xenobiotics leads to the increased production of free 
radicals. If the load of xenobiotics is high, there will be an increased activity of 
enzyme and more free radicals will be generated. 65Theophyllineclearance has 
been considered as a standard of measurement of cytochrome P 450-1 activity. 
One study demonstrated that theophylline clearance is faster in FCPD when 
compared to controls.66 Antioxidants such as Vitamin D and beta carotene levels 
are found to be lower in FCPD patients.67A preliminary study on FCPD patients 
have shown a high level of malondialdehydeand a decreased antioxidant 
level.68Antioxidant therapy have been found to reduce the analgesic requirement 
in patients with alcoholic pancreatitis.69-70 All the above factors that heighten 
oxidative stress may play a role in the causation of FCPD.  
4) Familial Aggregation of FCPD: 
Familial clustering of FCPD has been described by several authors.  The earliest 
study by Geevarghese et alshowedthat8% of his study patients had ‘‘Familial 
pancreatitis”.4Balakrishnan reported that the occurrence of FCPD in three pairs of 
twins and several siblings.26 Pitchumonihasreportedthatthe familial aggregation of 
FCPD in 17 families with two or more members had evidence of pancreatitis.  A 
study from Chennai detected that 8% of patients with FCPD has evidence of a 
familial aggregation. 71 In some families, there was evidence of vertical 
transmission of FCPD from parents to the offspring, while in others there was a 
horizontal distribution of the disease among siblings. However; many patients 
also had a family history of type 2 diabetes. A familial aggregation suggests, but 
does not necessarily prove a hereditary aetiology for FCPD, since several family 
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members could arguably be exposed to the same toxin or other environmental 
factors. However, recent studies have suggested that there is a significant genetic 
association with FCPD. 
5) Genetic Factors: 
Initial genetic studies on FCPD were conducted to detect anassociation with the 
HLA complex.  A study byKamboP K et al (1989) from Southern India has 
shown that 40% of FCPD patients share the HLA-DQ-B haplotype which is 
usually associated with Type 1 Diabetes Mellitus. Another 40% of FCPD patients 
have shown an association with the class 3 allele of the insulin gene which is 
similar to the association seen in some Type 2 Diabetes Mellitus patients.72 A case 
control study from Cuttack has demonstrated that the association between FCPD 
and HLA-DQ9 (A*0201-B*0303). 73 
More than a century ago, it was Dr.Chiari who postulated in 1896 that pancreatitis 
is caused by the premature activated trypsin resulting in autodigestion of the 
pancreas. However, identification of the PRSS -1 gene causing hereditary 
pancreatitishas led to a paradigm shift in our understanding of the pathogenesis of 
pancreatitis.74 In the last two decades a concerted effort has been made to identify 
the genes associated with various types of chronic pancreatitis.  Tropical 
Pancreatitis has many features similar to that of hereditary pancreatitis such 
asa)younger age of onset b) presence of calcification and c)risk for development 
of cancer, which hasgenerated interest among researchers to identify the genetic 
basis of FCPD.   
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The gene mutation associated with FCPD can be divided into the following 
categories. 
A)  Genetic alterations in the trypsinogen pathway 
1)  Cationic trypsinogen (PRSS1). 
2) Anionic trypsinogen (PRSS2). 
3)Serum protease inhibitor Kazal type 1 (SPINK1). 
4) Chymotrypsinogen C. 
B)  Alteration in other genes  
1)  Cystic fibrosis transmembrane conductance regulator (CFTR). 
2) Regenerating islet-derived genes 1α (REG1A & REG1B). 
3) Cathepsin B (CTSB). 
4) Angiotensin converting enzyme (ACE). 
5) Calcium-sensing receptor (CASR). 
Recently Mahurkar et al (2009) has proposed a two hit model for the pathogenesis 
of FCPD. The first hit model includes the mutation of one or more genes, 
resulting in the formation of supertrypsin in the acinar cell of the pancreas. The 
second hit probably involves certain unidentified genes which may lead to one or 
more phenotype. The two-hit hypothesis has been depicted below 
 
Two hits or multiple hits hypothesis in pathogenesis of 
TCP.Adapted from Mahurkar S et al. Genetic mechanisms 
underlying the pathogenesis of tropical calcific 
pancreatitis.World J Gastroenterol  2009; 21; 15 : 264-269.) 
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CLINICAL  FEATURES:    
The typical clinical presentation and natural history of FCPD have been elegantly 
described by Geevarghese et al in 1968.  
The typical clinical presentation of FCPD includes: 
a) Abdominal pain. 
b) Pancreatic calcification. 
c) Pancreatic exocrine deficiency (steatorrhea). 
d) Diabetes mellitus. 
COMPLICATIONS: 
Complications in FCPD can be classified into 4 broad categories: 
A) Complications related to chronic pancreatitis.  
B) Complications related to diabetes.  
C) Complications related to exocrine insufficiency.  
D) Pancreatic Osteodystrophy 
 
A) Complications related to Chronic Pancreatitis: 
Chronic pancreatitis can be associated with a variety of complications. Pancreatic 
pseudocyst, mechanical obstruction of the bile duct and duodenum are the 
common complications of FCPD.   Pancreatic abscesses, pancreatic ascitis or 
pleural effusion, splenic vein thrombosis with portal hypertension and 
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pseudoaneurysms are less frequent complications. The obstruction of the common 
bile duct and carcinoma of the pancreas can be associated with obstructive 
jaundice.  
 Pancreatic cancer : 
Patients with FCPD have increased the risk of pancreatic cancer. Several 
prospective and retrospective studies have described FCPD as a premalignant 
condition.  The risk of developing pancreatic cancer is 16.5-fold higher in chronic 
pancreatitis patients as compared to age matched controls. 75 Chari et al followed 
185 cases of FCPD over a period of 4.5 years, out of which 25 died during follow 
up and 6 (25%) cases of death were due to pancreatic carcinoma. When this data 
was compared with the back ground  pancreatic cancer  rate  (Madras Cancer 
Registry) the relative risk of pancreatic cancer among FCPD patients were found 
to be 100 (95% confidence interval 37 to 218) .76Augustine and Ramesh reported 
22 cases of pancreatic cancer among 266 patients with FCPD during a period of 8 
years. In this cohort, the factors associated with a higher risk of cancer were age > 
40 years, a shorter duration of symptoms and a mass on ultrasound.  Intractable 
pain, weight loss, worsening of diabetes and jaundice were the common 
presenting symptoms in FCPD patients with pancreatic carcinoma.77 
Adenocarcinoma is the most common type of pancreatic carcinoma in FCPD and 
occurs predominantly near the head of the pancreas and is locally invasive in 
nature. Pancreatic carcinoma is more common in FCPD than in alcoholic 
pancreatitis. Hereditary Pancreatitis has a similar risk of cancer when compared 
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with FCPD.  The exact reason as to why FCPD patients are prone for a higher risk 
of cancer is not  known.  A longer duration of disease, exposure to inflammation 
and smoking have been speculated as the major factors that are responsible for the 
transformation of cases of FCPD into malignancy. FCPD patients should be 
monitored with CA-19.9 and imaging (USG or CT scan) for the early diagnosis of 
pancreatic cancer.  
 
B) Complications related to Diabetes: 
 Diabetic   retinopathy: 
Earlier studies have presumed that patients with FCPD do not develop long-term 
complications of diabetes. This has been based on the assumption that patients 
with secondary diabetes have a shorter term of survival and do not live long 
enough to develop diabetes related complications.  This no longer appears to be 
the case, as several studies in the last decade had reported microvascular 
complications in FCPD.   As early as 1985, Diabetic Retinopathy was reported in 
an FCPD patient. Geevarghese in his monogram has mentioned of the occurrence 
of both mild Background Diabetic Retinopathy (BDR) and sight-threatening 
Proliferative Diabetic Retinopathy (PDR) in FCPD.4A study from Pune reported 
various patterns of retinopathy such as background retinopathy, maculopathy and 
proliferative diabetic retinopathy in patients with FCPD. Patients with 
proliferative diabetic retinopathy have long standing diabetes, the median duration 
being 5 years (1.5 -30 years), two patients had PDR requiring laser 
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photocoagulation and one patient was blind in an eye as a result of central retinal 
artery occlusion.45 A study from Madras by R Mohan et al observed diabetic 
retinopathy in 13 out of 40 patients, 3 patients had proliferative retinopathy and 1 
patient had maculopathy.78  A subsequent study by Barman et al reported a 30% 
prevalence of retinopathy in FCPD as compared to 32% in controls with type 2 
diabetes. 79 Other microvascular complications like neuropathy were reported in 
20.9% and nephropathy in10.1% in the same cohort.  
 Diabetic nephropathy: 
Earlier studies have reported that 21- 23.8% of patients with pancreatic diabetes 
had overt nephropathy, while 33% had microalbuminuria.80 A study from Chennai 
has shown a 10% prevalence of overt nephropathy in FCPD subjects. 79 
Nephropathy is possibly one of the leading causes of death among these 
patients.81 
 Diabetic   neuropathy: 
Diabetic neuropathy is the most common microvascular complication of FCPD.  
Symptoms   suggestive of peripheral neuropathies are reportedly more common 
than objective evidence of neuropathy. The prevalence of neuropathy varies from 
10 to 90% in different studies.  Studies done to determine peripheral neuropathy 
by nerve conduction velocity have a higher prevalence rate when compared to 
clinical studies. 82 Barman et al reported a 21 % prevalence of neuropathy in 
subjects with FCPD. 79 Nutritional deficiencies and the additive effect of alcohol 
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consumption might increase the occurrence of neuropathy.  Autonomic 
neuropathy is quite common in FCPD.83 A study from Chennai showed a 
prevalence rate of over 60 % in patients with duration of diabetes > 15 years as 
compared to 16% in those with a shorter duration of diabetes (0-5 years).84 In a 
recently published study by Nanaiah et al from Vellore using state of the art 
technology has shown that 63.1% had cardiac autonomic neuropathy, 42.3% 
parasympathetic dysfunction and 13.3% had combined sympathetic and 
parasympathetic dysfunction. 85Macrovascular complications are uncommon in 
FCPD. This has been attributed to three factors: a younger age of patients, a lower 
body mass index and absence of other risk factors of cardiovascular disease such 
as dyslipidemia. 86 
Data on the association between FCPD and macrovascular complications are 
currently based only on anecdotal case reports.86-87 However, reports of 
macrovascular complications such as stroke, peripheral vessel disease (PVD), 
coronary artery disease (CAD), and hypertension have been more frequently 
reported. 88-89 A study from Chennai has shown that 4.7% of patients with FCPD 
had peripheral vessel disease and about 5% had coronary artery disease.80 Insulin 
resistance and hyperinsulinemia are important predictors of cardiovascular disease 
in diabetes. Several studies were reported regarding co-existence of insulin 
resistance in patients with FCPD, however data was limited. Thus it requires 
further studies to determine the presence of insulin resistance in patients with 
FCPD. In a study, 15 normotensive FCPD patients with a normal ECG (rest and 
exercise) were assessed for their left ventricular function by means of systolic 
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time intervals. Abnormal PEP/LVET ratios were observed in 5/13 (38%) patients 
based on which it was suggested that the LV dysfunction may be due to diabetic 
cardiomyopathy. However, further studies are required to establish this 
hypothesis. 90 
 
C) Complications related to Exocrine Insufficiency:  
Malnutrition is quite common in patients with FCPD.  The pathogenesis of 
malnutrition in FCPD is probably multifactorial in nature and can be precipitated 
by chronic inflammation, exocrine pancreatic insufficiency (steatorrhea, fat 
soluble vitamins deficiencies) and under nutrition. Patients with FCPD prefer to 
consume low fat diets since there may be an increased frequency of steatorrhea 
and abdominal pain following a fatty meal.  Patients with FCPD are 
insulinopaenic and hence are prone to have poor glycaemic control and weight 
loss. Beyond steatorrhea and malabsorption, under nutrition and a lean body 
weight has been attributed to a restricted calorie and protein intake as advised by 
some physicians for achieving good glycaemic control. An associated low socio-
economic status deprives those patients of a balanced and nutritious diet.91 
D) Pancreatic Osteodystrophy: 
Pancreatic Osteodystrophy in patients with chronic pancreatitis comprises 
osteopaenia, osteoporosis and osteomalacia.  In chronic pancreatitis, factors that 
are associated with an increased risk of bone loss may be due to chronic 
inflammation, low body mass index, under nutrition, co-existing diabetes, poor 
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sunlight exposure and decreased physical activity due to a chronic illness. 
Vitamin D deficiency in chronic pancreatitis is attributed to pancreatic exocrine 
insufficiency and steatorrhea. 91 The deficiency of Vitamin D leads to reduced 
calcium absorption, bone formation and remodeling, which ultimately leads to 
osteopaenia, osteoporosis and osteomalacia.  Sudeep et al performed a study on 
bone mineral density, biochemical parameters and 72 hrs fecal fat in 31 patients 
(20 FCPD patients and 11 idiopathic pancreatitis) which were compared with 35 
healthy controls. The median vitamin D level was 19ng/ml, 64% of the subjects 
had vitamin D deficiency, among whom 24% had severe vitamin D deficiency as 
per Hollick’s criteria. Osteoporosis (T score minus 2.5) was detected in 29% of 
the subjects while 32% had osteopaenia (T-score between minus 1 and minus 
2.5). Subjects with steatorrhea had a significantly reduced bone mineral content 
when compared to patients without steatorrhea.92,93 This study has shown a high 
prevalence of vitamin D deficiency, osteopaenia and osteoporosis amongst 
patients with chronic pancreatitis. A similar study from Lucknow has shown a 
low bone mineral density in FCPD.94Thus it has been suggested that pancreatic 
Osteodystrophy in chronic pancreatitis is an under recognized disorder that 
requires further in depth evaluation. 
CRITERIA FOR DIAGNOSIS OF FCPD: 
The criteria for diagnosis of FCPD varies slightly according to various authors 
however the basic principles followed are similar. The previously proposed 
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criteria were: a) Bajaj point score system   b) Abuja’s criteria   c) Surabaya- Kobe 
criteria. 
The most commonly used and followed criteria are proposed by  
Mohan et al. and are as follows: 10, 86 
1) The patient should originate from a tropical country. 
2) Diabetes should be present. 
3) Evidence of chronic pancreatitis must be present (pancreatic calculi on 
abdominal X-ray or at least three of the following   a) abnormal pancreatic 
morphology on sonography/CT scan, b) recurrent abdominal pain since 
childhood, c) steatorrhoea, d) abnormal pancreatic function tests 
4) Absence of other causes of chronic pancreatitis. 
 
DIABETES IN FCPD : 
BACKGROUND: 
The onset of diabetes follows a decade or two after the first episode of abdominal 
pain, and 80-90% of the FCPD developed diabetes by adulthood.95It develops late 
in the course of disease, and denotes considerable damage to the endocrine 
pancreas prior to its development.  However a study from Lucknow has shown 
that 33% of patients had insulin requiring diabetes at the time of presentation.  
Diabetes tends to be more severe in lean and malnourished individuals while it is 
of insidious onset and less severe in well nourished individuals. 96During 
presentation these patients may have a high plasma glucose level but are usually 
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ketone negative following withdrawal of insulin. Ketosis resistance is attributed to 
residual beta-cell function adequate to prevent ketosis,97-101 loss of glucagon 
reserve,102-103 loss of subcutaneous fat and therefore reduced supply of Non 
Esterified Fatty Acids (NEFA) for ketogenesis.104Resistance of subcutaneous 
adipose tissue lipolysis to circulating adrenaline and carnitine deficiency affecting 
transfer of NEFA across the mitochondrial membrane have also been 
hypothesized as possible etiologies. Diabetes mellitus is usually severe with a 
mean fasting plasma glucose being 200-400 mg/dl. Most patients require insulin 
for glycemic control. The mean daily dose of insulin and it’s requirement is 40 ± 
12 units/day.105 However, there are patients in whom diabetes can be controlled 
with only diet and oral hypoglycemic drugs. Patients presenting with ketosis 
require insulin for their survival. Clinical insulin resistance may be present in 
some patients, though this finding is distinctly uncommon.106 Patients with FCPD 
are known to have brittlediabetes. This may be attributed to the loss of both alpha 
and beta cell mass. 
 
 
SPECTRUM OF DIABETES IN FCPD:  Mohan V, Alberti KGMM. Diabetes in the tropics. In: 
Alberti KGMM, DefronzoRA,Keen H, Zimmet P, eds. International Textbook of Diabetes 
Mellitus. Chichester, JohnWiley and Sons Ltd., 1997, pp.177-196 
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INSULIN SECRETION DEFECTS: 
A significant loss of beta cell mass is one of the major contributors to diabetes in 
chronic calcific pancreatitis. The partial preservation of beta-cell secretory 
capacity is suggested by the absence of ketoacidosis  during withdrawal of  
insulin and possibly better beta cell preservation in comparison with Type 1 
diabetic patients.  The beta-cell secretory capacity has been looked at in detail in a 
number of research studies.  
Oral glucose tolerance tests to stimulate insulin and C-peptide secretion have been 
utilized in analyzing insulin secretion functions. In a study involving ten normal 
non-obese controls and fifty-four diabetic patients with recent onset of diabetes 
under thirty years of age, Vannasaeng et al 107 from Thailand found peak C-
peptide levels in FCPD to be significantly higher in comparison with Type 1 
diabetes individuals. Although not as impressive as beta-cell secretion in Type 2 
Diabetes subjects, there is a partial preservation of beta-cell functions in 
FCPD. The continuous infusion of glucose with model assessment (CIGMA) has 
been utilized as a tool to assess beta-cell function and insulin sensitivity in FCPD 
subjects.  This model was utilized by Merhotra and colleagues108 to study β-cell 
function in subjects at different stages of the spectrum of FCPD  . Their findings 
further lend credence to the notion that diminished beta-cell reserve is a 
significant contributor to the pathogeneticmehcanisms in FCPD. The baseline 
insulin secretion capacity and its modulation with antidiabetic dug therapy has 
been a matter of active clinical research. When subjected to treatment period of 
two years,  Yajnik and colleagues 109 found a considerable improvement in fasting 
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and peak C-peptides in seventeen FCPD subjects. To further enhance the 
understanding of the natural course of development of FCPD, a link between 
exocrine and endocrine functions has been postulated. Using immunoreactive 
trypsin as a marker of exocrine pancreatic function, Yajnik et al 110 carried ot a 
cross-sectional study in forty FCPD subjects. More than two-thirds showed a 
significant reduction in beta-cell secretion, with a direct correlation between 
immunoreactive-trypsin and C-peptide (r s=0.55, p<0.01) being demonstrated for 
the first time. Thus the data generated from these studies have established a 
definite role for reduced beta-cell secretion in the evolution of FCPD. Whether 
the endocrine dysfunction is a secondary phenomenon to the initial pancreatic 
exocrine pathology, or a simultaneous involvement of both remains to be fully 
elucidated. 
 
 INSULIN RESISTANCE IN FCPD - DOES IT EXIST? 
For decades the loss of beta-cell mass and defect in insulin secretion were thought 
to be the crux of the aetiopathogenic mechanisms of FCPD.  However, over the 
past decade or so there has been increased interest over the possible role of insulin 
resistance in FCPD. Unfortunately, scientific evidence on the proposed 
mechanisms of insulin resistance and its role in FCPD remains scarce. 
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EVIDENCE FROM STUDIES IN CHRONIC PANCREATITIS: 
The possible pathogenetic mechanisms for insulin resistance have been elucidated 
in detail in subjects with chronic pancreatitis as a whole. Extrapolation of these 
mechanisms to the subset of FCPD could partly explain the development of 
insulin resistance in these subjects. A number of mechanisms have been proposed 
to cause the hepatic insulin resistance in chronic pancreatitis 9. There is an 
alteration in the endocytosis of hepatic insulin receptors. Coupled with this is a 
defect in internalization of the GLUT-2 transporter at the level of the hepatocyte 
plasma membrane. A loss or reduction in number or altered bioavailability of the 
hepatic insulin receptor (IR) and impairment of pancreatic polypeptide activity are 
additional factors that have been postulated as to play a role in pathogenesis. 
 
DEFECTS IN GLUT 2 (GLUCOSE TRANSPORTER 2): 
In the fasting state the GLUT2 resides at the surface of the hepatocyte plasma 
membrane. Feeding induces a shift in GLUT2 to the endosomal pool that plays a 
key role in suppressing postprandial glucose excursions. In studies  carried out by 
Nathan et al. 111  in fed and fasting rats in whom chronic pancreatitis (CP) had 
been induced,  this mechanism of  internalization of GLUT2 is absent in the 
hepatocyte.  This could be a possible pathogenetic trigger in FCPD subjects as 
well. 
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PANCREATIC POLYPEPTIDE AND INSULIN RESISTANCE: 
Pancreatic polypeptide (PP), a 36-amino-acid peptide has been shown in animal 
and clinical studies to play a role in satiety and in regulation of pancreatic 
exocrine and biliary secretion 112. Recent studies have shown that pancreatic 
polypeptide can regulate expression of insulin receptor gene and its availability at 
the level of the liver. Thus impairment of PP will in turn impair glucose 
homeostasis through insulin receptor expression. 
ROLE OF PANCREATIC POLYPEPTIDE (PP) IN FCPD: 
In five males with documented chronic pancreatitis, Brunicardi and 
colleagues 113  investigated the possible role of  PP on glucose metabolism based 
on  Hepatic glucose production (HGP) and overall glucose disposal rates 
determined by serial hyperinsulinemic-euglycemic clamps performed during three 
separate admissions . These were repeated after a month following PP 
administration. The baseline hepatic resistance in study subjects were reversed 
after intravenous  PP administration. Thus a deficient pancreatic polypeptide may 
be the contributor to development of hepatic insulin resistance in FCPD subjects. 
 
INSULIN RESISTANCE IN FCPD - THE INDIAN PERSPECTIVE: 
The exact pathogenetic mechanisms and implications of insulin resistance in 
FCPD have been sparsely studied in existing literature. Mohan and 
colleagues 114 assessed Insulin resistance by Insulin Tolerance Test (ITT) in 
twelve  patients with FCPD, ten with Non Insulin-Dependent Diabetes Mellitus 
(NIDDM) and twelve age and sex matched control subjects. The mean glucose 
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disposal rate (KITT), a measure of insulin sensitivity, was not significant 
statistically between FCPD and NIDDM groups suggesting that patients with 
FCPD have evidence of insulin resistance and this is similar to that seen in 
NIDDM patients. 
Singla and colleagues 115 in a recent study from eastern India evaluated insulin 
resistance in thirty-one consecutive patients with FCPD. They were evaluated for 
clinical and biochemical profile with special reference to quantifying insulin 
resistance (by HOMA-IR) and body fat percentage (by bioimpedence). HOMA-IR 
was abnormal (>2) in 24 (77.42%) of the subjects and there was significant 
positive correlation between HOMA-IR and body fat (by between feet method p < 
0.001) and by between hands method (p = 0.01). This further pointed to a 
pathogenetic role for insulin resistance in the etiology of diabetes along with a 
high body fat percentage despite a low BMI in a high percentage of patients. 
 
GLUCAGON IN FCPD -   AN OVERLOOKED ENTITY?          
The role of hyperglucagonemia in Type 2 Diabetes Mellitus has been a matter of 
intense scientific research in recent years. Pancreatic alpha-cells and their 
secretory product, glucagon, are often overlooked even though a “bihormonal 
abnormality” theory of T2DM pathology was proposed as long ago as 35 
years 116. The insulin secretion from beta-cells in intricately linked to the 
glucagon secretion from alpha-cells through the IR/IRS/AKT pathway.  In insulin 
resistant states, β cells attempt to compensate for the resistance by secreting more 
insulin. In pancreatic islets, this results in higher intra-islet insulin concentration 
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than normal . The higher insulin will in turn lead to a higher glucagon secretion 
from alpha-cellsand increased alpha-cell mass.117  The increased glucagon 
secretion paradoxically will further enhance insulin secretion from beta-cells. 
Thus there is a vicious cycle where both hyperinsulinemia and 
hyperglucagonemia act as mutual activators which in turn dysregulate the glucose 
metabolism in T2DM.118Studies in vivo have also shown that glucagon stimulates 
its own release by acting on the glucagon receptors on the alpha cells 119 Thus 
hyperglucagonemia in FCPD seems to be a fascinating concept that might hold 
the key to the disease pathogenesis.  
However, the role of glucagon in FCPD is more complex and has given rise to 
conflicting scientific evidence. While some have endorsed the traditional concept 
of decreased glucagon response owing to alpha-cell damage, others have 
postulated that a relatively preserved alpha-cell function and selective beta cell 
damage is seen in FCPD. Studies on plasma insulin and glucagon responses to 
glucose load in a group of patients with fibrocalculous pancreatic diabetes 
(FCPD),Mohan and colleagues 120found the plasma glucagon response to be 
similar to non-diabetic controls. This is contrary to the traditional belief of an 
impaired glucagon response in FCPD subjects.  However, not all studies have 
found an intact glucagon response in FCPD. From studies conducted by  Rao et 
al 120  evaluating  plasma glucagon levels in ketosis-resistant FCPD subjects 
following  oral glucose administration, glucagon responses fell significantly in the 
FCPD group compared to Type 1 diabetic and normal subjects..  Yajnik and co-
workers 121   utilized C-peptide, insulin and glucagon values obtained during an 
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oral glucose tolerance test in an elaborate study in twenty-eight FCPD subjects. 
Their findings point to the intriguing possibility of preserved glucagon secretion 
in FCPD, thus implicating a more selective beta-cell dysfunction in FCPD than 
hitherto believed. Whether the glucagon response is genuinely intact, and as to 
whether as in Type 2 Diabetes Mellitus this can aid in perpetuating insulin 
resistance needs further scientific corroboration. 
BODY COMPOSITION AND ENERGY EXPENDITURE IN FCPD 
SIGNIFICANCE OF FAT MASS IN INSULIN RESISTANCE: 
It is a well-recognized yet intriguing concept that individuals at both ends of the 
weight spectrum have abnormal fat metabolism impacting insulin sensitivity. In 
obesity, increased fat mass promotes fatty acid flux to non-adipose tissues 122. In 
apparent contradiction, similar metabolic features are observed in lipodystrophy, 
including insulin resistance, hepatic steatosis, hyperlipidemia and diabetes. In 
both obesity and lipodystrophy, a storage defect within adipocytes (due either to 
engorgement with lipid or a paucity of adipocytes) leads to excess accumulation 
of triglyceride in non-adipose tissues. Increased free fatty acid (FFA) availability 
in both conditions inhibits the effects of insulin on hepatic and peripheral glucose 
metabolism 123. Indeed, systemic insulin resistance is associated with increased 
adipose tissue lipolysis and resistance to the anti-lipolytic effects of insulin. Thus 
the evaluation of body composition and energy expenditure in FCPD subjects 
may provide a vital clue to demystifying the pathogenesis of FCPD. 
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A number of Indian studies have attempted to look at energy expenditure, body 
composition and nutritional intake in various subgroups of the Indian 
population. Low birth weight (LBW) is common in the Indian population and 
may represent an important predisposing factor for type 2 diabetes (T2D) and the 
metabolic syndrome. The metabolic impact of being born with LBW in a rural 
non-migrant Indian population was studied at Vellore, 124,125 in sixty normal 
(NBW) and sixty low birth weight individuals (LBW). Insulin secretion and 
peripheral insulin resistance were assessed utilizing hyper-insulinemiceuglycemic 
clamp studies and deconvolution curves.  There was no significant difference 
amongst the groups with respect to the insulin secretion and sensitivity patterns.  
Further, Nuclear Magnetic Resonance spectroscopy was used to measure the 
difference in the hepatic fat levels among LBW and NBW subjects. The 
difference was statistically significant (P = 0.04), with positive correlation with a 
number of factors including  intramyocellular fat content, waist circumference, 
total body fat (by DXA)  and insulin levels and C-Peptide levels during the clamp, 
independent of birth weights.  Thus, this study unravelled subtle features of the 
metabolic syndrome and changes in body composition among LBW rural Indians 
. Looking at energy expenditure and body composition specifically in FCPD 
subjects,   Behera and colleagues, 126utilized DXA scan and indirect calorimetry in 
over fifty subjects.  The predicted energy expenditure (PEE) and Resting Energy 
Expenditure (REE) was calculated using existing calorimetric equations. After 
adjustment of body mass index (BMI), the REE was significantly higher in 
patients with FCPD than in those patients with Type 2 diabetes. However, none of 
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the established PEE equations accurately predicted the REE as determined by 
indirect calorimetry in FCPD subjects.  Thus the energy expenditure in patients 
with FCPD while being significantly higher, the role of standard predictive 
equations in assessment of energy expenditure in them remains to be critically 
analysed. Further research is also required to recommend specific nutritional 
therapy for this group of patients. Modifying the nutritional intake in FCPD 
subjects might be a crucial determinant to optimizing their glucose homeostasis. 
Based upon the relationships described above, the possibility of deficient fat 
stores in individuals with FCPD may be an novel factor that promotes hepatic 
triglyceride storage, leading to elevated circulating fatty acids and insulin 
resistance. 
 
CONCLUSION: 
Despite many years since its first description, the aetiopathogenesis of FCPD 
remains obscure. While insulin secretion defects are definitely the crux of the 
problem, there is growing body of evidence to suggest that insulin resistance may 
play a key role in glucose metabolism in these individuals. Moreover, the role of 
free fatty acids, counter-regulatory hormones like glucagon and impact of hepatic 
and peripheral lipid distribution on the dynamics of insulin secretion remains to 
be explored. Other factors related to alterations in energy expenditure may 
compound the pathogenetic picture. In fact,   not all people with Fibrocalculous 
Pancreatitis will develop diabetes and a search for the exact triggers for 
hyperglycemia might provide the clue to this enigmatic disease pathophysiology. 
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MATERIALS AND METHODS: 
 SALIENT ASPECTS OF THE STUDY DESIGN: 
STUDY DESIGN: The study was an Observational Case Control Study. 
Institutional review board, IRB Min.No.8379, dated 18.07.2013 approval was 
obtained. 
STUDY PERIOD: The duration of the study was a period of 1 year (2013-14). 
 
STUDY SETTING:  
The study was carried out  at the Department  of   Endocrinology, Diabetes and 
Metabolism, Christian Medical College, Vellore, Tamil Nadu, India.  
 
 
Table-1: SAMPLE SIZE CALCULATION : 
Two Means - Hypothesis testing for two means 
Standard deviation in group I 
(controls) 
2.28 2.28 2.28 
Standard deviation in group II 
(FCPD) 
2 2 2 
Mean difference 4.5 3.42 2.8 
Effect size 1.86 1.59 1.3 
Alpha error (%) 1 1 1 
Power (1- beta) % 80 80 80 
1 or 2 sided 2 2 2 
Required sample size group I 5 7 10 
Required sample size group II 11 15 20 
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Based on the data generated from previous work  on insulin resistance in 
Fibrocalculous Pancreatic Diabetes (FCPD) subjects done by Mohan et al, 
(detailed in Review of Literature section, ref :114) , the mean (SD) Glucose 
Disposal Rate in the FCPD group was 2.15 (2.00) as opposed to that in the non-
diabetic control subjects which was 5.57 (2.28). Since there were more than two 
groups being considered, the sample size was calculated with alpha and beta 
errors at 1% and 20% respectively with varying differences. The required sample 
size for the FCPD and non-diabetic control groups were  in the ratio of 20:10. 
 
 STUDY PARTICIPANTSAND RECRUITMENT:   
The study subjects were divided into the following four groups : 
 
 Fibrocalculous Pancreatic diabetes (FCPD) : (N=20) male subjects 
 These subjects were selected as per established criteria for diagnosing 
FCPD based on Mohan and colleagues( detailed criteria has been defined 
below) 
 
 Type 1 Diabetes mellitus (T1DM): (N=10 ) male subjects  
 
 
 Type 2 Diabetes Mellitus (T2DM):(N=10) male subjects 
 
 
 Non-diabetic Subjects (controls):(N=10) male subjects 
 The non-diabetic subjects were selected from the local community. These 
were individuals in general good health with no known co-morbidities, 
taking no medications affecting glucose metabolism, with normal glucose 
tolerance and no family history of diabetes. These subjects were similar in 
age, ethnicity and BMI with the FCPD group.   
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 The controls were recruited through various means of community 
outreach, including notices in shops and newspapers. 
 
 SUBJECT  ELIGIBILITY CRITERIA: 
INCLUSION CRITERIA: 
• Individuals with Fibrocalculous Pancreatic Diabetes as evidenced by the 
diagnostic  criteria outlined below 
• Diabetes duration of at least one year (for the diabetes groups) 
• Stable glycemic control (HbA1c between  8%- 10%) 
• Able and willing to provide informed consent 
• Male subjects 
EXCLUSION CRITERIA:  
• Mentally disabled persons 
• Major psychiatric disorder on medication (excluding successfully treated 
depression)   
• HIV/AIDS 
• History of any cancer  
• Alcohol or substance abuse  or toxin exposure 
• Cushing’s syndrome  
• Untreated or uncontrolled hypertension  
• Any Chronic illness requiring medication  
• History of bleeding disorder or with a prolonged PT or PTT 
• Renal disease 
• Liver impairment 
• Prisoners 
• Non-diabetic patients on medications affecting glucose metabolism such 
as thiazides, phenytoin and corticosteroids. 
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 DIAGNOSTIC CRITERIA: 
Fibrocalculous Pancreatic Diabetes (A): 
The diagnosis of Fibrocalculous Pancreatic Diabetes is made based on the criteria 
are proposed by Mohan et al( ref A outlined below ): 
1) The patient should originate from a tropical country. 
2) Diabetes should be present. 
3) Evidence of chronic pancreatitis must be present (pancreatic calculi on 
abdominal X-ray or at least three of the following  : 
 abnormal pancreatic morphology on sonography /CT scan 
 recurrent abdominal pain since childhood 
 steatorrhoea 
 abnormal pancreatic function tests 
4) Absence of other causes of chronic pancreatitis  
American Diabetes Association (ADA)Criteria for the diagnosis of 
diabetes(b): 
AIC >  6.5%. The test should be performed in a laboratory using a method that is 
NGSP certifiedand standardized to the DCCT assay. 
OR 
Fasting Plasma  glucose > 126mg%.  
Fasting is defined as no caloric intake for at least 8 hours. * 
OR 
2-h plasma  glucose > 200mg% during an OGTT. The test should be performed as 
described the World Health Organization, using a glucose load containing the 
equivalent of 75g anhydrous glucose dissolved in water. * 
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OR 
In a patient with classic symptoms of hyperglycaemia or hyperglycemic crisis, a 
random plasma glucose> 200mg% 
* In the absence of unequivocal hyperglycaemia, criteria 1-3 should be confirmed 
by repeat testing. 
A. Mohan V, Alberti KGMM. Diabetes in the tropics. In: Alberti KGMM, 
Defronzo RA, Keen H, Zimmet P (Eds): International Textbook of 
Diabetes Mellitus. John Wiley and Sons Ltd, Chichester.1999;177-96. 
B. Diagnosis and Classification of Diabetes Mellitus. Position Statement. 
American Diabetes Association. Diabetes Care, January 2012, 35: S64-
S71. 
 
 SCREENING OF SUBJECTS: 
 All subjects presented to the Department of Endocrinology in a fasting 
state in the morning. 
 Before screening took place, the subjects were provided with written 
information about the study and the procedures involved accordance with 
local requirements.  
 Subjects were fully informed, orally and in writing, of their 
responsibilities and rights while participating in the study, as well as of 
possible advantages/disadvantages when being part of the study.  
 Subjects had the opportunity to ask questions and have ample time to 
consider participation.   
 Subjects who wished to participate in the study were asked to sign and 
date the informed consent form for the study before any study related 
procedure. 
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 All subjects were  provided with a copy of  duly dated informed consent 
form with their own signatures  
 The study being an observational case-control study, randomization was 
not done. 
 
Investigations and examinations during first screening visit: 
a) Signed informed consent , date and time 
b) Demography :   
o Name 
o Date of Birth 
o Sex 
o Medical History. 
o Concomitant Medications 
c) Full history and physical examination with special emphasis on history of 
pain abdomen and steatorrhoea , Blood Pressure measurement 
d) Detailed anthropometric measurements :  
 Height, weight, BMI  
 Waist circumference and hip circumference  
 Skinfold  thickness at : biceps, triceps, subscapular, abdomen and 
supra-iliac areas using Harpendens skinfold callipers. 
e) Laboratory tests/radiological investigations in eligible individuals: 
 Serum electrolytes, 
 Serum Urea and Creatinine 
 Liver function tests 
 Fasting lipid profile 
 HbA1c 
 Fasting and Postprandial blood glucose  
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 C-Peptide  
 GAD antibodies 
 PT/APTT 
 Urine routine and microscopy 
 Urinary microalbumin 
 Stool for routine/microscopy 
 Stool for 72 hr fat estimation  
 X-Ray abdomen/KUB (erect) 
 Electrocardiography 
 Chest X-Ray-AP view (erect) 
 Ultrasound Abdomen/KUB 
 
Investigations at subsequent visit: 
a. Mixed meal challenge test (MMCT) 
b. Indirect calorimetry 
c. DEXA Scan (Dual Energy X-Ray Absorptiometry Scan) 
d. MRI abdomen and  NMR-SPECTROSCOPY   
 
Investigations following overnight admission and glycemic control for 
>12hrs: 
o Euglycemic Hyperinsulinemic Pancreatic Clamp study 
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 STUDY PROTOCOL FLOWCHART: 
 
 
(Abbreviations used : FCPD: Fibro Calcific Pancreatic Diabetes Mixed meal  –
Mixed meal challenge test, DEXA – dual energy absorptiometry scan, NMR- 
Nuclear Magnetic Resonance Spectroscopy) 
 
ASSESSMENT METHODS: 
A) Physical Assessment:     
Physical assessmentincluded : 
 Careful assessment of upper extremity veins,  
 Musculo-skeletal examination , BP measurement 
 Detailed anthropometric measurements :  
 Height, weight, BMI (body mass index) 
 Waist circumference and hip circumference  
 Skinfold  thickness at : biceps, triceps, subscapular, abdomen and supra-
iliac areas using Harpendens skinfold calipers  
 Technique of anthropometric measurements: 
 Anthropometric measurements were done including measurement of 
height, weight, body mass index, body surface area, waist circumference, 
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hip circumference and waist –hip ratio.  
 Skin fold thickness was measured at biceps, triceps, subscapular regions 
and at the abdomen.  
 Body composition measurement were taken on healthy, undamaged and 
uninfected dry skin as moist skin is harder to grasp and can influence the 
measurement. Instruct the test subject to keep the muscles relaxed during 
the test.  
 The skinfold site was marked using a pen with water soluble ink. A tape 
measure was to accurately find the mid-points. The skinfold was firmly 
grasped by the thumb and index finger, using the pads at the tip of the 
thumb and finger and the skinfold gently pulled away from the body.  
 The Harpenden skinfold calliper was placed perpendicular to the fold, on 
the site marked, at approximately 1cm below the finger and thumb. While 
maintaining the grasp of the skinfold, the Caliper was released so that full 
tension was placed on the skinfold. The dial was read to the nearest 
0.50mm, 1 to 2 seconds after the grip has been fully released. 
 Two measurements were taken at each site. If repeated tests varied by 
more than 1 mm, the measurements were repeated.  
 Triceps skin fold thickness: measured at the midpoint between the 
acromion and olecranon processes on the left side with the arm hanging by 
the side. 
 Biceps skin fold thickness: measured at the anterior surface of the biceps 
midway between the anterior axillary fold and the antecubital fossa . 
 Subscapular region skin fold thickness: measured below the inferior 
angle of the scapula.  
 Abdominal skin fold thickness: measured 3 cm lateral to the umbilicus. 
Supra iliac skin fold thickness was measured 2 cm above the anterior 
superior iliac spine obliquely. 
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B) Laboratory assessment:  
Laboratory assessment included tests to determine eligibility, including serum 
electrolytes, serum urea and creatinine, PT/PTT, liver function tests, lipid 
profile, HbA1c, screening urinalysis, and blood glucose measurements. 
 
Body Composition and basal metabolic assessments 
C) MRI and Nuclear Magnetic Resonance Spectroscopy(MRS) :  
 
 Principle: 
The signal intensity in MRI is dependent on the different physical properties 
of protons within water and fatty acid molecules, resulting in differences in 
the time and phase dependent behaviours during relaxation, which can be 
made out during NMR-Spectrosocpy . The difference in the magnetic 
properties of bulk cylinders like Extramyocellular (EMCL) and 
Intramyocellular (IMCL) segments is made out by the NMR Spectroscopy. 
 An MRI abdomen scan was done in subjects with Fibrocalcific Pancreatic 
Diabetes (FCPD).  
 A Nuclear Magnetic Resonance Spectroscopy was done to assess the hepatic 
liver content, intramyocellular lipid and extramyocellular lipid content at the 
level of the soleus muscle. 
 MR imaging and spectroscopy was performed using a 3T Intera Achieva MR 
system (Philips Medical Systems, Netherlands). 
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NMR Spectroscopy showing the Hepatic lipid content (Panel A) and 
Intramyocellular and Extramyocellular (soleus) Lipid content (Panel B) 
PANEL B 
PANEL A 
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D) DXA Scan (Body fat and Bone Mineral Content measurement): 
 Principle: 
Dual Energy X-Ray Absorptiometry uses the principle of measuring the 
attenuation difference between two x-ray beams of different strengths.  This 
measures body fat and fat free mass with minimum radiation exposure (1 μ 
seivert).  The co-efficient of variation (CV) for total body fat measurement is 
<1% and for regional fat estimation <3% (precision error- 1kg).  It does not 
however differentiate visceral from subcutaneous fat in the abdomen.  
 
 In this study we used a Hologic Dual energy x ray absorptiometry 
(DEXA) machine (Discovery A- QDR 450) which has a One Pass 
single sweep scanning system for better quality and precision.  
 It also eliminates beam overlap errors and image distortion found 
in rectilinear acquisition techniques resulting in a better image 
quality and data stability.  
 It has a multi-element digital detector array paired with true fan-
beam acquisition geometry, enabling rapid, dual-energy bone 
density measurements 
 
E) Indirect Calorimetry: 
 Indirect calorimetry, the gold standard for measuring resting 
energy expenditure (REE) was used in our subjects.  
 The estimations were made anytime during the day, provided more 
than 2 hours had elapsed since the last meal so as to minimize 
measurement errors from diet induced thermogenesis.  
 The oxygen consumption and carbon dioxide production were 
measured to calculate respiratory quotient [(RQ) = VCO2 / 
 VO 2].  
 RQ within the normal physiological range confirms a 
consistent calorie intake by the study subjects. 
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Calculation of Resting and Predicted Energy Expenditure (REE and PEE); 
Resting Energy Expenditure (REE) 
Abbreviated Weir equation: 
3.9 (VO2) + 1.1 (VCO2) x 1.44 [(VO2 – Oxygen intake (ml/minute), 
VCO2Carbon dioxide output (ml/minute)]. 
 
Predicted energy expenditure (PEE): 
Harris Benedict’s Equation 
Male: 66.5 + 13.76 x weight (kg) + 5.9 x height (cm) – 6.76 x age 
(This calorie formula takes height, weight, age, and sex into consideration) 
Cunningham’s Equation : 
370 + 21.6 x Fat free Mass (FFM) in Kg 
(Since fat-free mass accounts for almost 80% of the variations seen in 
RMR, this equation uses fat free mass as the predictor variable to estimate 
RMR) 
 
ICMR (Indian Council of Medical Research) Equation for adult males 
Age ( yrs) Prediction equation (Kcal/24hr) 
18-30 14.5×BW (kg)+645 
30-60 10.9×BW (kg)+833 
>60 12.8×BW (kg)+463 
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Indirect 
calorimetry  is 
underway in a 
subject at CMC, 
Vellore, India. 
The indirect 
calorimeter 
readings are 
generated on 
this automated 
output device.  
A subject 
being 
prepared for 
the indirect 
calorimetry 
test  
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F) EuglycemicHyperinsulinemicPancreaticClamp studies : 
 Principle:  
 
• The administration of exogenous insulin reduces endogenous glucose 
production and increases the whole body glucose utilisation, resulting in 
decline of blood glucose concentration.  
• This decline is prevented by an exogenous glucose infusion which exactly 
matches the insulin induced glucose flux out of the glucose space into 
glucose utilising cells at the periphery.  
• By using a tracer tagged glucose infusion, the metabolic clearance rate and 
rate of appearance of glucose from the glucose concentrations  is 
measured. 
• The tracer tagged glucose (Deuterated Glucose-D2G) does not affect the 
endogenous metabolic pathways and does not disturb the body’s glucose 
metabolism  
 
 Clamp procedure: 
• All subjects were brought on the day of the study to the Endocrinology 
Department clamp study room after an overnight fast.  
• At 8:00 am 2 intravenous cannulae were established, one for infusions and 
a second one inserted in a retrograde fashion in a dorsal vein of the 
opposite arm for blood sampling. To obtain arterialized venous blood 
samples, this hand was maintained at 65°C in a heated blanket.  
• A primed continuous infusion of D2G- Glucose was initiated at t= -120 
min (2 hours prior to the onset of the ‘clamp’ study).  A bolus of D2G 
9deuterated glucose) 200 mg/m
2
 over 3 min was followed by continuous 
infusion of 2 mg/min/m
2
  for the entire study in all subjects (for total 
duration of 6 hours) to quantify glucose turnover, specifically rates of 
peripheral glucose disposal and hepatic glucose production.   
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• These ‘pancreatic clamp’ experiments also consisted of 420 min 
insulin/somatostatin (250 µg/hr) infusions with replacement of 
glucoregulatory hormones (glucagon 1 ng/kgmin; growth hormone 
3 ng/kgmin).  
• Throughout the entire 420 min the plasma glucose concentration 
was maintained at basal levels (~90 mg/dl). 
 
 Clamp Protocol - the 3 phases : 
 
 
 
 
The entire Clamp procedure is divided into 3 inter-connected phases 
spanning a duration of 6 hours. Prior to the six hours of the actual 
clamp study, there is a preparatory phase of 12-18 hours, during 
which the subject is admitted in the ward on the previous day and 
blood glucose levels are maintained at 90 mg/dl with the help of a 
controlled insulin infusion .  
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The clamp study performed on the subsequent day has the following phases: 
 
 Basal phase: From t=-120 min to t=0, optimal insulin infusion rates were 
selected in each individual by making frequent (~ every 20-25 mins) 
adjustments to the insulin infusion rates in order to establish insulin 
infusion rates required to maintain euglycemia (90 mg/dl) without the 
requirement for exogenous glucose infusion. In our experience, this 
approach has resulted in our ability to detect small changes in insulin 
sensitivity . 
 
 Low phase:Following establishment of basal insulin requirements during 
the basal phase, at T=0 the insulin infusion rate was  increased by 20 
mU/m
2
/min, and it was maintained at this rate for 2 hours (T=0-120 min). 
These rates are designed to optimally assess hepatic insulin sensitivity. 
Plasma glucose was maintained at euglycemic concentrations (~90mg/dl) 
by a variable infusion of 20% dextrose for the entire study . 
 
 High phase: At T=120 min, insulin infusion rate was increased by 80 
mU/m
2
/min above basal requirements, and was maintained at that rate for 
the final 2 hours of the study (T=120-240). These rates are designed to 
assess whole body insulin sensitivity. 
 
 Post-clamp observation phase:All infusions were stopped at t=240 min.  
The subjectswere given a standard meal and plasma glucose levels were 
monitored at 15-30 min intervals for the next one hour. Dextrose infusion 
were continued for approximately 45 minutes after the study in order to 
avoid hypoglycemia. The subject was discharged provided that his or her 
condition remained stable after observation for aa further period of 3-4 
hours.  
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 Measurements of plasma insulin, C-peptide, glucagon, and growth 
hormone are undertaken throughout the studies in order to evaluate the 
adequacy of the “pancreatic clamp” technique, i.e. the inhibitory 
effects of somatostatin on hormone secretion, and uniformity of 
hormone replacement. All samples were kept on ice until centrifuged 
(within 30 min). Plasma samples were then sorted and handled by the 
Special Assay Core, and were stored frozen at -20°C for later assays. 
 
Measurements obtained during the clamp study: 
 Plasma measurements: 
• From t=0 to t= 240 min., blood samples were obtained at hourly intervals for 
determination of plasma glucose, insulin, glucagon, C-peptide, and  Free fatty 
acids (FFA).  
• Additional samples for D2G glucose determinations were also  obtained every 
15 minutes. 
• Plasma glucose were measured every 5-10 min to adjust the glucose infusion 
rate.  
• Plasma lipids (LDL, HDL, VLDL, total Cholesterol and Triglycerides) were 
measured at t=-120).  
 
 Analytical procedures:  
• Plasma glucose was measured every 5 minutes to adjust the glucose infusion 
rate. Plasma glucose levels were measured using the glucose oxidase method 
(Analox GM9D; Analox Instruments, London, UK). Plasma insulin was 
measured by a chemiluminescent immunometric assay (%CV 7.3) 
(IMMULITE 2000 Insulin with IMMULITE 2000 Immunoassay System, 
Siemens healthcare Diagnostic products Ltd., Llanberis, Gwynedd, UK). 
Fasting plasma glucose for surrogate indices was measured by the glucose 
oxidase peroxidase method using reagents supplied by Roche, on Roche 
Modular P 800 system (% CV 3.6). 
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 Substrate determination:  
• Plasma FFA levels were determined by using an acyl-CoA oxidase based 
colorimetric kit (Wako, Osaka, Japan) . 
• Plasma lactate was measured by fluorometric enzyme techniques  
• Plasma for labeled glucose was treated as previously described . Rates of 
glucose appearance (Ra) and disappearance (Rd) and other indices of glucose 
turnover were estimated by using the steady-state equation of Steele.  
• Endogenous glucose production (EGP) was determined by subtracting the 
rates of glucose infusion from the tracer-derived rate of appearance of glucose. 
Data forglucose turnover represent the mean values during the final 60 min of 
the low insulin period (t=60-120 min), and during the final 60 min of the high 
insulin period (t=180-240 min). Samples for D2G glucose determinations were 
obtained every 15 minutes. D2G determinations were performed at Albert 
Einstein College of Medicine. Plasma samples for Gas Chromatography-Mass 
Spectroscopy (GC-MS) were derivatized after protein precipitation to the 
aldonitrile-pentacetate with hydroxylamine hydrochloride-acetic anhydride. 
GC/electron impact-mass spectrometry analysis was performed on an Agilent 
model 6890/5973 with a 7673 Agilent auto-sampler. 
 
Pancreatic Clamp studies at CMC Vellore: previous experience: 
 
Studies on Deleterious Metabolic Effects of Low Birth Weight using clamps:  
• These studies125 were performed at CMC Vellore in association with the 
University of Copenhagen, Denmark. 
• Low birth weight (LBW) is common in the Indian population and may 
represent an important predisposing factor for type 2 diabetes (T2D) and the 
metabolic syndrome. Intensive metabolic examinations in ethnic LBW Asian 
Indians have been almost exclusively performed in immigrants living outside 
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India. Therefore, the aim was to study the metabolic impact of being born 
with LBW in a rural non-migrant Indian population. 
Subjects and methods:  
• One hundred and seventeen healthy males participated in the study. They were 
selected according to their birth weight from the birth registry at the Christian 
Medical College, Vellore, India. The Community Health and Development 
(CHAD) programme run by the Department of Community Health, Christian 
Medical College, Vellore provides primary and secondary health care services 
to all the 82 villages in Kaniyambadi, a rural development block in the Vellore 
district located in Southern India. The CHAD programme has in place an 
ongoing surveillance system where information on pregnancies, deliveries, 
births, deaths, morbidity and immunisation status among mothers are recorded 
and updated in the Health Information System. All men were born between 
1986 and 1990 in a rural area in the south Indian state of Tamil Nadu, in north 
Arcot district, near the town of Vellore in the Kaniyambadi block and 
belonged to Dravidian ethnicity. The Dravidians are found particularly in 
Southern India and comprise about 20% of the Indian population. The subjects 
comprised 61 LBW and 56 normal birth weight (NBW) men, with NBW men 
acting as controls. Subjects underwent a hyperinsulinemic euglycemic clamp, 
i.v. and oral glucose tolerance tests and a dual-energy X-ray absorptiometry 
scan. The parents’ anthropometric status and metabolic parameters were 
assessed. 
Results:  
• Men with LBW were shorter (167G6.4 vs 172G6.0 cm, P!0.0001), lighter 
(51.9G9 vs 55.4G7 kg, PZ0.02) and had a reduced lean body mass (42.1G5.4 
vs 45.0G4.5 kg, PZ0.002) compared with NBW controls. After adjustment 
for height and weight, the LBW subjects had increased diastolic blood 
pressure (P=0.01). Five LBW subjects had impaired glucose tolerance. In 
vivo insulin secretion and peripheral insulin action were similar in both the 
groups. Mothers of the LBW subjects were 3 cm shorter than the control 
mothers. 
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• Conclusion: 
Only subtle features of the metabolic syndrome and changes in body 
composition among LBW rural Indians were found. Whether other factors 
such as urbanisation and ageing may unmask more severe metabolic 
abnormalities may require a long-term follow-up. 
 
Studies on impact of Vitamin D on insulin sensitivity using clamps: 
• These studies124 were performed at CMC Vellore in association with the 
Albert Einstein College of Medicine, Yeshiva University, New York, USA. 
• Eight vitamin D deficient subjects (4 Indian, 4 American) underwent 
euglycemic-hyperinsulinemic clamp studies before and after vitamin D 
repletion.  
• Among the Indian subjects, there was a 3% worsening in hepatic insulin 
sensitivity and 15% improvement in peripheral insulin sensitivity after 
vitamin D replenishment. Among American subjects, there was a 64% 
improvement in hepatic insulin sensitivity and 27% improvement in 
peripheral insulin sensitivity after vitamin D replenishment. The combined 
data analysis showed that there was a 18% improvement in hepatic insulin 
sensitivity and 20% improvement in peripheral insulin sensitivity after 
vitamin D replenishment.  
• The improvement in insulin sensitivity after vitamin D replenishment is likely 
directly proportional to the baseline HOMA and indirectly proportional to the 
baseline vitamin D status. This suggests that vitamin D replenishment may 
have a role in improving the insulin sensitivity of non-diabetic adult males 
with vitamin D deficiency, but a larger sample size will be required to achieve 
statistically significant results and establish this effect. 
 
Challenges and precautions during pancreatic clamp studies: 
 
The Euglyemic-Hyperinsulinemic pancreatic clamp studies being an elaborate and 
intensive physiological study, there are certain risks inherent to the procedure. 
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The subjects were made aware of these risks during the informed consent and the 
possible remediable measures were also clearly outlined. Some of the potential 
challenges during the clamp technique are enumerated here: 
Blood withdrawal: The total amount of blood sampled did not exceed 
190 ml per study, about half of that donated by a blood donor. A close 
monitoring of pulse, blood pressure and clinical evidence of hypotension 
was done during the study. 
a) 20% dextrose: The infusion of 20% dextrose may be associated with local 
venous irritation. This was be minimized by use of a large-bore ante-cubital 
vein in which the glucose was  infused.  
b) 6,6Deuterated glucose: 6,6 Deuterated glucose is a stable isotope and 
therefore there was no radiation exposure. 
c) Glucagon:In high doses , glucagon infusion can cause gastrointestinal 
symptoms such as cramps and nausea, and produce high blood glucose levels 
in persons with glucose intolerance. The doses employed here were intended 
to maintain plasma glucagon at basal levels and hence there was minimal 
chances of developing high blood glucose levels, which were anyhow being 
monitored at every five minute intervals. 
d) Growth Hormone: At higher doses and for prolonged periods of exposure, 
growth hormone (rHGH) has either insulin-like or insulin-opposing effects on 
carbohydrate and lipid metabolism; However ,the proposed infusion matched 
the physiological replacement and was not associated with significant adverse 
effects.  
e) Hypoglycemia:Is a potential complication in these subjects because of the 
desired plasma glucose targets (90 mg/dl during the entire clamp phase). 
However, the chances of developing hypoglycemia during the study were 
minimized by:  
• The subjects were on a continous dextrose infusion  
• They had strict and intensive blood glucose monitoring at every five minute 
intervals throughout the duration of the study 
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• However, since there remained a very low risk of developing hypoglycemia, 
the subjects were made aware of the potential symptoms of hypoglycemia in 
the form of sweating , increased heartbeat, dizziness and altered sensorium. If 
these developed, an immediate blood glucose was checked and the existing 
dextrose infusion they were on were increased and persisted with till the 
symptoms subside. He was   monitored for the next few hours to be certain 
that the hypoglycemic episode has been overcome successfully. 
f) Somatostatin: Somatostatin infusion can cause abdominal cramps, nausea 
and abdominal fullness. Since somatostatin was  infused at a dose which is 
normally required by the body, it did not cause any gastrointestinal side 
effects in the study subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Clamp study Nurses setting up the intravenous 
access and infusions prior to start of the clamp 
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A clamp study in progress at CMC Vellore  
The Glucose analyzer used to measure blood glucose at  
five minute intervals during the clamp 
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G) Mixed Meal challenge test : 
 Principle :  
 Mixed meal tests have been proposed to have similar sensitivity and 
reproducibility to oral glucose tolerance testing (OGTT) for the detection 
of hyperglycemia and diagnosis of glucose intolerance  
 We have substantial experience in performing these tests in older subjects.  
Indeed, a standard mixed meal challenge, rather than an oral glucose 
challenge, represents a more physiologically relevant stimulus in that it 
may more closely mimic the metabolic changes experienced by 
individuals in daily life, and is better tolerated than an OGTT. 
 It also represents a more integrated measure of nutrient metabolism than 
intravenous challenge tests, since it includes the contribution of the 
incretin hormones.   
 
 Study protocol:  
 Subjects were provided with a standard meal and snack to consume at home 
the night prior to the SMT and will fast after 10 pm, in order to minimize 
metabolic variability between tests.  
 Following the overnight fast , subjects were administered a the mixed meal of 
Ensure nutritional powder (carbohydrate 54%, fat 32% and protein 14%:) in a 
dose of 6ml/kg (maximum of 360 ml) to be drank over 5-10 minutes .  
 Blood sampling were performed through an indwelling intravenous catheter, 
fasting and 15, 30, 45, 60, 90, 120 and 180 minutes following the meal, for 
measurement of glucose, insulin , glucagon and C-peptide levels. Plasma 
triglycerides and FFA levels were measured at fasting and at 60, 120 and 180 
minutes. 
 Glucose-stimulated insulin secretion can be assessed using a variety of 
techniques, including hyperglycemic “clamp” studies and the frequently 
sampled intravenous glucose tolerance test.  However, these procedures could 
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be considered to be less physiologic, as they do not capture the contribution of 
incretin hormones, and may be more burdensome for older subjects. Standard 
mixed-meal tests with frequent blood sampling and application of 
mathematical modeling have been used to evaluate insulin secretion, and have 
been reported to produce results comparable to more invasive and less 
physiologic tests.  
 
 Insulin and Glucagon secretion rates:  
 Insulin secretion rate (ISR) 129 was estimated from plasma glucose and C-
peptide concentrations using the deconvolution technique derived from 
plasma C-peptide concentrations measured during the standard mixed 
meal and using parameters for C-peptide kinetics and volume of 
distribution . 
 Insulin secretory dynamics129 can be broken down into dynamic and static 
components of β-cell responsivity to glucose. The dynamic responsivity 
index, termed Ψdynamic, measures the β-cell secretory response to the rate 
of change of glucose concentration. This measure approximates the first 
phase of insulin release and defines the response to a given increment in 
glucose. Conversely, the static responsivity index  (Ψstatic) measures the 
beta cell secretory response to a given glucose concentration.   
 This static measure is believed to represent the provision of new insulin 
into the secretory pool. The two Phi factors can be combined into a Ψtotal.  
The appropriateness of the insulin secretion for the prevailing degree of 
insulin resistance can be determined by the disposition index (DI) 
calculated as the Ψdynamic, Ψstatic and Ψtotal times the insulin sensitivity , 
which uses the method of Matsuda allowing  calculation of a DI for 
subjects who do not undergo the euglycemic clamp.  
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 Statistical methods:  
 
 Descriptive statistics of the variable were presented in terms of mean and 
standard deviation.  
 Normality of the data was tested using Shapiro Wilk test and Q-Q plot.  
 For variables with normal distribution, parametric tests were used:  
o ANOVA for comparison of means among groups  
o Tukey test was used for post hoc analysis.  
 For variables without normal distribution, non-parametric tests were used:  
o Kruskall Wallis test for comparison of means among groups  
o Mann-whitney U test for post hoc analysis.  
 A  p - value of <0.05 is taken as statistically significant in all cases. 
 All statistical analysis was performed using IBM SPSS (Statistical 
Package for the Social Sciences) version 21.0. 
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RESULTS AND ANALYSIS : 
Data for analysis was obtained from 50 study subjects divided into the following 4 
groups: 
FCPD : (Fibrocalcific Pancreatic Diabetes):    N=20 subjects 
T1DM:  (Type 1 Diabetes Mellitus) :              N=10 subjects 
T2DM   (Type 2 Diabetes Mellitus)  :              N=10 subjects 
NORMAL (non-diabetic control subjects) :     N=10 subjects 
 
STUDY OVERVIEW FLOWCHART: 
 
 
 
 
 
 
 
 
 
 
72 subjects ( FCPD : 32 subjects , T2DM : 15 subjects , T1DM : 13 subjects ,  Non-
diabetic controls: 12 subjects )  were willing  participate after informed consent   
FCPD group: 7 had Hba1c >11%, 4 had HbA1c <6,5% and 1 patient  developed  a 
foot ulcer during the screening period 
T2DM: 2 subjects had Hba1c > 12%  , 2 had HbA1c < 7.5% and 1 subject  
developed  Urinary Tract infection during the screening period 
T1DM :  2 subjects had Hba1c >11%  and 1 subject had HbA1c <8%  
Non-diabetic control group:  2 subjects  were lost to follow-up as they had 
migrated to other cities due to work issues 
Out of the Initial Group  
A total of 50  subjects ( FCPD : 20 subjects , T2DM : 10 subjects , T1DM : 10 and  
non-diabetic controls :10 subjects )  were part of the final study and data analysis 
After final exclusion   
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Table-2: BASELINE  CHARACTERISTICS: 
Baseline  
Characteristics 
FCPD 
 (N=20) 
T2DM  
(N=10) 
T1DM  
(N=10) 
   NORMAL         
    (N=10) 
 
 
P-value 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
Age(years) 30.3 ± 6.6 36.8 ± 6.39 25.4 ± 4.38 24.7 ± 1.49 0.01* 
BMI(kg/m2) 19.8 ± 2.99 26 ± 0.66 20.7 ± 1.6 19.9 ± 2.41 0.01* 
Waist Hip ratio 0.91 ± 0.06 1 ± 0.04 0.8 ± 0.04 0.9 ± 0.04 0.22 
HbA1c (%) 9.09 ± 1.19 9.2 ± 1.25 9.2 ± 0.98 5.2 ± 0.15 0.95 
FPG (mg/dL) 201.3 ± 
82.73 
186.1 ± 
58.43 
176.8 ± 66.9 86.6 ± 5.58 0.12 
Duration of 
diabetes(years) 
5.1 ± 3.31 2.8 ± 1.93 13.8 ± 4.32 NA 0.01* 
(Abbreviations : FPG- Fasting plasma Glucose , BMI : Body Mass Index ) 
Age distribution:   
The age distribution in the study population  (FIGURE 1) showed that the mean 
age in the FCPD group was  30.3 ( ± 6.62 ) years while that in the T1DM , T2DM 
and normal (non-diabetic) control groups were 25.4 (±  4.38 )years,  36.8 (± 6.39)  
years and 24.7( ±1.49) years respectively .  The T2DM group , as expected had a 
significantly higher mean age (p=0.01) while the T1DM, FCPD and control 
groups were age-matched (p=0.56). 
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                                   FIGURE 1: DISTRIBUTION OF AGE 
BMI distribution:   
The mean BMI in the FCPD (19.8 ± 2.99 kg/m2) , T1DM ( 20.7 ± 1.6 kg/m2)  
and normal control ( 19.9 ± 2.41 kg/m2) groups were similar . The T2DM group 
as expected had a higher mean BMI of 26 ( ±  0.66) kg/m2 which was statistically 
significant (p=0.01) while the FCPD, T1DM and control groups had similar BMI 
( p=0.66). The BMI distribution has been depicted below in FIGURE 2. 
 
 
 
FIGURE 2: DISTRIBUTION OF BMI 
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Hba1c  and Duration of Diabetes:  
The HbA1c in the three groups were similar (p=0. 95) .  The FCPD group had an 
HbA1c of 9.09( ± 1.19) %, while that in the T2DM and T1DM groups were 9.2 (± 
1.25) % and 9.2( ± 0.98) % respectively .  
The duration of diabetes was 13.8 ± 4.3 years, 2.8 ± 1.93 years and 5.1 ±3.3 years 
respectively in the T1DM, T2DM and FCPD groups with significantly increased 
duration of diabetes seen in the T1DM group (p=0.01).  
The distribution of HbA1c and diabetes duration in the study population has 
been depicted below in FIGURE 3 AND FIGURE 4 respectively   
 
                   FIGURE 3: DISTRIBUTION OF HbA1c 
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FIGURE 4: DISTRIBUTION OF DIABETES DURATION 
Table-3: BODY COMPOSITION CHARACTERISTICS ( DXA SCAN) 
DXA 
FCPD 
 (N=20) 
T2DM  
(N=10) 
T1DM  
(N=10) 
   NORMAL         
    (N=10) 
 
 
 
P-value 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
Total fat (%) 15.6 ±4.13 26.4 ±6.08 16.4 ±5.27 15.9 ± 3.0 0.000* 
Trunk fat 
(%) 
14.4 ±3.73 28.1 ±6.87 13.5 ±5.17 13.5 ± 3.6       0.000* 
Total fat (g) 8455.0 
±3810.0 
18787.9 
±3479.7 
9396.7 
±3170.5 
9117.4 ± 
4808.8 
0.001* 
Trunk fat (g) 3618.3 
±1969.5 
10026.7 
±2098.0 
3642.1 
±1615.1 
4001.7 
±1789.7 
0.001* 
Peripheral 
fat (g) 
3982.5 
±1954.9 
7740.2 
±1631.8 
4859.1 
±1720.5 
5262.7 
±1758.5 
0.000* 
Central to 
peripheral 
fat ratio 
0.91 ±0.25 1.31 ±0.21 0.75 ±0.18 0.75 ± 0.14 0.000* 
(Abbreviations: DXA – Dual Energy X-Ray Absorptiometry Scan) 
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 The analysis of the baseline body composition characteristics as evaluated 
by DXA scan showed that the mean total fat % in the FCPD group ( 15.6 
± 4.13) and T1DM group (16.4 ± 5.27) was similar to the controls (15.9 ± 
3) while that in the T2DM was higher (26.4 ± 6.08). Similarly the mean 
truncal fat % in the T2DM group ( 28.1±  6.87)was greater than the FCPD 
( 14.4 ± 3. 73)  or the T1DM group ( 13.5 ± 5.17) . Comparing the central 
and peripheral fat ratios, the FCPD group had a ratio of 0.91(± 0.25) , 
while that in the T1DM and T2DM were 0.75 ( ± 0.18  ) and 1.31 (±0.21)  
respectively with a ratio of 0.75 ( ± 0.14) in the non-diabetic control 
group. 
 
 Comparing  these characteristics between the groups by ANOVA and 
post-hoc tukey test , it was seen that Total fat (%), Trunk fat (%), Fat in 
arms (%), Fat in legs (%) were significantly lower in  FCPD than in Type 
2 diabetes group(p=0.000) .  
 
 Lean mass (g) is significantly lower in FCPD when compared with Type 2 
diabetes and also normal subjects (p=0.000) . Bone Mineral Content 
(BMC) (g) is significantly lower in FCPD when compared with Type 2 
diabetes and Type 1 diabetes groups (p=0.000) . Central to peripheral fat 
ratio is also significantly lower in FCPD compared to the Type 2 DM 
group (p=0.000).  
 
Total fat (%), Truncal Fat (%) , central to peripheral fat ratio in 
FCPD was similar to T1DM group .  Lean mass (g)  in FCPD was 
significantly lower than non-diabetic controls while BMC (g) was 
significantly lower than T1DM group . 
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The distribution of total and truncal fat (%) has been shown in 
FIGURE 5:       
 
         FIGURE 5 : DISTRIBUTION OF TOTAL AND TRUNCAL FAT (%) 
Table-4: INDIRECT CALORIMETRY INDICES  
 (Abbreviations: Resting Energy Expenditure ; RER : Resting Energy Ratio) 
 
Calorimetry 
indices 
FCPD 
 (N=20) 
T2DM  
(N=10) 
T1DM  
(N=10) 
   NORMAL         
    (N=10) 
 
 
 
P-value 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
 
REE 1858.9 ± 452.61 1838.2  ± 155.4 1976.7 ± 294.1 1872.7± 451.5 0.64 
RER 1.03 ± 0.25 0.88 ± 0.08 0.84 ± 0.05 0.96 ± 0.09 0.76 
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 Analysis of indirect calorimetry indices of REE (Resting Energy 
Expenditure) and RER (Resting Energy Ratio)  between the groups  
revealed that REE in T1DM group was slightly higher  (1976.7 ± 294.1) 
than the FCPD (1858.95 ± 452.6 ) and T2DM groups (1838.20 ± 155.45) . 
This has been depicted in FIGURE 6. 
 Similarly RER in the FCPD group was slightly higher than the T1DM ( 
0.84 ± 0.05), T2DM  ( 0.88±  0.08) and non-diabetic control groups (0.96 
± 0.09).  
 
REE in the FCPD group had no significant difference from that in the 
T1DM, T2DM or non-diabetic control groups even after adjusting for  
BMI (p=0.98) and fat-free mass (p=0.69) 
 
 
 
       FIGURE 6 :DISTRIBUTION OF RESTING ENERGY EXPENDITURE (REE) 
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Table-5: 1-H-NMR (Nuclear Magnetic Resonance) SPECTROSCOPY 
INDICES 
 
(Abbreviations: HCL – Hepatocellular Lipid, IMCL – Intramyocellular Lipid, 
EMCL –     Extramyocellular Lipid) 
 
 
 Analysis of Hepatocellular Lipid (HCL) showed that the mean % of  HCL 
was similar in T1DM and FCPD groups ( 1.7 vs 1.31) while that in T2DM 
group was much higher (12.3  ± 5.11) . This has been depicted in 
FIGURE 7 below: 
 
FIGURE 7 : DISTRIBUTION OF HCL 
NMR 
indices 
FCPD 
 (N=20) 
T2DM  
(N=10) 
T1DM  
(N=10) 
   NORMAL         
    (N=10) 
 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
 
HCL (%)      1.31 ± 0.52        12.3 ± 5.11 1.7 ± 0.83 2.2 ±0.35 
IMCL (%) 1.03 ± 0.25 2.4 ± 1.47 1.5 ± 0.78 1.1 ±0.42 
EMCL (%) 1.29 ± 0.34 2.5 ± 0.78 1.4 ± 0.58 1.8 ± 0.42 
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 Comparison of Extramyocellular Lipid (EMCL) % showed lowest values 
in FCPD group ( 1.29 ± 0.34 ) while the T1DM group ( 1.4 ± 0.58) and 
T2DM group   ( 2.5 ± 0.78) had greater % of EMCL.  FIGURE 8 below 
depicts this distribution: 
 
         FIGURE 8 : DISTRIBUTION OF EMCL 
 The mean Intramyocellular Lipid (IMCL)was similarly lowest in FCPD 
group (1.03± 0.25) and highest in the T2DM group (2.4 ± 1.47) as shown 
in FIGURE 9 below:    
 
FIGURE 9: DISTRIBUTION OF IMCL 
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Table-6: BETWEEN GROUPS : HCL AND IMCL 
FCPD vs 
Type 1 DM Type 2 DM Normal subjects 
HCL 
(%) 
IMCL 
(%) 
HCL 
(%) 
IMCL 
(%) 
HCL 
(%) 
IMCL 
(%) 
Mann-Whitney U 99 99 20.5 75.5 95.5 46.5 
Wilcoxon W 154 154 230.5 286 305.5 101.5 
Z -0.04 -0.04 -3.5 -1.08 -0.2 -2.35 
Asymp. Sig. (2-tailed) 0.96 0.96 0.00046 0.28 0.84 0.02 
Exact Sig. [2*(1-tailed Sig.)]        
(p-value) 
0.983 0.983 0.000* 0.29 0.846 0.017* 
(Abbreviations: HCL – Hepatocellular Lipid, IMCL – Intramyocellular Lipid , 
EMCL –     Extramyocellular Lipid ) 
 
 
Table-7: BETWEEN GROUPS : EMCL 
(Abbreviations : EMCL: Extramyocellular Lipid) 
 The characteristics of  hepatic and muscle lipid deposition obtained from 
the NMR-Spectroscopy in the FCPD group was compared with that in the 
other 3 groups. 
 Findings from ANOVA and Post hoc Tukey tests showed  EMCL (Extra-
myocellular lipid) was significantly lower in FCPD than in Type 2 
diabetes and normal groups (p= 0.007 ). HCL (Hepatocellular lipid) is 
significantly lower in FCPD than in Type 2 diabetes group (p=0.000).  
EMCL(%) Sum of Squares df Mean 
Square 
F Significance  (p-
value) 
Between Groups 6.39 3 2.13 4.54 0.007* 
Within Groups 21.55 46 0.47   
Total 27.94 49    
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IMCL (Intramyocellular Lipid)is significantly lower in the FCPD group 
(p=0.017) than in the normal group. 
 
HCL , EMCL and IMCL were similar in FCPD and T1DM group, 
while FCPD group  had significantly lower IMCL and EMCL than 
non-diabetic controls  
 
 
MIXED-MEAL CHALLENGE TEST (MMCT): 
 
Table-8: INSULIN AND GLUCAGON SECRETION PROFILES 
 
 Insulin Secretion Rate (ISR) for each group was calculated from the C-
peptide values utilizing the deconvolution technique.  
 
 The Insulin Secretion Rate (ISR) in the FCPD group was 358.35 ( ± 
244.95) pmol/kg/min was reduced in comparison to the non-diabetic 
control group ( 984.28± 245.01 pmol/kg/min and the T2DM group ( 
919.67 ± 244.01 pmol/kg/min). However, the ISR in T1DM group ( 34.27 
± 73.36 pmol/kg/min) was lower than that in the FCPD group.  
 
MMCT 
FCPD 
 (N=20) 
T2DM  
(N=10) 
T1DM  
(N=10) 
   NORMAL         
    (N=10) 
 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
 
Insulin 
secretion 
rate (AUC) 
358.35 ± 
244.95 
919.67 ±   
244.01 
34.27 ± 
73.36 
984.28 ± 
245.01 
Glucagon 
secretion 
(AUC) 
26686.91 ± 
10302.25 
46277.69 ± 
13970.12 
12516.2 ± 
1074.46 
8222.2 ± 
2037.5 
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 The Glucagon Secretion Rate was calculated separately from the Area 
under the Curve (AUC) for glucagon secretion folloing an oral mixed 
meal challenge test. The AUC for the glucagon secretion rates showed that 
the FCPD  group had greater glucgon secretion rate ( 26686.91 ± 
10302.25) in comparison to the control group (8222.2 ± 2037.5) and 
T1DM group ( 12516.2 ± 1074.46) . The T2DM group, however, had the 
highest glucagon secretion rates ( 46277.69 ± 13970.1) in comparison to 
FCPD as well as the T1DM and control groups. 
Table-9:  COMPARISON BETWEEN THE GROUPS: INSULIN SECRETION RATE (ISR): 
 
Insulin secretion rate (ISR) T1DM T2DM NORMAL 
FCPD  vs 6 6 4 
Wilcoxon W 42 216 214 
Z -3.78 -3.76 -3.86 
Asymp. Sig. (2-tailed) 0.0002 0.00017 0.0001 
Exact Sig. [2*(1-tailed Sig.)]           
(p-value ) 
0.000* 0.000* 0.000* 
 
 Post-Hoc analysis revealed significant differences in Insulin Secretion 
Rate (ISR) between the groups . The FCPD group had a significantly 
reduced ISR (p=0.000) in comparison to the non-diabetic controls and 
T2DM group. However, the ISR in the FCPD group was significantly 
greater than that in the T1DM group (p=0.000) .  
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FIGURE 10 :   Insulin Secretion Rate (ISR) comparison showed that the 
FCPD group had significantly reduced ISR compared to T2DM and non-
diabetic controls , while ISR in the FCPD group was significantly greater than 
the T1DM group 
Table-10:COMPARISON BETWEEN GROUPS : GLUCAGON SECRETION  
 Groups Mean 
Difference (I-J) 
Std. 
Error 
95% Confidence 
Interval 
Significance 
    Lower Upper p-value 
FCPD 
vs 
T1DM 14170.68750* 3529.76 4762.12 23579.25 0.00 * 
 T2DM -19590.77250* 3529.76 -28999.34 -
10182.21 
0.00* 
 NORMAL 18464.73750* 3529.76 9056.17 27873.3 0.00* 
 
 Post-Hoc analysis revealed that the Glucagon Secretion after the mixed 
meal challenge test was significantly greater in the FCPD group (p=0.00) 
than that in the  non-diabetic controls and T1DM group, while being 
FCPD 
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significantly lower than that in the T2DM group (p= 0.00). Overall, the 
T2DM group had the highest levels of Glucagon Secretion followed by the 
FCPD, T1DM and non-diabetic control groups respectively. 
 
FIGURE 11: Comparison of Glucagon Secretion showed that the FCPD group 
had significantly greater glucagon secretion  compared to T1DM and non-
diabetic controls, and significantly reduced glucagon secretion compared to  
the T2DM group 
 
EUGLYCEMIC HYPERINSULINEMIC CLAMP:  
Table-11: INSULIN SENSITIVITY INDICES   
 
(Abbreviations: EGP – Endogenous Glucose Production; Rd :Rate of 
disappearance of glucose) 
 
CLAMP 
INDICES 
  FCPD (N=20) T2DM (N=10)     T1DM (N=10) NORMAL (N=10)        
     
Mean SD Mean SD  Mean SD Mean 
EGP 0.29 0.39 0.5 0.57 EGP 0.29 0.39 0.5 
Rd 8.27 2.09 3.9 1.87 Rd 8.27 2.09 3.9 
FCPD 
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 The data from the Euglycemic Hyperinsulinemic Pancreatic Clamp studies 
were analysed . EGP (endogenous glucose production) was indicative of 
the hepatic insulin sensitivity while Rd ( rate of disappearance of glucose ) 
signified peripheral glucose uptake and in effect peripheral insulin 
sensitivity for all the four groups.   
 Increased EGP was suggestive of reduced hepatic insulin sensitivity  
 The mean EGP (endogenous glucose production) for FCPD group was 
higher than the non-diabetic controls (0.29vs 0.0) while being similar to 
that in the T1DM group (0.4 ± 0.64) and the T2DM group (0.5 ± 0.57) . 
This has been shown below (FIGURE 12): 
 
 
 
 
 
 
 A reduced Rd signified reduced peripheral insulin sensitivity. 
 The mean Rd ( rate of disappearance of glucose ) values for the FCPD 
group (8.27 ± 2.09) was lower than that in the non-diabetic group ( 11.1 ± 
FIGURE 12: Hepatic insulin sensitivity (EGP) in FCPD group was 
significantly lower than non-diabetic controls , while being similar to that 
in the T2DM and T1DM groups. 
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2.97) and T1DM group ( 8.5 ± 1.34) .The Rd in T2DM group ( 3.9 ± 1.87) 
was however higher than the FCPD group. 
 Reduced Rd was suggestive of reduced peripheral insulin sensitivity  
 The distribution of Rd has been depicted below in FIGURE 13: 
 
 
FIGURE 13 : Peripheral  insulin sensitivity (Rd) in FCPD group was 
significantly  lower than non-diabetic controls and T1DM groups, while being 
more than T2DM group. 
 
Table-12:COMPARISON BETWEEN GROUPS : EGP (endogenous glucose production) 
 
FCPD vs T1DM T2DM Normal 
Mann-Whitney U 78 60 18 
Wilcoxon W 288 270 73 
Z -0.97 -1.76 -3.61 
Asymp. Sig. (2-tailed) 0.33 0.08 0.0003 
Exact Sig. [2*(1-tailed Sig.)] 
(p-value) 
0.35 0.082 0.000* 
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 The characteristics of EGP  (endogenous glucose production) in the FCPD 
group was compared with that in the other 3 groups. EGP was an indicator 
of the hepaticinsulin sensitivity. 
 Post-Hoc analysis of the clamp data revealed that the EGP in FCPD group 
was significantly greater than the non-diabetic controls (p= 0.000).  
 The difference in EGP between FCPD group and the T2DM (p=0.08)and 
T1DM group (0.35) did not achieve statistical significance.  
 
Hepatic insulin sensitivity (as indicated by EGP) in FCPD group was 
reduced when compared  to the non-diabetic control group, while it 
was similar to that in the T2DM and T1DM groups  
 
 
Table-13:COMPARISON BETWEEN GROUPS : Rd (rate of disappearance of glucose) 
 
 The characteristics of Rd (rate of disappearance of glucose ) in the FCPD 
group was compared with that in the other 3 groups. Rd was an indicator 
of the peripheral insulin sensitivity. 
 Rd in the FCPD group was significantly lower than the non-diabetic group 
(p=0.01) while it was significantly greater than that in the T2DM group 
(p=0.00).  
 The Rd between FCPD and T1DM group were similar (p=1.00). 
 
FCPD  
vs 
Mean Difference (I-J) Std. Error 
95% CI P - 
value Lower Bound Upper Bound 
T1DM -0.18 0.83 -2.39 2.02 1.00 
T2DM 4.384000* 0.83 2.18 6.59 0.00* 
NORMAL -2.783000* 0.83 -4.99 -0.58 0.01* 
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Peripheral insulin sensitivity (as indicated by Rd) in the FCPD group 
was reduced in comparison to the non-diabetic control group, while 
being similar to the T1DM group.  However, the FCPD group had 
greater peripheral insulin sensitivity than the T2DM group. 
 
ANALYSIS OF FACTORS AFFECTING THE FCPD GROUP: 
FACTORS INFLUENCING INSULIN SECRETION AND SENSITIVITY 
IN FCPD : 
We analyzed a number of factors that could potentially influence insulin secretion 
rate (ISR), Glucagon secretion,  Hepatic insulin sensitivity (EGP) and Peripheral 
insulin sensitivity (Rd) in the FCPD group.  Association with these factors were 
tested using Pearson’s correlation for variables with normal distribution and 
Spearman’s correlation for variables without normal distribution. 
Table-14: FACTORS AFFECTING INSULIN SECRETION RATE (ISR) 
 
(Abbreviations: DOD – duration of diabetes ; TG- triglycerides; Vit .D – vitamin D) 
 
 
 
 
 
 
  Age BMI HbA1c DOD TG HDL LDL VLDL Stool fat Vit.  D 
ISR r 0.452* -0.07 -0.04 0.16 0.26 -0.08 -0.05 0.26 0.28 0.638* 
p 0.05* 0.78 0.86 0.49 0.28 0.74 0.85 0.28 0.23 0.003 
N 20 20 20 20 20 20 20 20 20 20 
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Table-15: FACTORS AFFECTING INSULIN SECRETION RATE (ISR) 
(Abbreviations: EGP-endogenous glucose production ; Rd- rate of disappearance ; 
IMCL- intramyocellular lipid ; EMCL- extramyocellular lipid ; REE – resting energy 
expenditure;HCL – hepatocellular lipid ) 
 Factors like BMI, Hba1c, duration of diabetes, lipid content, body fat 
resting energy expenditure, hepatic and peripheral insulin sensitivity 
did not  affect Insulin Secretion Rate (ISR ) in the FCPD group  
 Serum 25-hydroxy Vitamin D levels (r = 0.638, p = 0.003) (FIGURE 
14) and age of the patients (r=0.452, p=0.05) were signifcantly 
correlated with ISR in FCPD group. 
 
 
 
 
 
 
  EGP Rd IMCL HCL EMCL REE Total Fat 
(%) 
Trunk Fat 
(%) 
ISR r 0.31 -0.28 0.27 -0.12 -0.129 0.11 0.30 0.24 
p 0.18 0.22 0.25 0.61 0.587 0.65 0.20 0.31 
N 20 20 20 20 20 20 20 20 
FIGURE 14:  Scatter plot showing significant correlation between Insulin Secretion Rate 
(ISR) and serum Vitamin D (25-hydroxy) levels in FCPD group  
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Table-16:FACTORS AFFECTING GLUCAGON SECRETION IN FCPD GROUP 
(Abbreviations: DOD – duration of diabetes ; TG- triglycerides; Vit .D – 
vitamin D) 
Table-17:FACTORS AFFECTING GLUCAGON SECRETION IN FCPD GROUP 
 (Abbreviations: EGP-endogenous glucose production ; Rd- rate of 
disappearance ; IMCL- intramyocellular lipid ; EMCL- extramyocellular lipid ; 
REE – resting energy expenditure; HCL- hepatocellular lipid ) 
    
 Factors like age, BMI, Hba1c, duration of diabetes, lipid profile , body 
fat, resting energy expenditure, insulin secretion rate , hepatic and 
peripheral insulin sensitivity did not  affect Glucagon Secretion in the 
FCPD group 
 REE (Resting energy expenditure)  (r=0.556, p=0.01) was significantly 
correlated with Glucagon secretion in the FCPD group.  
  Glucagon Age BMI DOD HbA1c Total 
Fat 
(%) 
Trunk 
Fat 
(%) 
TG HDL LDL VLDL 
 r -0.29 -0.29 -0.14 -0.07 -0.33 -0.34 -0.14 -0.15 -0.09 -0.14 
p 0.22 0.21 0.57 0.77 0.16 0.15 0.56 0.52 0.70 0.56 
N 20 20 20 20 20 20 20 20 20 20 
Glucagon EMCL REE Stool fat Vit D EGP Rd IMCL HCL ISR 
 r 0.06 0.556* 0.17 0.14 -0.20 -0.31 -0.34 -0.22 -0.08 
p 0.81 0.01 0.48 0.56 0.41 0.19 0.14 0.36 0.73 
N 20 20 20 20 20 20 20.00 20.00 20.00 
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Table-18: FACTORS AFFECTING EGP (endogenous glucose production) 
and Rd (rate of disappearance of glucose) 
 
(Abbreviations: DOD – duration of diabetes ; TG- triglycerides; Vit .D – vitamin D) 
 
Table-19: FACTORS AFFECTING EGP and Rd  
(Abbreviations: EGP-endogenous glucose production ; Rd- rate of 
disappearance ; IMCL- intramyocellular lipid ; EMCL- extramyocellular lipid ; 
REE – resting energy expenditure HCL – hepatocellular lipid). 
  EMCL REE Total 
Fat (%) 
Trunk 
Fat (%) 
Stool fat IMCL HCL 
EGP r 0.536* 0.02 -0.27 -0.08 -0.02 -0.26 0.04 
p 0.01 0.92 0.24 0.73 0.95 0.27 0.86 
N 20 20 20 20 20 20 20 
Rd r 0.21 0.04 0.26 0.38 -0.12 0.01 -0.01 
p 0.36 0.86 0.27 0.09 0.63 0.95 0.95 
N 20 20 20 20 20 20 20 
  Age BMI DOD HbA1c TG HDL LDL VLDL Vit D 
EGP r 1.00 -0.18 -0.268 -0.12 -0.16 -0.31 -0.26 -0.26 -0.07 
p 0.46 0.44 0.254 0.62 0.51 0.19 0.27 0.27 0.75 
N 20 20 20 20 20 20 20 20 20 
Rd r -0.18 1.00 0.020 -0.21 -0.04 0.19 0.01 0.01 0.36 
p 0.44 0.56 0.932 0.36 0.88 0.43 0.95 0.95 0.12 
N 20 20 20 20 20 20 20 20 20 
Results and Analysis  
 
 
 
 
 
 While most of the factors had no significant correlation with EGP 
(endogenous glucose production) or  Rd (rate of disappearance of 
glucose)  in the FCPD group, EMCL (extramyocellular lipid) (r=-0.536, 
p=0.01) had significant correlation with  EGP (endogenous glucose 
production) in the FCPD group.   
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DISCUSSION: 
We performed a comprehensive study on the metabolic characteristics of an 
unique group of male subjects with Fibrocalcific Pancreatic Diabetes (FCPD). In 
this group, we evaluated the various aspects of body compostion,   hepatic and 
muscle lipid content, insulin and glucagon secretory capacities and peripheral and 
hepatic insulin sensitivity.  
We compared these metabolic parameters with that in male subjects with Type 1 
Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus(T2DM) and non-diabetic 
healthy controls . We also analyzed the different factors affecting insulin secretion 
and sensitivity in FCPD subjects.  Our study comprised of 20 FCPD subjects, 10 
T1DM subjects , 10 T2DM subjects and 10 non-diabetic age and BMI matched 
controls. 
The baseline demographic characteristics were: 
 The mean age (SD) of the FCPD group was 30.3(± 6.62 )  years which was 
similar to the T1DM and non-diabetic control groups but as expected lower 
than the mean age of the Type 2 Diabetes group.  The age of presentation of 
diabetes in FCPD has been classically described to be between 20-40 years9 
and hence the mean age of our population is in keeping with that observation.  
 The mean(SD) BMI of the FCPD group was 19.8 ( ± 2.99) kg/m2   which was 
similar to the T1DM group and the non-diabetic controls. The lean BMI of 
individuals with FCPD have been a striking feature in previous studies on this 
disease . Yajnik and Shelgikar127 followed up a fifty-five FCPD patients in 
Pune, India over a period of six years and reported their clinical and 
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biochemical features. They found a mean BMI of 17 kg/m2 in their FCPD 
subjects as compared to a mean BMI of 15.7 kg/m2 in the T1DM group, while 
the mean BMI of the control group was 23 kg/m2 in their study. Moreover, 
they also found clinical signs of malnutrition in six FCPD subjects and 
cachexia in seven of them .  Mohan and colleagues have also reported similar 
experience from their studies on FCPD subjects10. The higher mean BMI of 
the T2DM group in our population was also expected as T2DM subjects have 
been classically found to be overweight or obese 4 .  
 Comparing the Hba1c amongst the different study groups , they were found to 
have similar Hba1c although it ranged from 8-10 %. This was intentionally 
kept as an inclusion criteria to have a homogenous population with respect to 
glycemic control . Since it is well-known that glucotoxicity itself can affect 
the insulin sensitivity 128, people with very good (Hba1C < 7%)  or poor 
(Hba1c >11%) glycemic control would have affected the insulin sensitivity 
measures in our study. By choosing a population with stable and good-to-
moderate glycemic control we have negated the possibility of such 
heterogenous results. Moreover, all the subjects were admitted at least twenty-
four hours prior to the clamp study and a prolonged period of (>12hrs) insulin 
infusion was started in all the diabetic subjects . This has been shown in 
previous studies to account for any effect of acute hyperglycemia on the 
insulin sensitivity measures129. 
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The key findings from our study were : 
A) EUGLYCEMIC  PANCREATIC CLAMP STUDIES : INSULIN 
SENSITIVITY: 
 Findings from our study : 
 Our study has used the technique of Euglycemic- Hyperinsulinemic 
Pancreatic clamps to separately evaluate hepatic and peripheral insulin 
sensitivity in FCPD subjects. The measures of EGP (endogenous glucose 
production) and Rd (rate of disappearance of glucose) were assessed and were 
indicative of the hepatic and peripheral insulin sensitivity respectively. The 
results showed that the Hepatic insulin sensitivity in the FCPD group was 
significantly lower than the normal group and was  similar to that in the 
T1DM group . Peripheral insulin sensitivity in the FCPD group was 
significantly lower than the normal group while being similar to T1DM group. 
Thus, the FCPD group when compared with the non-diabetic controls, had 
evidence of both hepatic and peripheral insulin resistance. Moreover, both 
FCPD and T1DM seemed to have similar levels of hepatic and peripheral 
insulin sensitivity. At the same time, the T2DM group, as conventional 
literature suggests, were the most insulin resistant out of the four groups , both 
at the hepatic and peripheral levels .   
 Insulin sensitivity in FCPD : previous evidence : 
 Traditionally, the loss of beta-cell mass and defect in insulin secretion were 
thought to be the core of the aetiopathogenic mechanisms of FCPD.  Over the 
past decade or so there has been attempts at studying insulin resistance in 
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FCPD subjects. Mohan and colleagues 114 assessed Insulin resistance by 
Insulin Tolerance Test (ITT) in twelve  patients with FCPD, and found 
evidence of insulin resistance which was is similar to that seen in ten Type 2 
Diabetes  patients and greater than  twelve age and sex matched control 
subjects. In another study in  thirty-one consecutive patients with FCPD , Singla 
and colleagues 115 found insulin resistance as evidenced by abnormal  HOMA-
IR (>2) in 24 in 77.4%  of the subjects .   
 Hyperinsulinemic clamps in chronic pancreatitis: indirect evidence: 
 Though none of the previous studies have utilized the gold-standard technique 
of  hyperinsulinemic clamps in FCPD subjects , there have been few studies 
which have looked at insulin sensitivity in chronic pancreatitis 114  and their 
findings may provide an indirect evidence of insulin resistance in these 
subjects. In a Polish study 130 study involved thirty patients (mean age 50.83 
±6.61 years; 23.33% women, 76.66% men) diagnosed with chronic 
pancreatitis (using imaging tests), insulin sensitivity with regard to the 
coexistent obesity, dyslipidemia, and arterial hypertension was measured 
using the euglycemic hyperinsulinemic clamp method. Most of these patient 
had pre-existing history of alcoholism and none of them  had  classical FCPD 
features. The researchers  have looked at whole-body insulin sensitivity and 
not at hepatic and peripheral insulin sensitivity separately.  Their findings 
showed that insulin resistance was present in 22 patients (73.33%), in whom a  
higher prevalence of diabetes (77.27% vs. 62.5%) and prediabetes (13.63% 
vs. 12.5%) was observed. Further, they found lack of correlation between 
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insulin sensitivity and metabolic syndrome components in these patients, 
suggesting that insulin resistance maybe related to primary disease or an 
additional mechanism underlying pancreatic diabetes operates. 
 Mechanisms for insulin resistance in FCPD : 
 Mechanisms leading to insulin resistance in FCPD are scarcely explained in 
literature. However studies in chronic pancreatitis (predominantly 
alcoholic) 41 have identified  . Three major mechanisms have been proposed to 
cause the hepatic insulin resistance in chronic pancreatitis   : The endocytosis 
of hepatic Insulin Receptor linked to the endocytosis of the glucose 
transporter 2 (GLUT-2) from the hepatocyte plasma membrane110 ,  a loss of 
hepatic insulin receptor (IR) expression/availability and impairment in hepatic 
IR function95 .Further  studies have also implicated impaired pancreatic 
polypeptide  (PP) secretion as a possible mechanism. Animal and clinical 
studies 44 have suggested a role for PP in satiety and in regulation of 
pancreatic exocrine and biliary secretion 111. It has since been shown to play a 
role in glucose homeostasis through its mediation of hepatic sensitivity to 
insulin by means of its regulation of hepatic insulin receptor (IR) gene 
expression and hepatocyte IR availability. In a study in five human 
subjects 113  with chronic pancreatitis, it was seen that hepatic insulin 
sensitivity as measured by an euglycemic-hyperinsulinemic clamp, was 
significantly improved form baseline after infusion of pancreatic polypeptide . 
This was associated with a lower mean fasting plasma glucose after checked 
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after a month of the infusion. Thus the authors postulated a role for pancreatic 
Polypeptide in predominantly affecting the hepatic insulin sensitivity. 
 
 Findings of  hepatic and peripheral insulin resistance in FCPD in our 
study  point to a paradigm shift in the evolution of diabetes in FCPD. 
The use of hyperinsulinemic clamps in our study has also helped in 
analyzing the insulin sensitivity at the hepatic and peripheral levels 
independently, as opposed to previous studies that have focussed 
mainly on whole-body insulin sensitivity. Elucidation of these 
mechanisms in FCPD subjects and larger studies evaluating insulin 
resistance in FCPD subject can have a potential therapeutic role in 
future. 
 
B) MIXED MEAL CHALLENGE TEST : GLUCAGON SECRETION : 
 Findings from our study : 
 Glucagon Secretion after the mixed meal challenge test was significantly 
greater in the FCPD group than that in the non-diabetic controls and T1DM 
group, thus suggesting a significant degree of hyperglucagonemia in subjects 
with FCPD when compared to age and BMI-matched T1DM and normal 
subjects.  This is an intriguing finding as FCPD has traditionally been 
considered to be a secondary form of diabetes associated with global 
destruction of alpha and beta-cells of the pancreas. Our findings are contrary 
to this view and suggest a preserved alpha-cell function in FCPD. At the same 
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time, T2D subjects had the highest levels of glucagon in comparison to the 
other three groups, which is consistent with recent scientific evidence of 
hyperglucagonemia as a contributing factor in T2DM 131.  
 Glucagon secretion in FCPD : previous evidence : 
 Interestingly, previous studies on glucagon secretion in FCPD subjects are 
dichotomous. While Rao and colleagues 121 have demonstrated a fall in 
glucagon levels following an oral glucose load in FCPD subjects, Yajnik et 
al  122 in their studies in twenty-eight FCPD subjects have depicted a 
preserved glucagon response. Similarly Mohan and colleagues 120 have also 
reported similar glucagon response in FCPd subjects when compared to a 
group of non-diabetic controls. The preserved glucagon response also raises 
the possibility of hyperglucagonemia playing a role in the pathogenesis of 
diabetes in FCPD. In recent years, studies in Type 2 Diabetes mellitus have 
suggested a bihormonal abnormality 131 whereby both hyperinsulinemia and 
hyperglucagonemia act as mutual activators which in turn dysregulate the 
glucose metabolism in T2DM . Whether the hyperglucagonemia can have a 
similar role in  perpetuating the insulin resistance in FCPD subjects needs 
further scientific corroboration in larger studies.   
 Glucagon secretion and Resting energy expenditure (REE): 
 Our study has also shown a significant correlation of glucagon levels in FCPD 
subjects with the resting energy expenditure.  Although a novel finding in 
these group of diabetic patients, the role of glucagon in regulating energy 
expenditure has been elaborately studied in Type 2 Diabetes Mellitus 132 and 
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non-diabetic obese subjects133. Early studies by Davidson et al.133  in rats, 
showed that pharmacological infusion of glucagon increased oxygen 
consumption in rats. Tthis effect was mirrored by a report in human study 
participants, in whom infusion of a pharmacological dose of glucagon 
increased resting energy expenditure during acute insulin deficiency produced 
by the additional infusion of  somatostatin 134  .  Further studies conducted in 
vitro showed that hyperglucagonemia may increase energy expenditure via 
stimulation of oxygen consumption and heat production in brown adipose 
tissue 135.   
 Studies have also suggested a pivotal role of  the sympathetic nervous system 
in regulating glucagon-induced thermogenesis 136. Taken together, these 
findings if  further corroborated in FCPD subjects can point to an integral role 
of glucagon in not only glucose metabolism but energy expenditure in these 
subjects. 
 
 The significantly elevated levels of glucagon following a mixed meal 
challenge in the FCPD subjects is one of the most important findings 
from our study. Not only does it contradicts the traditional notion of 
global pancreatic destruction in FCPD , but also raises the exciting 
possibility of hyperglucagonemia being a major factor in the evolution 
of diabetes in these group of people. If substantiated in larger studies, 
it would be worthwhile to look into the incretin axis as well in FCPD 
and could very well help in exploring novel therapeutic options. 
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C) 1-H-NMR  SPECTROSCOPY: MUSCLE AND HEPATIC LIPID 
CONTENT: 
 Findings from our study : 
 Analysis of the 1-H-NMR Spectroscopy data showed that the IMCL 
(Intramyocellular lipid) , EMCL (Extra-myocellular lipid) and HCL 
(Hepatocellular lipid) in the FCPD group were similar to the T1DM group.  
Further, the FCPD subjects had significantly lower EMCL and IMCL than the 
non-diabetic controls.  Moreover, EMCL in the FCPD group was found to 
have a significant correlation with the Endogenous Glucose Production (EGP) 
,latter being indicative of the hepatic insulin sensitivity. The differences in 
EMCL and HCL between the FCPD and T2DM group, though statistically 
significant , were expected .given the inherent differences in weight and BMI 
between the two groups 
 Muscle and Hepatic fat and insulin sensitivity : 
 This is the first study to have explored hepatic and muscle lipid content 
utilizing NMR-spectrosocpy in FCPD subjects. Currently, the ectopic 
deposition of fat in non-adipose tissue is considered an important aspect in 
development of insulin resistance 137 . In muscle tissue, lipids are stored either 
as interstitial adipocyte triglycerides (termed extramyocellular lipids 
[EMCLs]) or as intramyocellular lipids (IMCLs), accumulating as droplets in 
the cytoplasm of muscle cells. Muscle triglycerides themselves do not seem to 
interfere directly with insulin action in the myocytes but rather to act through 
some other fatty acid– derived metabolite to impair insulin signaling.  
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Longchain fatty acyl-CoAs have been suggested as possible candidates 138 .  
Recent data indicate a strong correlation between accumulation of IMCLs and 
insulin sensitivity in humans, not only in diabetic patients but also in glucose-
tolerant and-intolerant individuals with or without obesity 139 .  An unifying 
hypothesis involving accumulation of diacylglycerol within insulin-sensitive 
tissues, activation of novel Protein Kinase C and interference with insulin 
signalling have been proposed 140.  
 However, till now EMCL has  been considered to be metabolically relatively 
inert141 and there have been no studies implicating its’involvement in insulin 
sensitivity. Thus the finding of EMCL having a significant impact on hepatic 
insulin sensitivity (EGP) is a novel finding that needs to be looked at both 
mechanistically and pathogenetically  in larger studies. 
 The evaluation of hepatic and muscle (intramyocellular and 
extramyocellular)lipid content in FCPD subjects utilizing Magnetic 
Resonance Spectrosopy has not been attempted before. Presence of 
reduced EMCL and IMCL in the FCPD subjects in comparison to 
non-diabetic controls and the possible role of EMCL in regulating 
insulin sensitivity in FCPD needs to be looked at greater detail in 
future larger studies. Ectopic fat deposition could hold the key to the 
pathogenesis of diabetes in FCPD. 
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The additional findings from our study were : 
Apart from the three major aspects discussed previously, there were certain 
additional findings that helped us in understanding the demographic profile, body 
composition and energy expenditure patterns in FCPD better.These findings were-  
Body composition parameters: 
 The data from the DXA studies have shown that the truncal and peripheral fat 
content, including the upper and lower limb fat are significantly lower in the 
FCPD group than the T2DM group. When we compared the central to peripheral 
fat ratio, the findings were similar. Lean body mass(g) was also significantly 
lower in FCPD subjects than in T2DM and even the normal control groups. 
However  , the body composition parameters in the FCPD and T1DM groups 
were similar. This has been seen in previous studies in FCPD subjects. 
Padmalayam and colleagues91 in their study in thirty-five males with FCPD , 
compared skin-fold thickness, mid upper-arm circumference and fat mass with 
that in thirty-seven and forty-seven Type 1 DM and Type 2 DM subjects 
respectively. They found similar anthropometric measures and fat mass  indices in 
FCPD and Type 1DM subjects , while they were significantly lower than the Type 
2 DM subjects. Singla and colleagues115 in their study in thirty-one FCPD 
subjects had used Bio-impedance techniques to measure body fat . They have also 
reported similar findings in the FCPD subjects, in addition to which they have 
also found an interesting correlation between body fat % and insulin sensitivity 
indices (measured by HOMA-IR technique).  Our study however did not find any 
such correlation between the total or truncal fat content and insulin sensitivity 
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indices. However, it must also be considered that none of the previous studies in 
FCPD subjects had used DXA scan as the method for determining body 
composition, neither have euglycemic –hyperinsulinemic clamps been used 
previously in FCPD subjects . Thus the difference in methodology with the 
previous studies can explain the variations in the results obtained.  
Indirect calorimetry : energy expenditure indices: 
 Indirect calorimetry was used to analyze  Resting Energy Expenditure (REE) in 
the study subjects. The REE in the FCPD group was similar to the T2DM group 
and slightly lower than the T1DM group. However, these differences failed to 
achieve any statistical significance. Even after adjusting for BMI (p=0.98) and 
fat-free mass (p=0.69), the REE between the study groups was similar. Accurate 
determination of  energy expenditure in a person with diabetes mellitus is a vital 
element in the disease pathogenesis. While studies in T2DM and T1DM9 have 
shown significant contribution of REE to the metabolic milieu , only few studies 
are available on the energy expenditure in subjects with chronic pancreatitis. 
Dickerson et al 125 assessed the REE in a small group of hospitalized patients 
with chronic pancreatitis without diabetes. Another study by Hebuterne et 
al 124  assessed the REE in patients with alcoholic chronic pancreatitis. The REE 
in ambulant, non-alcoholic subjects with pancreatitis and diabetes has been 
scarcely studied so far. Behera and colleagues 126 carried out Indirect 
Calorimetry studies in fifty-one male subjects with FCPD. On comparison with 
Type 2 Diabetes subjects, they found no differences in the unadjusted REE 
which is similar to our findings. However, on adjusting for BMI, their study had 
Discussion  
 
92 
 
a shown a significant increase in REE in the FCPD group as compared to the 
Type 2 Diabetes group. Our study however has not found any significant 
differences in energy expenditure between the study groups. 
Mixed Meal challenge test : Insulin Secretion Rate (ISR) : 
 Insulin Secretion Rate (ISR) in our study population was evaluated by 
deconvolution technique from serial C-peptide measurements following a mixed-
meal challenge test . The ISR in the FCPD group was significantly reduced in 
comparison to the T2DM and non-diabetic control groups. However, the ISR was 
significantly greater than that in the T1DM group.  Insulin secretion in FCPD has 
been studied by various techniques in different studies. In two separate studies 
performed by Vannasaeng et al 107 and Merhotra et al 108, the Insulin secretion 
was significantly reduced in FCPD subjects in comparison to Type 2 diabetes 
patients. These studies109  have further showed partial preservation of beta-cell 
secretory functions, as evidenced by greater insulin secretion than Type 1 
Diabetes patients. These findings are similar to that in our study.  
 Our results have also shown a significant correlation of Insulin secretion rate 
(ISR) with serum Vitamin D levels. Over the last decade, numerous nonskeletal 
disease associations have been reported with vitamin D deficiency, including type 
2 diabetes mellitus (T2DM). 
 Multiple studies have shown association between Vitamin D levels and insulin 
resistance as well as insulin secretory defects.142,143   Studies have shown that 
pancreatic β-cells depend on an acute intracellular calcium144increase for insulin 
secretion which may be attenuated with elevated cytosolic calcium seen with 
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Vitamin D deficiency secondary to increased PTH levels,145. Sustained  elevations 
of intracellular calcium leading to  interference with insulin-stimulated tyrosine 
phosphorylation and PI3-kinase activation 146,147 has also been studied as possible 
mechanisms. Despite  the mechanistic evidence, numerous cross-sectional or 
prospective studies have failed to show conclusive evidence of a direct link of 
Vitamin D levels with insulin secretion and sensitivity 148. Inherent flaws in the 
study designs, mutiple confounding factors and lack of large, randomized 
controlled studies have futher clouded the scenario.  Role of Vitamin D in 
influencing insulin secretion in FCPD has not been explored previously. Given 
the increased predisposition to Vitamin D deficiency in these subjects owing to 
the pancreatic exocrine insufficiency, further studies in larger populations might 
throw light on this intriguing association. 
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SUMMARY AND CONCLUSIONS: 
A total number of fifty subjects which included 20 Fibrocalcific Pancreatic 
Diabetes (FCPD), 10 Type 1 Diabetes Mellitus (T1DM), 10 Type 2 Diabetes 
Mellitus(T2DM) and 10 non-diabetic (Normal) age and BMI-matched healthy 
controls , were included in this study over a period of one year from 2013-2014 . 
   
To summarize our conclusions at the end of our analysis : 
 Hepatic insulin sensitivity in the FCPD group was significantly lower than 
the non-diabetic controls and was similar to that in the T1DM group .  
 Peripheral insulin sensitivity in the FCPD group was significantly lower 
than the non-diabetic controls while being similar to T1DM group.   
 Thus, the FCPD group when compared with the non-diabetic controls, had 
evidence of both hepatic and peripheral insulin resistance.  
 Moreover, both FCPD and T1DM seemed to have similar levels of hepatic 
and peripheral insulin sensitivity.  
 
 Glucagon Secretion after the mixed meal challenge test was significantly 
greater in the FCPD group than that in the non-diabetic controls and 
T1DM group 
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 Thus, there is significant hyperglucagonemia in subjects with FCPD when 
compared to age and BMI-matched T1DM and non-diabetic controls.  
 Glucagon secretion was further significantly correlated with Resting 
Energy expenditure in the FCPD group. 
 
 EMCL (Extra-myocellular lipid) and HCL (Hepatocellular lipid) in the 
FCPD group were similar to the T1DM group.   
 FCPD subjects had significantly lower EMCL and IMCL than the non-
diabetic controls.   
 EMCL in the FCPD group was found to have a significant correlation with 
the Endogenous Glucose Production (EGP) , latter being indicative of the 
hepatic insulin sensitivity.  
 
 
 Insulin Secretion Rate (ISR) in the FCPD group was significantly reduced 
in comparison to the T2DM and non-diabetic control groups.  
 
 ISR in the FCPD group was significantly greater than that in the T1DM 
group. 
 
 ISR in the FCPD group was found to have a significant correlation with 
serum 25-hydroxy-Vitamin D levels.  
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 Total fat (%), Truncal fat (%), Fat in arms (%), Fat in legs (%) and Central 
to peripheral fat ratio was significantly lower in FCPD group compared to 
the T2DM group but was similar to the T1DM group. 
 
 
 Resting Energy Expenditure (REE) in the FCPD group was similar to that 
in the T1DM and T2DM groups. 
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RECOMMENDATIONS AND FUTURE SCOPE : 
Based on the salient findings from our study, we would like to propose the 
following areas of future research that can have diagnostic and therapeutic impact 
in subjects with Fibrocalcific pancreatic diabetes (FCPD): 
 Insulin-sensitizers might prove to be a vital addition to the therapeutic options 
for treating FCPD , if the role of hepatic and peripheral insulin sensitivity is 
further elucidated 
 Presence of hyperglucgonemia, if  further substantiated ,can be a potential target 
of treatment in FCPD  
 Defining the Role of incretins in affecting insulin secretion and insulin 
resistance in FCPD can prove to be invaluable in understanding disease 
pathogenesis. 
 Intramyocellular, extramyocellular and hepatic fat need to be assessed 
individually as each can have  unique effects on glucose metabolism in FCPD  
 Resting energy expenditure and its accurate estimation can have both 
pathogenetic and therapeutic implications. 
Limitations  
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LIMITATIONS OF THE STUDY 
 
Stable isotope studies to perform metabolism of amino-acids could also have been 
done to make the studies more comprehensive, however there were limitations in 
funding which made this difficult to perform.  
 
Because of the low prevalence of Fibrocalcific Pancreatic diabetes in the general 
population, it is difficult to get an ethnically homogenous study population across 
all the groups. However, we have tried to maintain the same ethnic background 
for all the study groups as far as practicable. 
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DEPARTMENT OF ENDOCRINOLOGY, DIABETES AND 
METABOLISM 
CHRISTIAN MEDICAL COLLEGE, VELLORE. 
 
INFORMED CONSENT AND PATIENT INFORMATION SHEET 
 
PATIENT INFORMATION SHEET 
 
1.You are being asked to join this research study.  
The title of the study is:  
 
A COMPREHENSIVE STUDY ON METABOLIC CHARACTERISTICS 
IN SUBJECTS WITH FIBROCALCULOUS PANCREATIC DIABETES 
FROM INDIA  
 
The study is being done under the supervision of:  
 
Principal Investigator: DR. RIDDHI DASGUPTA 
Designation of Principal Investigator: PG SENIOR REGISTRAR 
Employment Number: 20917 
Address for communication (including telephone and fax numbers and email id):  
Dept of Endocrinology, Diabetes and Metabolism, 
Christian Medical College, Vellore 
Tamil Nadu- 632004. 
Phone: +91-416-2282528, +91-9585169862 
e.mail ID: riddhi_dg@rediffmail.com 
   
DO I HAVE TO TAKE PART IN THIS RESEARCH STUDY?  
Your participation is voluntary. This means that you decide whether or not you 
want to join the study after speaking with the researcher, or other member of the 
research team.  If you decide to take part you will be asked to sign this consent 
form. Your signature  means that you agree to be a subject in this research.  
After reading this form and having a discussion about what it says, you should ask 
all the questions you want to ask. You should take as much time as you need 
tomake a decision.  If you do not understand some of the terms used in this form, 
ask the person who is discussing the study with you to give any additional 
information that may make this easier to understand.  
You do not have to consent to participate in the study immediately, or ever. Take 
time to decide whether or not you wish to join. You may take home a copy of this 
consent form to think about it or discuss the information with family or friends 
before you decide.  
If you decide not to participate the care providers at this facility will give you all 
of the standard care that is appropriate for you. You will be given a copy of this 
form whether or not you agree to participate in this study.  
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Do not sign the form unless you have had all your questions answered and 
understand exactly what is involved. If you decide to take part you are still free to 
withdraw at any time without giving a reason. This will not affect your care and 
you will continue to be treated at this facility.  
   
If you decide to withdraw after receiving the study drug, you should talk with the 
research study doctor to see how best to complete the withdrawal process.  
   
 
The form discusses:  
a) WHAT THE RESEARCHERS WILL LEARN FROM THE RESEARCH  
 
b) WHAT WILL HAPPEN TO YOU DURING THE RESEARCH  
 
c)  WHAT RISKS AND/OR DISCOMFORTS YOU 
MIGHT  EXPECT/EXPERIENCE 
 
d) AS A RESEARCH SUBJECT IF YOU CAN EXPECT ANY BENEFITS, 
AND ARE THERE ANY ALTERNATIVES TO THIS RESEARCH FOR 
YOUR CONDITION.  
 
STUDY SPECIFICS : 
   
The purpose of this research is to study the physiological role of insulin in 
regulating the metabolism of glucose and fat in people with fibrocalculous 
pancreatic diabetes and to understand the body composition in these individuals 
and their relation with insulin mediated glucose metabolism. 
   
WHY HAVE I BEEN ASKED TO TAKE PART IN THIS RESEARCH 
STUDY?  
   
You are being asked to participate as a subject (case) with Fibrocalculous 
Pancreatic Diabetes (FCPD).   
If you agree to take part in this study you will have tests and examinations to be 
sure that you qualify for the study.  
   
WHY IS THIS RESEARCH STUDY BEING DONE?  
 
This research is being done to characterize body composition and liver fat 
deposition in individuals with fibrocalculous pancreatic diabetes , to characterize 
insulin’s ability to regulate metabolism of glucose and fat in people with 
fibrocalculous pancreatic diabetes,  and to assess the response of insulin and 
glucagon secretion to a meal challenge in people with fibrocalculous pancreatic 
diabetes.  
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 HOW MANY PEOPLE WILL TAKE PART IN THE RESEARCH 
STUDY?  
 
You will be one of approximately 20 patients with FCPD who will be 
participating in this study.  
The study will be conducted at Christian Medical College, Vellore.  
   
WHAT WILL HAPPEN IF I TAKE PART IN THIS RESEARCH STUDY?  
   
You will undergo medical testing to determine your eligibility at the Clinical 
Research  
Center (CRC), located at Department of Endocrinology Diabetes and Metabolism, 
Christian Medical College, Vellore-632004.  
   
This visit will include a full history and physical examination, a mixed meal test, 
and additional laboratory tests to determine eligibility, as well as a urine test and 
blood pressure measurements. An ECG will be performed at the screening visit as 
well.  
 
For the screening you will have to come to the CRC after you have not eaten any 
food from 11 pm the night before (fasting), therefore the visits will be scheduled 
in the morning.  
 
The mixed meal test will consist of drinking a sugary soda and having your blood 
drawn before and 3 hours afterwards. Physical examination will include a careful 
assessment of the veins in your arms, measurement of height, weight and waist 
circumference and percent body fat. 
 
Also, additional blood tests (about 2 tablespoons) may be drawn in order to do 
other laboratory tests. You will receive of copy of the laboratory results from the 
screening visit.  
   
If you meet all eligible study criteria, you will be invited to participate in the 
study. There  
will be about 20 patients with FCPD participating in this study and it is important 
that you complete all parts of the study. You will meet with study personnel to 
discuss dietary  
recommendations. You will be instructed to follow a standardized diet plan and 
asked to refrain from vigorous exercise for three days prior to each clamp study. 
A “clamp study” is a procedure where you will be given hormones in the veins 
(somatostatin, insulin, growth hormone and glucagon), in doses based upon your 
weight, in order to maintain normal glucose levels.  
   
In addition, if you experience any side effects you will asked to come to the CRC 
to be examined by study physicians.  
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For the clamp study, you will have to come to the CRC on the evening prior to the 
study. You will receive an early dinner in the hospital and then remain fasting 
after 10:00 pm. An intravenous catheter will be placed in your arm and you will 
receive an insulin infusion starting at 3:00 am in order to bring your blood sugar 
to normal levels. 
   
At 8:00 am a second small plastic tube (intravenous catheter) will be placed in 
your other arm. One catheter is used for infusions and one for blood sampling. 
The amount of blood drawn is approximately half a pint. One arm will be warmed 
in a heated blanket and maintained at approximately 65• C (149• F) to keep the 
veins enlarged for blood draws. You will be able to move your arm.  
   
Your blood glucose levels will be controlled by giving insulin and glucose 
(sugar). A special glucose compound will be given in small amounts continuously  
throughout the study. Your blood sugar level will be maintained throughout the 
study at a  
level of 90 mg/dl. Other medicines will be added to the glucose; somatostatin, 
insulin, glucagon and growth hormone. All these hormones help control blood 
sugar.  
   
Blood will be drawn at 5-15 minute intervals for the 6-hour study period. You 
will be lying in bed for approximately 8 hours until the intravenous lines or 
catheters are in place. Your urine may be collected at the end of the study. At the 
end of the study your blood sugar levels will be kept at normal levels and you will 
be given a meal.  
   
These visits will be approximately 6-8 hours long and may include an 
examination of your muscle strength and joints.  
  
You will be interviewed by a member of the study team to review any symptoms 
and undergo complete physical examination including muscle strength and joints. 
Blood tests and urine tests will be done to check for any adverse effects. These 
visits should last about 1.5 hours.  
   
   
WHAT ELSE DO I HAVE TO DO?    
   
You must tell the research study doctor about any past and present diseases or 
allergies  
You are aware of and about all medications you are taking including over-the-
counter  
Remedies and nutritional supplements or herbs.  
     
If any other doctor recommends that you take any medicine, please inform 
him/her that  
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you are taking part in a research study. You should give the other doctor the 
research study doctor's name and phone number.  
   
You may carry out all your normal daily activities.  
   
WHAT ARE THE POSSIBLE SIDE EFFECTS, DISCOMFORTS, RISKS 
OR  
INCONVENIENCES I CAN EXPECT FROM BEING IN THIS 
RESEARCH STUDY?  
 
Here is a list of the known risks associated with this drug/device/research:  
 
1. Blood withdrawal: The total amount of blood drawn from your body will not 
exceed 190 ml per person, which less than half of that donated by a blood donor.  
2. 20% dextrose: The infusion of 20% dextrose may cause local irritation and 
itching and redness at the site of injection. This will be minimized by use of the 
antecubital vein of the forearm which has a large diameter and will reduce the 
irritation in the veins. 
3. 6,6 Deuterated glucose: 6,6 Deuterated glucose is a stable isotope and therefore 
there will be no radiation exposure.  
4. Glucagon infusion in high doses can cause abdominal symptoms such as 
cramps and nausea, and produce high sugars in persons with impairment of 
glucose metabolism. The doses to be employed here are intended to maintain 
plasma glucagon at basal levels.  
5. Growth Hormone: At higher doses and for prolonged periods of exposure, 
growth hormone (rhGH) has either insulin-like or effects that are opposite to 
insulin on carbohydrate and lipid metabolism. However the proposed infusion is 
for replacement at levels normally required by the body and hence no such side 
effects are expected. 
6. Hypoglycemia: Hypoglycemia (low blood sugar) - The risk of using insulin 
therapy includes hypoglycemia (or low blood sugar). In order to minimize this 
risk, blood glucose levels will be checked frequently. Symptoms of low blood 
sugar include dizziness, fainting, lightheadedness. If hypoglycemia is noted, 20% 
dextrose will be infused to maintain blood glucose levels.  
7. Somatostatin at the proposed physiological replacement doses has no known 
side effects.  
8. DEXA: No complications are expected with the DEXA procedure, as the 
dosage of radiation is minimal. Pregnant women are excluded from study to 
reduce this radiation exposure.  
9. MRI AND NMR Spectroscopy: The present study does not constitute a 
significant risk study. Subjects may experience sense of suffocation in MR 
scanner and main complaint of noise and feeling cold.  
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ARE THERE LIKELY TO BE ANY BENEFITS TO TAKING PART IN 
THIS RESEARCH STUDY?  
   
This study will be of direct benefit to you. It will help you gain a better 
understanding of your own metabolic processes.  
   
The study can also be of benefit to others. It could lead to increase our 
understanding of fibrocalcific diabetes and help direct future therapy for such 
patients in the future. 
   
WHAT OTHER CHOICES DO I HAVE IF I DO NOT TAKE PART IN 
THIS  
RESEARCH STUDY?  
 
You may choose not to participate in this study.  
   
WHO MAY SEE MY RECORDS?  
 
The research records will be kept private and your name will not be used in any 
written or verbal reports.  
   
Your research records and medical records may be inspected by members of the 
research team. As this research involves a drug or device, the U.S. Food and Drug 
Administration (FDA), the agency for regulating the drugs, may inspect your 
research records and medical records.  
   
The researcher and research staff will review your medical records and will keep 
the information private.  
   
The research records will be kept in a secured manner and computer records will 
be password protected.  
   
The research records will be kept in a secured manner and computer records will 
be password protected in the Department of Endocrinology Diabetes and 
Metabolism,Christian Medical College,Vellore.  
   
The Clinical Research Center staff, as well as the research personnel authorized 
by the researcher will have access to these records.  
   
The people who reviewed this research study as members of the Christian 
Medical College Institutional Review Board (IRB) may also review your research 
and medical records.  
   
The Office of Human Research Protections (OHRP) may also review your 
research study records.  
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All of these groups have been requested to keep your name private.  
   
WHO CAN ANSWER MY QUESTIONS ABOUT THE STUDY?  
   
If any questions arise related to this research project, or you believe you have any 
injury  
related to this study, you can call the following person: 
  
 
Principal Investigator (Researcher Study Doctor) 
 
Dr. Riddhi Das Gupta,  
PG Senior Registrar,  
Dept of Endocrinology, Diabetes and Metabolism  
Vellore.  
Ph:-0416-2282694.  
Ph:-0416-4200844.  
 
USE OF IDENTIFIED SPECIMENS FOR FUTURE RESEARCH:  
 
In addition to the research you are consenting to under this research study, 
Dr.Riddhi Das Gupta or other researchers at this or other institutions may wish to 
study the samples in future research  
Information about you may be shared with other researchers who will keep the 
information confidential. However, it is possible that information about you may 
become known to people other than the researchers.  
   
  PARTICIPANT:  
 
PLEASE INDICATE YOUR CHOICE BY INITIALING ONE (1) OF THE 
FOLLOWING OPTIONS : 
 
___ I consent to have my specimens used for future research studies.  
 
___ I consent to have my specimens used for future research studies only for the 
study of  
_____________________________________.  
 
___ I do NOT consent to have my specimens used for future research studies. The 
specimens will be destroyed at the end of the study.  
   
PARTICIPANT:  
 
FOR FUTURE CONTACT, PLEASE INITIAL YOUR CHOICES BELOW : 
 
I consent to be contacted in the future to learn about:  
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_____ New research protocols that I may wish to join.  
_____ General information about research findings.  
_____ Information about the test on my sample that may benefit me or my family 
members in relation to choices regarding preventive or clinical care.  
   
I DO NOT AGREE TO BE CONTACTED IN THE FUTURE, EVEN IF 
THE RESULTS MAY BE IMPORTANT TO MY HEALTH OR MY 
FAMILY'S HEALTH.  
   
Your wish does not constitute a guarantee that you will be contacted.  
   
CAN I BE ASKED TO STOP PARTICIPATING IN THIS STUDY 
BEFORE THE STUDY IS FINISHED?  
 
Your Study Doctor may discontinue your participation in this study. Reasons for 
discontinuation could be, for example:  
You experience an unexpected side effect or you have abnormal laboratory results 
that  
would be considered unsafe  
You develop, during the course of the study, symptoms or conditions that are 
excluded in the study  
   
You do not follow instructions  
   
You use a medication or drug not allowed by the study (except: medications for 
arthritis, hypertension and hyperlidemia)  
   
 
WHAT IF NEW INFORMATION BECOMES AVAILABLE?  
   
If the research study doctor obtains new information that might lead you to 
change your  
mind about continuing in this study, the research study doctor will tell you about 
it.  
If you decide to withdraw, the research study doctor and your personal doctor will 
make  
arrangements for your care to continue.  
   
MAY I STOP THE STUDY AT ANY TIME?  
   
Your participation in this study is voluntary, and you may withdraw from the 
study at any time without giving a reason.  
   
If you decide to withdraw after receiving the study drug, you should talk with the 
research study doctor to see how best to complete the withdrawal process.  
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If you agree to participate and withdraw at a later time, some of your information 
may  
have already been entered into the study and that will not be removed.  
   
In addition, you may be asked to return to the research study doctor again for any 
final  
tests in order to close the record and tests or monitoring that are necessary for 
your health  
as a result of your participation. These results may be recorded.  
   
Your treatment by doctors and staff at the institution(s) involved in this study, 
now and in the future, will not be affected in any way if you agree to participate 
and withdraw later.  
   
WHAT ARE MY RIGHTS IF I TAKE PART IN THIS RESEARCH 
STUDY?  
 
Your participation in this study is voluntary.  
   
You do not waive any of your legal rights by participating in this research study.  
   
Your treatment by doctors and staff at the institution(s) involved in this study, 
now and in the future, will not be affected in any way if you refuse to participate 
or if you enter the study and withdraw later.  
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INFORMED CONSENT SIGNATURE PAGE 
 
DEPARTMENT OF ENDOCRINOLOGY DIABETES AND 
METABOLISM 
CHRISTIAN MEDICAL COLLEGE, VELLORE 
 
 
Study Title:  “A comprehensive study on metabolic characteristics in subjects 
with  Fibrocalculous Pancreatic Diabetes from India” 
 
Participant’s name:  
 
Date of Birth / Age (in years): 
 
I______________________________________________________, son/daughter 
of  ___________________________________ 
 
(Please tick boxes): 
 
Declare that I have read the information sheet provide to me regarding this study 
and have clarified any doubts that I had. [ ] 
 
I also understand that my participation in this study is entirely voluntary and that I 
am free to withdraw permission to continue to participate at any time without 
affecting my usual treatment or my legal rights [ ] 
 
I have also been given the name and contact information of the principal 
investigator and members of the research team whom I can contact for any 
research related queries [ ]  
 
I also understand the possible risks and benefits involved in taking part in the 
study and have been made fully aware of the steps taken by the researchers to 
minimize all potential adverse events  [ ] 
 
I understand that I will receive free treatment for any study related injury or 
adverse event but I will not receive and other financial compensation [ ] 
 
I understand that the study staff and institutional ethics committee members will 
not need my permission to look at my health records even if I withdraw from the 
trial. I agree to this access [ ]  
 
I understand that my identity will not be revealed in any information released to 
third parties or published [ ]   
 
I voluntarily agree to take part in this study [ ] 
The signature section is specially formatted - please do not modify.  
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Printed Name of Participant                                    Signature of Participant  
Date  
   
   
   
Printed Name of Person conducting the                 Signature of Person conducting 
the  
Informed Consent Process                                      Informed Consent Process  
Date: 
 
 
 
Printed Name of Witness                                         Signature of Witness 
 
 
                                                                                          
Date:                                                                         Thumb Print of Witness  
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xg;g[jy; gotk; 
1. mfRug;gpay; gphpt[ fpUj;Jt kUj;Jt fy;Y}hp/ ntY}h;?4                                 
 ,e;j Ma;tpd; jiyg;g[  
tsh;rpij khw;w gz;g[fs; gupnrhjidapy; g=;nfw;Fk; ,e;jpa egh;fSila 
igg;nuhfy;Fy!; fiza ePupHptpd; Ratptuj;ij fz;lwpa elj;jg;gLk; Ma;t[ 
MFk;.  
2. ,e;j Ma;t[ bra;a[k; egh;:  
Kjd;ik Ma;thsu; (Ma;t[ kUj;Jtu;) 
lhf;lu;. upjp jh!;; Fg;jh 
     mfRug;gpay; epupHpt[ kw;Wk; tsh;rpijkhw;wk; gphpt[ 
  fpUj;Jt kUj;Jt fy;Y}hp/ ntY}h;?4 
  bjhiyg;ngrp vz;: 0416?2282528;/ 9585169862 
 
3. ehd; ,e;j Ma;tpy; g=;nfw;f ntz;Lkh ? 
j=;fSila g=;nfw;g[ RakhdJ jh=;fs; Ma;thshplnkh my;yJ Ma;t[f; FHtpy; 
cs;s ntW egh;fsplnkh ngrpa gpwF ,e;j Ma;tpy; g=;nfw;f ntz;Lkh ,y;iyah 
vd;gij Kot[ bra;ayhk;. 
j=;fSf;F g=;nfw;f tpUg;gkhdhy; ,e;j gotj;jpy; ifbaGj;jpLk;go 
nfl;Lf;bfhs;sg;gLtPh;fs;.  ifbaGj;;J jh=;fs; ,e;j Ma;tpy; ,Uf;f rk;kjk; vd;gij 
typa[Wj;jk;. 
,e;j gotj;ij goj;J tpl;L ,jdpy; vd;d Twg;gl;Ls;sJ vd;gijg; gw;wp tpthjpj;j 
gpd;dh; j=;fsJ re;njf=;fisf; nfl;f ntz;Lk;.  jh=;fs; xU Kot[f;F tu j=;fSf;F 
njitahd neuj;ij vLj;Jf; bfhs;syhk;.  ,e;jg; gotj;jpy; cgnahfpf;fg; 
gLj;jg;gl;Ls;s kUj;Jtf; Fwpg;g[fs; VnjDk; g[upatpy;iy vdpy; ,g;gotj;ij 
c=;fSf;F tpsf;Fgtuplk; ,ij vspjhfg; bjupe;Jf;bfhs;s njitahd jftiyf; 
nfl;Lg; bgwt[k;. 
jh=;fs; ,e;j Ma;tpy; g=nfw;f clnd rk;kjk; bjuptpf;f ntz;Lk; vd;gjpy;iy.  
g=;nfw;f ntz;Lkh ntz;lhkh vd;gij Kot[ bra;a njitahd mst[ neuk; 
vLj;Jf;bfhs;st[k;.  ,e;j gotj;jpd; xU gpujpia vLj;Jf; brd;W j=;fSila 
FLk;gj;jpdhplKk; ez;gh;fsplKk; fye;J Mnyhrpj;J gpd;dh; KontLf;fyhk;. 
jh=;fs; g=;nfw;f ntz;lhk; vd;W Kot[ bra;jhYk; j=;fSila eyd; fUjp Kiwahd 
rpfpr;ir mspg;ghh;fs;.  jh=;fs; g=;nfw;f ,ire;jhYk; ,y;iynad;whYk; ,g;gotj;jpd; 
xU gpujp c=;fSf;F mspf;fg;gLk;. 
jh=;fs; midj;J nfs;tpfSf;Fk; gjpy; fpilf;fhknyh> Ma;tpy; vd;d elf;fg;nghfpwJ 
vd;gij bjspthf mwpahknyh ,g;gotj;jpy; ifnaOj;jpl ntz;lhk;.  jh=;fs; ,e;j 
Ma;tpy; g=nfw;f Kot[ bra;jhYk; ve;j neuj;jpYk; fhuzk; Twhky; ,e;j Ma;tpy; 
,Ue;J tpyfpf; bfhs;syhk;.  ,jdhy; j=;fSf;F mspf;fg;gLk; rpfpr;irapy; ve;j tpj 
ghjpg;g[k; ,Uf;fhJ.  nkYk; bjhlh;e;J ,=nfna rpfpr;irg; bgw;Wf; bfhs;syhk;. 
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Ma;t[ kUe;ijg; bgw;w gpwF Ma;it tpl;L tpyf Kot[ bra;jhy; Ma;t[ kUj;Jtuplk; 
ngrp Ma;tpy; ,Ue;J tpyFjy; Kiwg; gw;wp mwpayhk;.   
,g;gotj;jpy; tpthpf;fg;gl;Ls;sit: 
1. ,e;j Ma;tpd; Kyk; Ma;thsh;fs; mwpe;J bfhs;sg;nghtJ vd;d> 
2. ,e;j Ma;tpy; j=;fSf;F neug;nghtJ vd;d> 
3. vd;d mbrsfupa=;fs; kw;Wk; ghjpgg[fs; j=;fSf;F Vw;glyhk; vd;W vjph;ghh;f;fyhk;  
 
,e;j Ma;tpd; g=;nfw;ghsuhf ,Ug;gjd; @yk; eP=;fs; vjh;g;ghh;f;Fk; mDFTy=;fSk; 
kw;Wk; c=;fs; epiyikf;F Vw;wthW khw;W epge;jidfisg;gw;wp ,e;j Ma;t[ 
Fwpg;gplt[k; bra;a[k;. 
,e;j Ma;t[ elj;jg;gLtjpd; nehf;fk; vd;d>  
,e;j Ma;tpy; bkype;j rh;f;fiu nehahspfspd; fPH; fz;l Fz=;fis mstpL 
bra;fpnwhk;. 
itl;lkpd;?o nru;g;gjhy;  clypy; ,d;Rypd; ve;j mstpw;F gjpyspf;Fk; (,uj;j 
rh;f;fiuia fl;Lg;gLj;Jk; ]\hh;nkhd;)/ tPf;fk;; my;yJ Fwpg;gpl;l bry;fs; kw;Wk; 
bfhGg;g[ jpRf;fspd; bray; Kiwfs;/ mjDld; vYk;g[ jir bray;ghL Fwpj;J 
mstpL bra;fpnwhk;. 
ehd; Vd; ,e;j Ma;tpy; fye;J bfhs;s nfl;Lf; bfhs;sg; gl;oUf;fpnwd;> 
jh=;fs; xU Mnuhf;fpakhd jd;dhu;tsuhf ,e;j Ma;tpy; fye;J bfhs;s 
nfl;Lf;bfhs;sgLfpwPu;fs;. 
,e;j Ma;tpy; jh=;fs; fye;Jf;bfhs;s rk;kjk; bjhptpj;jhy; eP=;fs; ,e;j Ma;t[f;F jFjp 
cilatuh vd;gij cWjp bra;a[k; bghUl;L rpy gupnrhjidfs; bra;ag;gLk;. 
,e;j Ma;t[ Vd; elj;jg;gLfpwJ> 
,e;j Ma;tpd; nehf;fk; “tsh;rpij khw;w gz;g[fs; gupnrhjidapy; g=;nfw;Fk; ,e;jpa 
egh;fSila igg;nuhfy;Fy!; fiza ePupHptpd; Ratptuj;ij fz;lwpa elj;jg;gLk; 
Ma;t[ MFk;;;”. 
vj;jid ngh; ,e;j Ma;tpy; g=;nfw;f cs;sdh;>  
Vwf;Fiwa c=;fSld;; nrh;j;J ,e;j Ma;tpy; 40 ngh; g=;nfw;ghh;fs;.  ,e;j Ma;t[ 
ntY}h; fpUj;Jt kUj;Jtf; fy;Y}hpapy; eilbgWk;.  
ehd; ,e;j Ma;tpy; g=;nfw;gjhdhy; vdf;F vd;d elf;Fk;? 
ntY}h; fpUj;Jt kUj;Jtf; fy;Y}hapd; mfRug;gpay; epupHpt[ kw;Wk; tsh;rpijkhw;wk; 
gphtp;y;; mike;Js;s Ma;t[ miwapy; fPnH bfhLf;fg;gl;Ls;s gupnrhjidfs;  
bra;g;gl;L Ma;t[f;fhd jFjp mwpag;gLk;. 
,e;j tUifapd; nghJ j=;fSila kUj;Jt tuyhW mwpag;gl;L/ clw;gupnrhjid/ 
,uj;j mGj;jk;/ rpWePu; gupnrhjid/ fyg;g[ czt[ gupnrhjidapd;  (,uj;j ru;f;fiu neha; 
fz;lwpa[k; gupnrhjid)/ ,rp$p kw;Wk; rpy Ma;t[Tlg; gupnrhjidfSk; bra;ag;gLk;.   
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Ma;Tlj;jpw;F eP=;fs; fhyp tapw;Wld; (Ke;ija ehs; ,ut[ 11 kzpf;F gpwF vJt[k; 
cz;zhky;) tuntz;Lk;.  Mjyhy; gupnrhjidfs; fhiy ntisfspy; elj;jg;gLk;.   
fyg;g[ czt[ gupnrhjidapd; nghJ ru;f;fiu fye;j nrhlhit mUe;j ntz;Lk;.  mjw;F 
Kd;Dk;/ 2 kzp neuk; fHpj;Jk; ,uj;jg; gupnrhjid bra;ag;gLk;.  clw;gupnrhjidapd; 
nghJ c=;fsJ iffspy; cs;s jkzpfs;/ cauk;/ vil/ ,ilr; Rw;wst[ kw;Wk; 
clw;bfhHg;g[ rjtpfpjk; Mfpait fz;lwpag;gLk;.   
nkYk; eP=;fs; xU bgz;zhf ,Ug;gpd; fu;gg; gupnrhjidAk; bra;ag;gLk;.  c=;fSf;F 
fy;yPuy; gupnrhjida[k; bra;ag;gLk;. 
nkYk; rpy ,uj;jg;gupnrhjidfs; bra;a gupnrhjid Kot[fspd; xU gpujp j=;fSf;F 
mspf;fg;gLk;.   
j=;fSf;F Ma;tpy; fye;J bfhs;Sk; midj;J jFjpfSk; ,Uf;Fkhdhy; Ma;tpy; 
g=;nfw;f miHf;fg;gLtPu;fs;.  ,e;j Ma;tpy; g=;nfw;Fk; 40 ngUk; Ma;tpd; midj;Jg; 
gFjpfisAk; epiwt[ bra;tJ Kf;fpakhFk;.  czt[g; gupe;Jiufisg; gw;wp Ma;t[f; 
FGtpdUld; re;jpj;J fye;jhnyhrpf;f ntz;Lk;.  xt;bthU fpshk;g[ Ma;tpw;F Kd; 
@d;W ehl;fSf;F fLikahd clw;gapw;rp bra;tijj; jtpu;f;f ntz;Lk;.  fpshk;g; Ma;t[ 
vd;gJ ru;f;fiu msit ,ay;g[ epiyapy; itg;gjw;fhf viliag; bghWj;J jkzp 
tHpahf Rug;g[ ePu;fis brYj;Jk; xU KiwahFk;. nrhknlh!;nld;/ ,d;Rypd;/ 
FSf;fnfhd;/ f;nuhj; \hu;nkhd; Mfpa kw;w kUe;JfSk; FSf;nfh!;t[ld; nru;f;fg;gLk;.  
,e;j midj;J Rug;g[ ePu;fSk; ,uj;j ru;f;fiu msit fl;Lg;gLj;j cjt[k;. 
c=;fSf;F VnjDk; gf;f tpist[fs; Vw;gl;lhy; kUj;Jt gupnrhjid ,lj;jpw;F 
tutiHf;fg;gl;L Ma;t[ kUj;Jtu;fshy; gupnrhjpf;fg;gLtPu;fs;. 
eP=;fs; ePupHpt[ neha[ilathuhf ,Ue;jhy;; Ma;tpw;F Kd; ehsd;W eP=;;fs fpUj;Jt 
kUj;Jt fy;Y}upapy; mDkjpf;fg;gLtPu;fs; (10 kzp neu gl;odp epiyf;Fg; gpwF). c=;fs; 
ifapy; euk;g[ tHp toFHha; bghWj;Jthh;fs; nkYk; ru;f;fiu msit ,ay;g[ epiyapy; 
itg;gjw;fhf mjpfhiy 3 kzpapy; ,Ue;J jkzp tHpahf Rug;g[ePiu brYj;Jthh;fs;. 
fhiy 8 kzpastpy; c=;fs; ifapy;; ,uz;lhtJ rpW gpsh!;of; FHha; (euk;g[ tHp 
toFHha;) brYj;jg;gLk;.  xU FHha; ,uj;jk; vLg;gjw;Fk; kw;nwhU FHha; kUe;Jfis 
brYj;Jtjw;Fk; gad;gLj;jg;gLk;.  c=;fs; clk;gpypUe;J vLf;fg;gLk; ,uj;jj;jpd; 
mst[ xU igz;l; MFk;.  ,uj;jk; vLg;gjw;F VJthf jkzpfis tpupe;j epiyapy; 
itg;gjw;fhf xU ifapd; nky; btg;g Kl;lgl;l nghu;it nghu;j;jg;gl;L fjfjg;ghf 
itf;fg;gLk; (65º rp – 149º vBg;).  c=;fs; ifia mirf;f Koa[k;.   
c=;fs; ru;f;fiu mst[ ,d;Rypd; kw;Wk; FSf;nfh!;; Ma;t[ KGtJk; rpwpa mstpy; 
bjhlu;e;J brYj;jg;gLk;.  c=;fs; ru;f;fiu Ma;t[ KGtJk; 90 kpyp ∕ ovy; mstpy; 
itf;fg;gLk;.  ,jDld; nrhknlh!;nld;/ ,d;Rypd;/ FSf;fnfhd;/ f;nuhj; \hu;nkhd; 
Mfpa kw;w kUe;JfSk; FSf;nfh!;t[ld; nru;f;fg;gLk;.  ,e;j midj;J Rug;g[ ePu;fSk; 
,uj;j ru;f;fiu msit fl;Lg;gLj;j cjt[k;. 
,e;j tUiffs; Vwf;Fiwa 8 kzp neuk; ePOf;fyhk;.  ,tw;wpd; nghJ c=;fSila jpir 
kw;Wk; @l;Lfspd; typika[k; gupnrhjpf;fg;gLk;. 
TLjyhf ,e;j Ma;tpd; Muk;gj;jpy; c=;fsplk; ,Ue;J rpwpa mst[ ,uj;j khjpup 
vLf;fg;gLtjd; @ykhf c=;fSf;F ilg; 1 ilag;go!; kw;Wk; kugQ @ykhf nkho 
(,sk; tajpy; njhd;Wk; Kjph;e;j ePupHpt[ neha;) ,Uf;fpwjh vd;W fz;lwpa Koa[k;. 
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eP=;fs; ,e;j Ma;t[ tUifapd; nghJ Ma;tpd; FGtpdh; @ykhf neu;fhzy; 
bra;ag;gLtPh;fs; gpd;g[ KG cly; gupnrhjid/ rpy Ma;tf nrhjidfs;/ ,uj;j 
gupnrhjid/ rpWePu; gupnrhjid kw;Wk; ,uj;j mGj;jk; msf;;;;fg;gLk;.  ,e;j tUifapd; 
fhy mtfhrk; xd;uiw (1.5) kzp neukhFk;. 
ehd; ntW vd;d bra;a ntz;Lk;> 
eP=;fs; Ma;t[ kUj;Jthplk; c=;fSf;F ,g;bghGJ ,Uf;fpd;w kw;Wk; Kd;dh; ,Ue;j 
neha;fisg; gw;wpa[k; xt;thikiag; gw;wpa[k; Tw ntz;Lk;.  eP=;fs; cl;bfhs;Sk; 
kUe;Jfs; gw;wpa[k; Tw ntz;Lk;. 
c=;fSf;F vg;nghGnjDk; cly; eykpy;yhjJ nghy; njhd;wpdhy;/ clnd c=;fs; 
kUj;Jtiunah Ma;t[ kUe;Jtiunah bjhlu;g[ bfhs;s ntz;Lk;. ntW xU kUj;Jtu; 
c=;fSf;F VnjDk; kUe;ij cl;nfhs;s mwpt[Wj;jpdhy;/  eP=;;fs; mtuplk; Ma;t[ 
kUj;Jtupd; bgaiua[k; bjhiyngrp vz;iza[k; mspf;ft[k;. 
c=;fSila jpdrup eltof;iffis tHf;fk; nghy; bra;ayhk;.    
,e;j Ma;tpy; g=;nfw;gjdhy; vdf;F vd;ndd;d gf;ftpist[fs; Vw;gl tha;g;g[ 
,Uf;fpwJ> 
,e;j Ma;tpy; g=;nfw;gjhy; c=;fSf;F gf;ftpist[fs; ,y;iy.   
,e;j Ma;t[ kUe;jpd; ghjpg;g[fs; gpd;tUkhW: 
,uj;j khjpup vLf;Fk; Kiw:  ,e;j Ma;tpd; nghJ Fiwe;jgl;rkhf 190 kpyp ,uj;jk; 
vLf;fg;gLk; ,J ,uj;j jhdk; bra;ag;gLk; msit tpl Fiwe;j msthFk;. 
6.6 oa[onull; FSf;nfh!;:  6.6 oa[onull; FSf;nfh!; xU epiyahd Inrhnlhg;g[ 
vdnt ve;j fjpupaf;f btspg;gLk; ,Uf;fhJ. 
20 rjtpjk; blf;!;l;nuh!;:  20 rjtpjk; blf;!;l;nuh!; brYj;Jtjd; @ykhf jkzpapy; 
vupr;ry; Vw;gLk;. ,jid bgupa Jis Ke;ija tpyhtpd; cl;gFjp euk;ig cgnahfpj;J 
jtph;f;fyhk;. 
FSf;fnfhd; : the;jp tUtJ nghd;w mwpFwp ru;f;fiu rfpg;g[j;jd;ik ,y;yhjtu;fSf;F 
jirg;gpog;g[/ the;jp nghd;w tapw;W cghijfs; ru;f;fiu msit cau;j;jyhk;.  ,e;j 
mwpFwpfs; ehk; cgnahfg;gLj;Jk; msit tpl mjpfkhd mstpy; jhd; Vw;gLk;.  
Ma;tpy; ehk; cgnahfg;gLj;Jk; kUe;jpd; mst[ bgupa gf;f tpist[fis Vw;gLj;jhJ. 
f;nuhj; ]\hu;nkhd; : Ma;tpy; cgnahfg;gLj;jg;gLk; mstpy; gf;f tpist[fs; fpilahJ. 
fhy;rpak; mst[ cau;jy;.  fhy;rpak; mst[ kpjkhf caUk; gl;rj;jpy; ve;j mwpFwpAk; 
,Uf;fhJ.  c=;fs; ,uj;jk; mof;fo gupnrhjid bra;ag;gLtjhy; ,t;thW fhy;rpak; 
cau;tJ clnd fz;Lgpof;fg;gLk;.  kpf ntfkhf fhy;rpak; mst[ mjpfkfh cau;e;jhy; 
mof;fo rPWePu; tUjy;/ jhfk; vLg;gJ/  grp Fiwjy;/  the;jp/ jir typikapd;ik Mfpa 
gf;f tpist[fs; neUk;.   
i\g;nghfpisrpkpah (Fiwe;j ,uj;j ru;f;fiu): 
,d;Rypd; brYj;Jtjhy; ,uj;jj;jpy; ru;f;fiu mst[ Fiwayhk;.  ,e;j Mgj;ij 
Fiwg;gjw;F/ ru;f;fiu mst[ mof;fo gupnrhjpf;fg;gLk;.  ru;f;fiu Fiwe;jhy; kaf;fk;/ 
jiy Rw;wy; nghd;w mwpFwpfs; Vw;gLk;. ru;f;fiu mst[ Fiwe;jhy;/ 20 rjtpjk; 
blf;!;l;nuh!;/ brYj;jp ru;f;fiu mst[ ,ay;ghf;fg;gLk;.   ,d;Rypd; ? ,e;j 
,aw;ifapnyna Ruf;Fk; Rug;gp ePu; ,uj;j msit kpft[k; cauhknyh Fiwahknyh 
ghJfhf;f ftdkhff; fl;Lg;gLj;jp brYj;jg;gLk;.  
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jkzp FGha;:  jkzp FGha; jkzpapy; cl;brYj;Jk; nghJ typ kw;Wk; rpwpjst[ ,uj;j 
frpt[ Vw;g;gl tha;g;t[ cs;sJ. 
nrhknlh!;nld;:  ,jdhy; jiytyp/ tapw;Wj; jir gpog;g[/ tapw;Wg; nghf;F Mfpait 
Vw;glyhk;. 
blf]!h !;;nfd;:  ,J vYk;gpd; mlh;j;jpia gw;wp mwpa vLf;fg;gLk; !;nfd;.  
,e;j !;nfd; Fiwe;j fjph;tPr;ira[ilaJ.  ,e;j ]!;nfd; gyUf;Fk; tHf;fkhf 
bra;ag;gLk; xd;W.  Mdhy; fu;g fhyj;jpy; bgz;fSf;F ,e;j !;nfd; 
bra;af;TlhJ.  ,jdhy; typ Vw;glhJ.  ve;jtpj cghijAk; ,Uf;fhJ.  ,jw;fhf 
vil/ cauKk; Fwpj;Jf;bfhs;sg;gLk;.  ,jw;F 15?20 epkpl=;fs; MFk;. ,e;j 
!;nfd; vLf;Fk; nghJ gLf;ifapd; kPJ xU epiyapy; ,Uf;fitj;J me;j 
,ae;jpuj;ij xU epiyapy; itj;J c=;fis mirahky; ,Uf;fr;bra;thh;fs;.   
 
vd;.vk;.Mu;. epwkhiyapay;:   ,jdhy; ve;j tpj cghjifSk; ,Uf;fhJ.  
g=;nfw;ghsu;fSf;F  vk;.Mu;. !;nfd; @ykhf; @oa ,lk; gw;wpa mr;rKk;/ ,jd; 
@ykhf Vw;gLk; rj;jKk; kw;Wk; Fsph;e;j czh;t[ gw;wpa mDgtk; Vw;gLk;. 
,e;j Ma;tpy; g=;nfw;gjhy; vdf;F VjhtJ ed;ikfs; cz;lh>   
,e;j Ma;t[ c=;fSf;F neuo Mjhak; jUk;.  ,jd; @ykhf c=;fs; tsh;rpij 
bray;ghLfisg; gw;wp vspjpy; bjupe;J bfhs;s Koa[k;.  
,e;j Ma;t[ kw;wth;fSf;Fk; gad; mspf;f ToajhFk;. ,J bkype;j ePupHpt[ 
nehiag;gw;wp mjpfkhf bjupe;J bfhs;s cjt[k;. nkYk; vjpu;fhyj;jpy; ,J nghd;w 
nehahspfSf;F vspjhf rpfpr;ir mspf;ft[k; cjt[k;. 
 
ehd; ,e;j Ma;tpy; g=;nfw;ftpy;iy vd;why; vdf;F ntW vd;d tHpfs; cs;sJ>    
eP=;fs; ,e;j Ma;tpy; g=;nfw;fhky; ,Uf;fyhk;.   
 
vdJ Ma;t[ jfty;fis ahh; ghh;g;ghh;fs;> 
c=;fs; Ma;t[ mwpf;if ufrpakhf ghJfhf;fg;gLk; c=;fs; bgah; btspaplg;glkhl;lhJ. 
c=;fs; Ma;t[ mwpf;if kw;Wk; kUj;Jt mwpf;if Ma;t[ FGthy; nrhjpf;fg;gLk;.  
Ma;t[ FG c=;fs; Ma;t[ mwpf;ifia nrhjpj;J tpl;L jfty;fs; ufrpakhf 
ghJfhf;fg;gLk;.   
Ma;t[ mwpf;if gj;jpukhf ghJfhf;fg;gLk;.  
c=;fsJ Ma;t[f; nfhg;g[fSk; kUj;Jt nfhg;g[fSk; Ma;Tf; FG cWg;gpdu;fshy; 
gupnrhjpf;fg;gLk;.  ,e;j Ma;t[ kUe;J rk;ge;jg;gl;ljhy;/ mbkupf;f czt[ kw;Wk; kUe;J 
fHfk; (vg;.o.V) kUe;Jfis xG=;FgLj;Jk; mikg;g[ c=;fsJ nfhg;g[fis nrhjid 
bra;ayhk;. 
Ma;thsUk;/ Ma;t[f; FGtpdUk; c=;fsJ kUj;Jtf; nfhg;g[fis Ma;t[ bra;J 
jfty;fis ,ufrpakhf itg;gu;. 
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ntY}u; fpUj;Jt kUj;Jtf; fy;Y}upapd; mfRug;gapy; Jiwapy; mike;Js;s my;ngu;l; 
vapd;!;bld; kUj;Jt fy;Y}upapd; Ma;t[ epiyaj;jpy; Ma;t[f; nfhg;g[fs; ,ufrpakhf 
itf;fg;gLk;.  fzpdp mwpf;iffs; ufrpa Fwpnal;L vz;zhs; ghJf;fg;gLk;. 
 Ma;t[ epiyaj;jpdUk;/ Ma;thsupdhy; bra;ag;gl;l Ma;t[f; FGtpdUk; ,e;j 
nfhg;g[fis ghu;itaplyhk;.   
kdpj Ma;t[ ghJfhg;g[ mYtyfj;jpdUk; x.gr;.Mu;.gp. egh;fs; Ma;t[f; nfhg;g[fis 
ghu;itaplyhk;.   
,e;j midj;J FGf;fSk; j=;fsJ bgaiu ,ufrpakhfg; ghJfhf;FkhW 
nfl;Lf;bfhs;sg;gl;Ls;sdu;.   
I.Mu.;gp. egh;fs; c=;fs; Ma;t[ mwpf;ifia nrhjpg;ghh;fs; x.gr;.Mu;.gp. egh;fs; c=;fs; 
Ma;t[ mwpf;ifia nrhjpg;ghh;fs; FHtpd; egh;fs; c=;fs; jftiy ufrpakhf 
ghJfhg;ghh;fs;.  
Ma;itg; gw;wpa vd;Dila nfs;tpfSf;F ahh; gjpyspg;ghh;fs;>  
,e;j Ma;itg; gw;wp c=;fSf;F VnjDk; nfs;tpfs; njhd;wpdhnyh my;yJ ,e;j 
Ma;tpdhy; c=;fSf;F VnjDk; ghjpg;g[ Vw;gl;oUf;fpwJ vd;W eP=;fs; fUjpdhnyh 
nkny Twg;gl;Ls;s Ma;thsiu eP=;fs; clnd bjhlh;g[ bfhs;syhk;.  
Ma;tpd; ika Ma;thstiua[k; (Ma;t[ kUj;Jth;) eP=;fs; bjhlh;g[ bfhs;syhk;. 
lhf;lu;. upjp jh!;; Fg;jh 
     mfRug;gpay; epupHpt[ kw;Wk; tsh;rpijkhw;wk; gphpt[ 
  fpUj;Jt kUj;Jt fy;Y}hp/ ntY}h;?4 
  bjhiyg;ngrp vz;: 0416?2282528;/ 9585169862 
 
j=;fisg; gw;wpa jfty;fis ep\hy; jhk!; my;yJ kw;w Ma;thshh;fSld; gfph;e;J 
bfhs;sg;glyhk;.  mth;fs; me;j jftiy ,ufrpakhf itg;ghh;fs;.  MapDk; rpy 
rka=;fspy; j=;fisg; gw;wpa jfty; Ma;thsh;fisj; jtpu kw;wth;fSf;Fk; bjupa 
tuyhk;.  ,e;j Ma;t[f; Fwpg;g[fs; lhf;lu;. upjp jh!;; Fg;jh jtpu ,=;;F cs;s kUj;Jt 
Muha;r;rpahsh;fs; vjph;fhyj;jpy; gad; gLj;Jthh;fs;. 
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g=;nfw;ghsh;: 
 
j=;fSila tpUg;gj;ij fPH;f;fz;l VnjDk; xU thf;fpaj;jpy; ifnaHj;jpl;L 
bjuptpf;ft[k;.   
1. vd;Dila khjphpfis vjph;fhy Ma;t[f;F gad;gLj;jpf;bfhs;s rk;kjpf;fpnwd;. 
2. vd;Dila khjphpfis vjph;fhy Ma;gt[f;F gad;gLj;j rk;kjk; ,y;iy. 
 
vjph;fhyj;jpy; fPH;f;fz;ltw;iwg; gw;wp mwpe;J bfhs;s vd;idj; bjhlu;g[ bfhs;s 
rk;kjpf;fpnwd;: 
ehd; g=;nfw;ff; Toa g[jpa Ma;t[ tiuKiwfisg; gw;wp mwpa Ma;t[ Kot[fisg; gw;wp 
bghJkhd jfty;fis mwpe;J bfhs;s vdf;nfh vdJ FLk;gj;jpdUf;nfh kUj;Jtg; 
gadspf;fToa vdJ khjpupapd; kPjhd gupnrhjidiag; gw;wpa jftiy mwpe;J bfhs;s 
ehd; rk;kjpf;fpnwd; 
 
,e;j Ma;tpd; Kotpy; khjphpfs; mHpf;fg;gl ntz;Lk; g[jpa jfty; fpilj;jhy;> 
,e;j Ma;tpy; jh=;fs; g=;nfw;gjh ,y;iyah vd;W c=;fis vz;zitf;ff; Toa g[jpa 
jfty; Ma;t[ kUj;JtUf;Ff; fpilj;jhy; mijg;gw;wp mth; c=;fsplk; TWthh;.  eP=;fs; 
Ma;tpypUe;J tpyf epidj;jhy; mjw;F mth; cjt[thh;. 
 
Ma;tpy; g=;nfw;gij ehd; vg;bghGJ ntz;LkhdhYk; tpyfpf; bfhs;syhkh> 
eP=;fs; Ma;tpy; g=;nfw;gJ jd;dpr;irahdJ.  ve;j neuj;jpYk; fhuzk; vJt[k; Twhky; 
tpyfpf; bfhs;syhk;. 
 
ehd; ,e;j Ma;tpy; ,Ue;J vg;bghGJ ntz;LkhdhYk; tpyfpf; bfhs;syhkh: 
eP=;fs; ,e;j Ma;tpy; ,Ue;J vg;bghGJ ntz;LkhdhYk; tpyfpf; bfhs;syhk;.   
eP=;fs; Ma;tpy; g=;nfw;f rk;kjpj;J tpl;L gpwF tpshf epidj;jhy; Ma;tpy; Vw;fdnt 
gjpt[ bra;ag;gl c=;fis gw;wpa jftiy ePf;f ,ayhJ.   
 
nkYk; Ma;t[ kUj;Jth; c=;fs; ,Wjp fl;l nrhjidfis bra;tjw;fhft[k;. cly; 
Mnuhfpaj;ij gupnrhjpg;gjw;fhft[k; rpy njitahd gupnrhjidfis bra;thh;.  
gupnrhjidapd; Kot[fs; Ma;tpy; gjpt[ bra;a eP=;fs; ,e;j Ma;tpy; g=;nfw;f 
rk;kjpj;Jtpl;L gpwF tpsfp;bfhz;lhYk; c=;fSf;F ,e;j kUj;Jtkidapy; fpilf;Fk; 
rpfpr;irapy; ve;j khw;wKk; ,Uf;fhJ.  
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g=;nfw;ghsh;: 
 
vjph;fhyj;jpy; bjhlhg[ bfhs;s/ fPnH bfhLf;fg;gl;Ls;s tha;g;g[fspy; tpUg;gkhdtw;iw 
ifnaHj;jpl;L vjph;fhyj;jpy; fPo;fz;ltw;iwg; gw;wp mwpe;J bfhs;s vd;idj; bjhlh;g[ 
bfhs;s rk;kjpf;fpnwd;. 
• ehd; g=;nfw;ff; Toa g[jpa Ma;t[ tiuKiwfisg ; gw;wp mwpa  
• Ma;t[ Kofisg; gw;wp bghJthd jfty;fis mwpe;J bfhs;s  
• vdf;Fnfh vdJ FLk;gj;jpdUf;nfh kUj;J gadspf;Fkh vd;gij mwpa  
• vd;Dila cly; eyj;jpw;nfh vd;Dila FLk;gj;jpdh; cly; eyj;jpw;nfh 
gadspf;ff;Toajhf ,Ue;jhYk; vjph;fhyj;jpy; vd;idj; bjhlh;g[ bfhs;tjpy; vdf;F 
rk;kjkpy;iy. 
 
c=;fSila tpUg;gk; fz;og;ghf vjph;fhyj;jpy; eP=;fs; bjhlh;g[ bfhs;sg;gLtPh;fs; 
vd;gjw;F cj;jputhjk; ,y;iy. 
 
,e;j Ma;t[ Kotjw;F Kd;dnu ,e;j Ma;tpy; ehd; g=;nfw;gij epWj;j Koa[kh> 
c=;fs; Ma;t[ kUj;Jth; eP=;fs; Ma;tpy; g=;nfw;gij epWj;j Koa[k;;.  ,ilepWj;jk; 
bra;tjw;fhd fhuz=;fs;: 
vjph;ghuhj gf;ftpist[fs; cz;lhjy; 
mghafukhd ,ay;g[f;F khwhd gupnrhjid Kot[fs; Ma;tpy; tpyf;fg;glf; Toa 
mwpFwpfnsh epiyiknah cz;lhjy;. 
tpjpKiwfis gpd;gw;whik Ma;tpy; mDkjpf;fglhj kUe;Jfis cgnahfpj;J 
(Kl;Ltyp/ ,uj;j bfhjpg;g[/ mjpf bfhGg;g[ Mfpatw;Wfhd kUe;Jfis jtpw). 
 
,e;j Ma;tpy; g=;nfw;gjhy; vdf;F fpilf;Fk; chpikfs; vd;d> 
eP[=;;fs; ,e;j Ma;tpy; g=;nfw;gJ c=;fs; Ra tpUg;gg[k; ,e;j Ma;tpy; g=;nfw;gjhy; 
c=;fSila rl;l g[u;tkhd ve;j xU chpikiaAk; eP=;fs; ,Hf;fgnghtJ ,y;iy. 
 
eP=;fs; ,e;j Ma;tpy; g=;nfw;f rk;kjpj;J tpl;L gpwF tpsfpf; bfhz;lhYk; c=;fSf;F 
,e;j kUj;Jtkidapy; Kiwahd rpfpr;ir fpilf;Fk; 
,e;j Ma;it gw;wp c=;fSf;F tpsf;fg;gl;l midj;J jiyg;g[fSk; fPnH 
bfhLf;fg;gl;Ls;sJ.  c=;fSf;F VnjDk; xU jiyg;gpy; re;njfk; ,Ue;jhy; ,e;j 
Ma;it gw;wp c=;fsplk; tpsf;Fk; eguplk; mijg; gw;wp bjspthf nfl;L bjupe;J 
bfhs;st[k;. 
,e;j Ma;t[ vijg;gw;wpaJ ? 
,e;j Ma;t[ tsh;rpij khw;w gz;g[fs; gupnrhjidapy; g=;nfw;Fk; ,e;jpa egh;fSila 
igg;nuhfy;Fy!; fiza ePupHptpd; Ratptuj;ij fz;lwpa elj;jg;gLk; Ma;t[ MFk;. 
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,e;j Ma;tpy; ,Uf;Fk;bghGJ ehd ; vd;d bra;a ntz;Lk;> 
,e;j Ma;tpy; g=;nfw;gjhy; vdf;F fpilf;fg; nghFk; ed;ikfs; kw;Wk; jPikfs;  vdf;F 
,e;j Ma;itg;gw;wp ve;j re;njfnkh my;yJ cly;ey Fiwghnlh ,Ue;jhy; ehd; ve;j 
egiu bjhlh;g[ bfhs;s ntz;Lk;.  
ehd; ,e;j Ma;tpy; ,Ue;J ve;j tpj epge;jidAk; ,d;wp vg;nghJ ntz;LkhdhYk; 
tpsfpf; bfhs;syhk; ,e;j Ma;itg; gw;wp jfty;fs; midj;Jk; xU Tl;lhfnt 
btspaplg;gLk; vd;idg; gw;wpa Ra milahyk; ufrpakhf ghJfhf;fg;gLk;.  
Ma;t[ kUe;ij vg;go vLf;f ntz;Lk; vd;w neu ml;ltid ,Ue;jhy; me;j neu 
ml;ltiz vdf;F bfhLf;fg;gLk;. 
Ma;t[f; FGitg;gw;wpa jfty;fs; vdf;F bfhLf;fg;gl;Ls;sJ. 
Ma;itg; gw;wpa nfs;tpfis nfl;f vdf;F KG cupik cs;sJ. 
 
bgah;:  ..................................................................................... 
 
ifbaGj;J: ..................................................................................... 
 
xg;g[jy; gotj;ij g=;nfw;ghsUf;F        xg;g[jy; gotj;ij g=;nfw;ghsUf;F 
tpsf;Fk; egupd; bgau;    tpsf;Fk; egupd; ifnag;gk; 
 
 
....................................................       .................................................. 
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Subject details 
STUDY PROFORMA 
 
Name  Age  Sex M/F 
Patient ID  Hosp. no  Proforma date  
Address  Urban/rural  
Occupation  Phone  
 
HISTORY: 
 
History of Diabetes Mellitus: 
 
Age of onset  
Symptoms at 
diagnosis: 
 
Initial glucose 
values 
 
Admission details, 
if any: 
 
Initial treatment  
Current 
medications for 
diabetes : 
 
Current clinical 
symptoms 
 
 
Complications of 
Diabetes Mellitus 
 
ANNEXURE-III 
History Related to Fibrocalculous Pancreatic Disease 
 
Age of onset  
Symptoms at 
diagnosis: 
 
Presence of 
abdominal pain 
 
Presence of 
steatorrhoea 
 
Initial 
Investigations done 
 
Initial medications 
for Pancreatitis 
 
Current clinical 
symptoms 
 
Complications of 
Pancreatic disease 
 
Current 
investigations 
 
Current Treatment  
Details of 
Insulin/Oral 
antidiabetic drug 
treatment 
 
ANNEXURE-III 
SYSTEMIC REVIEW 
Cardiac  
Respiratory  
Gastrointestinal  
Renal  
CNS  
Other endocrine  
 
 
 
 
Past history 
 
 
Medical  
Surgical  
Others  
ANNEXURE-III 
CHILDHOOD HISTORY 
Maternal antenatal history  
Gestation at birth  Birth weight 
(underweight at 
birth) 
 
Duration of breastfeeding  
Consumption of Casava/ 
Tapioca (how many 
times/month) 
 Frequency of non 
veg consumption 
 
Main diet  
Lean/obese as a kid  
 
Personal history 
 
Diet  
Smoking  
Alcohol  
Exercise and 
activity 
 
 
 
 
 
 
 
 
Participation in any other study- Yes/ No 
 
 
 
Allergies: 
 ANNEXURE-III 
 
 
 
 
 
Medications other than that for Diabetes: 
 
 
 
 
Family history (At least 3 generation pedigree) 
 
 
 
 
 
 
 
Consanguinity Y/N Degree  
Type 2 DM  
Hypertension  
Lipid disorders  
 
Other disorders 
(cancers/bleeding 
disorders etc) 
 
 
 
 
Pedigree chart 
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GENERAL AND SYSTEMIC EXAMINATION: 
 
General Examination 
Built & nourishment  Fat distribution  
Pallor  Icterus  Clubbing  Cyanosis  LNE  Edema  
Goitre  Acanthosis  Skin tags  
Pulse rate  Blood 
pressure 
 Distal pulses  Venous 
access 
 
Tanner staging 
Height  Weight  BMI  Waist circumference  Hip  
SFT Abdomen  Triceps  Subscapular  WHR  
 
 
Systemic Examination 
 
Cardiovascular  
Respiratory  
Gastrointestinal  
Nervous system  
Other endocrine 
systems 
 
Thyroid 
 
Tanner’s staging 
 
 
 
 
 
Diabetes Complications 
Neuropathy  
Nephropathy  
Retinopathy  
 ANNEXURE-III 
 
INVESTIGATIONS: 
 
 
Investigations 
Hb  TC  DC  ESR  PT/APTT  
Creatinine  BUN  Na/K  Bilirubin  SGOT/PT  
HbA1c  Total- 
Cholesterol 
 TG  HDL-C  LDL-C  
FBS/PPBS  Urine ketones  Fasting 
insulin 
 C-peptide  
TSH  Urine microalbumin  GAD antibodies  
ECG  Stool for 72 hr fat  Straight X-Ray 
Abdomen 
 
USS abdomen Date: DEXA Date: Bioimpedence Date: 
   
MRI Date: Findings: 
 
 
Assessment and plan: 
 
 
 
 
 
 
 
 
Eligibility for clamp procedure: 
 
 
 
 
 
 
 
 
 
 
Instructions to the patient: 
DM HISTORY
Lean type 1 DM subjects
Name Hospital # diabetes duration
1 Ramanan 166100d 11
2 Rajeshkumar 931954d 12
3 Jeevanandan 947997A 14
4 Johnson clement 435662c 16
5 Udayakumar 148454b 15
6 Kishore 344992b 18
7 Gokul 769058B 17
8 Singaravela 692890d 20
9 Murali R 842477b 6
10 Gowtham 146789c 9
Obese type 2 DM subjects
Name Hospital # diabetes duration
1 Murali B 041577f 5
2 Munnu Subramanium 078857f 2
3 Mohammed jaffer 169529f 2
4 Prabhu 178799f 1
5 Yuvraj 040471f 2
6 Nicholas 969312c 2
7 Gajendran 267415f 1
8 Siva kumar V.N 620928f 2
9 vaideeswaran D 491172F 7
10 Karthikeyan B 608754f 4
Lean non DM subjects
Name Hospital # diabetes duration
1 Sankar P 405664f na
2 Ramesh C 197387d na
3 Paneer selvam 245968d na
4 TG Ramkumar 325123d na
5 Rajesh Kumar 081488d na
6 Vinodh kumar 402049d na
7 Satish kumar 191320d na
DM HISTORY
8 Prem kumar 199071d na
9 vivekanandan 076597d na
10 vinod m 365772d na
Pancreatic diabetes
Name Hospital # diabetes duration
1 Srinivasan 926741c 9
2 Raj kumar patra 489555f 3
3 Sadhan bashik 663426f 4
4 Ahmed basha 526332d 3
5 Sanjib roy 711816f 7
6 Koushik ghosh 306232f 5
7 Rajesh 514231d 3
8 Polas bag 783803F 2
9 Uttam Maiti 656674f 6
10 Panchanan Mahato 805508f 2
11 M.P.Muhammed Hassan 783692f 10
12 Arun kumar 853457d 3
13 Ramesh Rai 642111f 4
14 Sankar 759758f 2
15 Elumalai 397542F 14
16 Sk.MD Belal 876846F 2
17 Kumar 098560d 5
18 Manaranjan Bag 001831g 4
19 Prabhakaran 382773d 4
20 Nantu das 719059f 10
MRI
abbreviations used HCL
IMCL
EMCL
Lean type 1 DM subjects
Name Hospital # Date HCL IMCL/water% EMCL/water %
1 Ramanan 166100d 10/11/2011 0.22 1.47 1.86
2 Rajeshkumar 931954d 1.86 0.86 1.55
3 Jeevanandan 947997A 10/13/2011 0.51 1.00 2.01
4 Johnson Clement 435662c 12/8/2011 0.00 1.35 1.91
5 Udayakumar 148454b 6/5/2012 0.70 2.25 1.48
6 Kishore 344992b 13/3/2012 0.11 2.95 0.80
7 Gokul 769058B 3/15/2012 0.12 1.27 0.19
8 Singaravela 692890d 2/7/2012 0.22 0.78 0.96
9 Murali R 842477b 2/9/2012 9.80 0.60 1.45
10 Gowtham 146789c 6/24/2012 3.22 2.33 1.75
Obese type 2 DM subjects
Name Hospital # Date HCL IMCL/water% EMCL/water %
1 Murali B 041577f 11/15/2011 11.00 4.64 1.72
hepatocellular lipid
intramyocellualr
extramyocellular
MRI
2 Munnu Subramanium 078857f 11/22/2011 29.74 2.62 3.02
3 Mohd Jaffer 169529f 4/2/2012 13.35 3.09 1.57
4 Prabhu 178799f 7/12/2012 0.59 1.44 2.07
5 Yuvraj 040471f 6/21/2012 12.11 1.55 1.75
6 Nicholas 969312c 11/22/2012 18.60 1.07 3.71
7 Gajendran 267415f 16/08/12 21.01 4.35 2.33
8 Siva kumar V.N 620928f 23/07/2013 11.40 1.41 2.47
9 Vaideeswaran D 491172F 01/08/2013 1.00 0.20 2.61
10 Karthikeyan B 608754f 05/11/2013 4.60 3.28 3.71
Lean non DM subjects
Name Hospital # Date HCL IMCL/water% EMCL/water %
1 Sankar P 405664f 12/09/2013 8.88 0.60 1.40
2 Ramesh C 197387d 2/14/2013 0.05 0.59 1.31
3 Paneer selvam 245968d 2/12/2013 2.10 0.66 2.12
4 TG Ramkumar 325123d 8/27/2013 1.00 0.58 2.36
5 Rajesh kumar 081488d 26/06/2013 0.30 0.24 2.54
MRI
6 Vinodh kumar 402049d 7/4/2013 1.10 0.26 1.80
7 Sathish kumar 191320d 7.95 3.58 1.90
8 Prem kumar 199071d 03/09/2013 0.00 0.55 1.98
9 vivekanandan 076597d 10/10/2013 0.22 2.95 1.67
10 vinod m 365772d 28/11/2013 0.30 0.60 1.40
Probable MODY
FCPD
Name Hospital # Date HCL IMCL/water% EMCL/water % Pancreatic fat Liver
1 Srinivasan 926741c 05/09/2013 0.00 0.41 2.50 thin(unable to do)
Focal  fatty  change  involving  the  subcapsular  and  
GB  fossa  regions.  No  focal  lesions/  IHBRD.
2 Raj kumar patra 489555f 26/09/2013 0.00 0.35 3.21 1.70 Normal.  No  focal  lesions/  IHBRD
3 Sadhan bashik 663426f 01/10/2013 1.06 1.98 1.35 thin(unable to do) Normal.  No  focal  lesions/  IHBRD.
4 Ahmed basha 526332d 10/07/2014 0.02 0.67 1.28
5 Sanjib roy 711816f 14/11/2013 0.60 0.85 0.78 1.31 Normal.  No  focal  lesions/  IHBRD.
6 Koushik ghosh 306232f 18/11/2013 0.20 0.82 1.79 0.68 Focal  fatty  changes.  No  focal  lesions/  IHBRD.
7 Rajesh 514231d 17/12/2013 3.20 7.05 1.28 0.00
T2W  hyperintense  area  in  segment  4/5  adjacent  to  
GB  fossa
8 Polas bag 783803F 30/01/2014 0 1.18 3 Exaggerated
MRI
9 Uttam maiti 656674f 18/02/2014 0.00 4.57 1.02 not possible
10 Panchanan Mahato 805508f 06/03/2014 1.76 0.96 2.36 5.96
11 M.P.Muhammed Hassan 783692f 04/03/2014 0.4 5.08 0.61 0
12 Arun kumar 853457d 08/07/2014 1.43 1.07 1.57 2.62 Mild IHBRD
13 Ramesh rai 642111f 23/05/2014 3.1 1.6 0.84 Exaggerated
14 Sankar 759758f 03/07/2014 1 0.96 3.13 not possible
15 Elumalai 397542F 15/07/2014 1.50 2.12 1.89 awesome saala..
16 Sk.MD Belal 876846F 26/06/2014 0.5 0.66 2.09 Exaggerated Normal
17 Kumar 098560d 23/02/2012 3.7 2.4 2.06 Exaggerated
18 Manaranjan Bag 001831g 22/07/2014 1.12 1.88 1.06
19 Prabhakaran 382773d 24/07/2014 0.45 2.12 1.87
20 Nantu das 719059f 09/09/2014 1.26 2.01 1.55 not possible normal
Obese normal
ISR
ISR 
(pmol/k
g/min)
Lean T1DM 0 min 15 min 30 min 60min 90 min 120 min 150 min 180 min
1 Ramanan 0.31 0.67 0.93 1.28 1.49 1.43 1.14 0.83
2 Rajeshkumar 0 0 0 0 0 0 0 0
3 Jeevanandan 0 0 0 0 0 0 0 0
4 Johnson Clement 0 0 0 0 0 0 0 0
5 Udayakumar 0 0 0 0 0 0 0 0
6 Kishore 0.27 0.28 0.33 0.39 0.42 0.44 0.46 0.49
7 Gokul 0 0 0 0 0 0 0 0
8 Singaravela 0 0 0 0 0 0 0 0
9 Murali R
10 Gowtham
T2DM
1 Murali B 4.18 6.97 8.53 8.54 7.67 7.51 7.41 6.99
2 Munnu Subramanium 2.1 3.21 3.68 3.42 3.49 3.64 3.37 2.94
3 Mohammed jaffer 3.87 4.23 4.89 7.65 6.12 6.02 5.64 3.22
4 Prabhu 2.95 3.56 4.95 7.15 6.35 5.95 5.46 3.12
5 Yuvraj
6 Nicholas
7 Gajendran 2.58 4.13 4.88 8.32 7.34 4.86 4.21 2.98
8 Siva kumar V.N 1.75 0 4.55 8.06 4.2 1.72 1.69 0.96
9 vaideeswaran D 2.66 3.24 4.75 8.15 5.98 5.05 4.25 3.66
10 Karthikeyan B 3.59 4.13 4.59 5.22 5.42 5.21 4.82 4.3
FCPD
1 Srinivasan 0.94 1.03 1.12 1.3 1.49 1.67 1.86 2.04
2 Raj kumar patra 0.49 0.77 0.99 1.27 1.37 1.34 1.25 1.14
3 Sadhan bashik 0.28 0.42 0.53 0.69 0.79 0.85 0.88 0.9
4 Ahmed basha 0.48 0.63 0.78 1.03 1.24 1.39 1.49 1.58
5 Sanjib roy 0.38 0.8 1.15 1.3 1.13 1.02 1 1.01
6 Koushik ghosh 0.99 2.54 3.47 4.68 6.07 5.86 4.66 3.44
7 Rajesh 0.29 0.53 0.61 0.58 0.67 0.72 1.2 7.15
8 Polas bag 1.98 2.34 2.66 3.01 3.05 2.86 2.54 2.28
9 Uttam maiti 1.68 2.51 3.11 3.72 3.76 3.59 3.32 3.06
10 Panchanan Mahato 1.93 2.81 3.57 4.74 5.37 5.44 5.07 4.48
11 M.P.Muhammed Hassan 1.11 2.01 2.81 4.17 5.18 5.87 6.33 6.7
12 Arun kumar 0.89 1.21 1.47 1.87 2.04 1.99 1.81 1.59
13 Ramesh rai 1.08 2.31 3.16 3.71 3.13 1.94 1.03 0.83
14 Sankar 0.37 0.38 0.39 0.42 0.44 0.47 0.49 0.52
15 Elumalai 0.53 0.72 0.87 1.07 1.17 1.14 1.03 0.88
16 Sk.MD Belal 0.28 0.48 0.65 0.93 1.14 1.19 1.13 1
17 Kumar 1.5 1.62 1.73 1.91 2.05 2.15 2.22 2.28
18 Manaranjan Bag 0.27 0.3 0.33 0.39 0.45 0.51 0.57 0.63
19 Prabhakaran 1.38 1.76 2.09 2.63 2.98 3.15 3.18 3.16
20 Nantu das 0.57 0.86 1.1 1.46 1.73 1.77 1.67 1.94
Insulin secretion rate(ISR)
ISR
NORMAL
1 Sankar P 0.98 3.38 5.15 9.85 7.17 5.32 3.38 1.01
2 Ramesh C
3 Paneer selvam
4 TG Ramkumar 1.34 6.51 9.44 9.13 5.73 2.24 1.88 1.56
5 Rajesh Kumar 0.82 3.91 5.09 5.98 4.54 1.13 0.34 0.54
6 Vinodh kumar 1.12 5.56 9.98 10.01 6.54 4.25 2.27 1.18
7 Prem kumar 1.14 6.82 9.73 9.28 6.79 3.55 2.06 0.73
8 vivekanandan 1.53 6.09 10 11.13 7.04 2.71 2.14 1.23
9 Satish kumar 3.01 8.15 11.87 13.12 8.85 4.59 5.34 5.46
10 vinod m 0.85 8.22 11.85 9.82 5.94 1.39 0.73 1.06
DEXA
Lean type 1 DM subjects
Name Hospital # Date BMC L Arm BMC R Arm BMC Trunk BMC L Leg BMC R Leg BMC subtotal BMC head
1 Ramanan 166100d 11/10/2011 194.17 207.9 579.6 489.96 488.1 1959.74 473.09
2 Rajeshkumar 931954d 26/06/2012 1103.07 183.83 516.91 350.52 499.22 2653.55 535.5
3 Jeevananthan 947997A 16/11/2011 831.24 139.31 404.88 370.7 306.08 1989.21 515.3
4 Johnson Clement 435662c 08/12/2011 977.84 173.68 453.23 210.01 291.57 2106.33 513.05
5 Udayakumar 148454b 15/12/2011 1275.84 164.95 640.04 401.03 427.56 2909.41 535.51
6 Kishore 344992b 22/12/2011 744.72 165.27 574.45 396.38 416.15 2296.98 555.31
7 Gokul 769058B 29/12/2011 1147.37 150.29 522.84 319.73 381.65 2521.88 567.9
8 Singaravela 692890d 02/02/2012 693.58 139.08 458.73 324.6 366.28 1982.27 430.01
9 Murali R 842477b 09/02/2012 1103.81 145.14 587.19 314.27 369.35 2519.76 775.68
10 Gowtham 146789c 25/06/2012 1422.04 181.66 655.58 373.11 492.75 3125.14 643.22
e type 2 DM subjects
1 Murali B 041577f 15/11/2011 734.26 190.54 605.97 386.68 535.5 2452.95 469.05
2 Munnu Subramanium 078857f 22/11/2011 998.71 180.46 589.4 325.86 459.43 2553.86 474.96
3 Mohd Jaffer 169529f 27/07/2012 146.32 162.19 601.67 361.82 366.22 1638.22 459.96
4 Prabhu 178799f 12/07/2012 1692.39 176.09 539.68 381.29 475.98 3265.43 512.79
5 Yuvraj 040471f 21/06/2012 1904.48 235.28 702.88 493.63 564.6 3900.86 705.9
6 Nicholas 969312c 06/11/2012 124.71 136.14 451.84 311.35 281.23 1305.27 383.34
7 Gajendran 267415f 16/08/2012 166.94 159.3 508.59 371.24 358.46 1564.54 413.85
8 Siva kumar V.N 620928f 08/11/2013 264.99 257.18 664.01 543.71 529.54 2259.43 656.33
9 vaideeswaran D 491172F 29/07/2013 160.68 163.1 677.78 467.38 461.4 1930.33 500.11
10 Karthikeyan B 608754f 05/11/2013 175.18 185.34 519.11 379.79 387.31 1646.72 491.71
n non DM subjects
1 Sankar P 405664f 184.5 186.5 645.39 498.68 577.6 2210.72 585.35
2 Ramesh C 197387d 31/07/2013 176 184.69 698.8 528.88 574.34 2162.71 641.02
3 Paneer selvam 245968d 14/02/2013 220.39 230.89 886.56 591.95 612.41 2542.21 579.19
4 TG Ramkumar 325123d 27/08/2013 220.02 225.27 744.78 604.93 604.6 2399.08 591
5 Rajesh Kumar 081488d 13/06/2013 160.41 186.75 663.27 505.71 463.02 1979.17 617.44
DEXA
6 Vinodh kumar 402049d 169.5 211.88 638,50 499,6 523.7 2100.7 620.9
7 Satish kumar 191320d 13/07/2013 180.67 182.66 613.49 464.65 452.65 1894.12 596.5
8 Prem kumar 199071d 13/08/2013 175.82 192.53 672.33 458.13 436.98 1935.79 520.81
9 vivekanandan 076597d 02/09/2014 155 164 520 399 394 1632 579
10 vinod m 365772d 01/03/2013 136.79 145.21 570.49 371.24 392.18 1615.95 432.12
FCPD
1 Srinivasan 926741c 02/09/2013 147.17 155.57 568.18 383.2 399.98 1654.09 534.71
2 Raj kumar patra 489555f 23/09/2013 172.06 179.15 603.31 478.1 483.14 1915.77 600.12
3 Sadhan bashik 663426f 30/09/2013 167.11 163.51 416.92 358.84 342.42 1448.8 586.24
4 Ahmed basha 526332d 18/10/2013 146.57 151.88 461.23 576.46 407.59 1743.73 556.88
5 Sanjib roy 711816f 14/11/2013 169.73 178.16 483.78 412.81 391.4 1635.89 639.32
6 Koushik ghosh 306232f 15/11/2013 146.3 172.92 493.28 408.38 395.79 1616.66 561.89
7 Rajesh 514231d 20/12/2013 182 191 565 476 463 1877 454
8 Polas bag 783803F 11/02/2014 130.02 148.27 363.81 355.45 365.38 1362.94 396.01
9 Uttam maiti 656674f 18/02/2014 151.39 170.63 630.42 456.23 421.99 1830.67 530.73
10 Panchanan Mahato 805508f 25/02/2014 158.91 165.64 416.48 316.75 328.19 1385.97 362.63
11 M.P.Muhammed Hassan 783692f 03/03/2014 185 195 509 431 425 1745 506
12 Arun kumar 853457d 21/04/2014 186.02 183.8 595.95 489.39 477.93 1933.09 440.34
13 Ramesh Rai 642111f 23/05/2014 179.12 205.82 642.41 496.48 500.54 2024.37 490.03
14 Sankar 759758f 03/07/2014 130 147 350 283 307 1216 469
15 Elumalai 397542F 14/04/2014 128.98 123.79 375.78 306.54 294.84 1229.92 449.32
16 Sk.MD Belal 876846F 25/06/2014 167.03 167.03 481.33 350.45 350.45 1516.29 682.85
17 Kumar 098560d 20/08/2012 179.03 205.04 718.03 420.39 404.56 1927.05 519.17
18 Manaranjan Bag 001831g 21/07/2014 96.63 105.67 250.88 233.87 256.28 943.34 398.71
19 Prabhakaran 382773d 21/10/2014 215.88 234.21 659.45 588.82 590.28 2288.65 612.01
20 Nantu das 719059f 10/09/2014 172 179 591 438 442 1822 628
DEXA
Hospital # BMC Total Fat L Arm Fat R Arm Fat Trunk Fat L Leg Fat R Leg Fsubtotal Fhead F Total Lean L arm Lean R Arm lean trunk lean L leg
166100d 2432.82 285.2 241.7 2122.5 1038.3 1054.6 4742.4 837.8 5580.2 3118 3163.5 23666.8 8401.9
931954d 3189.05 288.9 294.6 2169.1 1316 1548.1 5616.6 933.4 6550 2541.9 3020.9 22989.2 7159.2
947997A 2504.52 615.5 734.4 4993.3 2433.9 2507.2 11284.4 900.5 12184.8 2189.3 2509.2 20568.6 5862.1
435662c 2619.37 581.7 603.2 5828.4 3282.1 3651 13946.4 888 14834.4 3197.6 3513.2 20886.1 2835.9
148454b 3444.92 508.4 494.1 6423 2554.6 2433.8 12413.8 849.5 13263.4 2552.8 2951.3 25053.2 7841.8
344992b 2852.29 321.9 354.6 2985.3 1387.7 1345.5 6395 870.7 7265.7 2256 2465.5 19866.5 6234.8
769058B 3089.78 416.5 411.9 4254.3 1878.4 1913 8874.2 910.2 9784.4 2150 2799.2 22953.2 6446.9
692890d 2412.28 366.6 280.3 2190.2 1547 1552.3 5906.5 814.8 6721.3 2142.6 2412.4 21168 6724.5
842477b 3295.44 408.6 421.2 2921.1 2552.8 2813.8 9117.5 1029.7 10147.2 2198.8 2709.5 21703.4 7133.6
146789c 3768.36 333 390.4 2534.4 1613.6 1814.8 6686.2 950.3 7636.5 2386.9 2814.1 24563.9 7952.3
041577f 2922.05 1155.67 1274.2 10999.7 3213 3437.9 20080.5 922.4 21002.9 2670.9 2982.6 25801.4 8377.8
078857f 3028.82 538.5 477.6 7246.9 1495 1832.7 11590.6 1043.5 12634.1 3041.1 3160.4 28436.5 8593.8
169529f 2098.18 992.3 885.6 12242.1 3255.8 3134.4 20510.2 1063.1 21573.3 2416.8 2567.1 21411 7325.2
178799f 3778.21 723.8 749.4 7965.1 3162.4 3490.1 16090.7 1009.5 17100.2 2229.5 3155.3 27275.2 8530.5
040471f 4606.77 643.6 846.2 7282.4 2242.5 2315 13329.7 1088.9 14418.6 2702.2 3710.8 29665.3 7717.8
969312c 1688.6 996.9 1114.3 11927.5 3996.4 3916.5 21951.6 968.5 22920.1 2136 2417.4 18421.5 6651
267415f 1978.39 1095.7 971 12518.9 3544.5 3494 21624.2 994.3 22618.5 2497.4 2227 21593.6 6816.5
620928f 2915.77 1047.1 1301.2 10700.2 2795 2471.5 18315 1270.7 19585.8 3944.9 3726.6 29887.3 9222.8
491172F 2430.44 751.4 872.3 11061.5 2823.7 2881.6 18390.6 831.1 19221.8 2209.4 2350.7 28591.2 7615.2
608754f 2138.43 989.9 1053.1 8322.7 2636.1 2784.2 15785.9 1018.6 16804.5 2858.9 3128.6 23388.1 7537.5
405664f 2490.25 559 754 2985.7 2006.87 2145.38 8005.85 933.45 12350.2 3100.7 3250.75 25105.8 9505.3
197387d 2803.73 319.1 359.6 2527.6 2152.8 2090.4 7449.5 965.2 8414.7 2907.9 3004.4 24022.9 9068.2
245968d 3121.4 665.4 797.6 6301.4 3395.8 3403.1 14563.4 955.8 15519.2 3043.3 3399.9 29311.7 11684.4
325123d 2990.8 548.2 559 4718.6 2026.6 2435.7 10288 1039.9 11328 3185.3 3446.4 27094.6 10392.8
081488d 2596.62 461.3 475.4 3229.6 1930.4 2145 8241.8 922.2 9163.9 2948.4 3101.4 23073.6 8664.4
DEXA
402049d 2989.9 675.3 549.8 4905.8 2211.6 2880.8 9189.7 945.7 11155.8 2990.6 3200.7 24565.4 10198.7
191320d 2490.62 850.6 877.7 6845.7 2615.8 2738.4 13928.2 888.1 14846.3 3137.1 3150.4 25122.7 8309.1
199071d 2456.6 338.9 308.6 2127.7 921.7 1103 4800 762 5562 2460.5 2630.6 20928.4 7343.6
076597d 2211 435.1 411.3 2524.3 1446.3 1514.7 6331.7 782.7 7114.5 2288.8 2547.7 20217.2 7173.1
365772d 2048.07 350.1 336.6 3739 2053.2 2034.4 8513.2 878.1 991.3 2263.6 2397.3 22653.5 7798.6
926741c 2188.81 364.1 455.4 3398.3 1214.7 1342 6774.5 801.3 7575.8 1962.3 2117.2 19608.8 6226.2
489555f 2515.89 485.9 539.6 4557.2 1369.6 1508.4 8460.8 870.3 9331.1 2530.4 2634.5 22033.7 7606.8
663426f 2035.04 286.1 304.8 1828.8 835 955.1 4209.7 921 5130.8 2542.4 2571.4 21186.9 6622
526332d 2300.61 594 706.6 5640.6 2709.4 2787.7 12438.3 928.6 13366.9 2247.7 2184.1 19460.7 6572.5
711816f 2275.21 521.6 595.3 3102.9 1190.8 1256.8 6667.4 879.6 7547 2159.4 2291.7 22047.5 6829.8
306232f 2178.56 318.2 341.5 2716.9 1288.2 1366.6 6031.4 841.6 6873 2406.6 2867.6 20347.9 7090.2
514231d 2331 935.7 930.7 6747.7 2018 2383.4 13015.5 768.9 13784.3 2820 2869.1 24800.4 8484.2
783803F 1758.95 360 425.6 2094 985.6 870.3 4735.5 784.4 5519.9 2164.1 2561.1 17163.8 6982.6
656674f 2361.39 550.8 530.1 3840.1 1665 1903 8489 874.6 9363.6 1548 1733.5 24494.2 8069
805508f 1748.6 642.2 621.1 2829.1 1605.3 1726.3 7424 775.8 8199.8 2125.4 2330.5 19118.4 6240.8
783692f 2251 794.4 925.8 5409.1 2568.5 2707.5 12405.1 972.3 13377.4 3103.9 3418.5 26710.6 9622.5
853457d 2373.43 1024.9 1052.2 6074.5 3216.2 3340.4 14708.3 927.8 15636.1 2842.8 3076.8 25437.1 8998.9
642111f 2514.4 229.5 280.8 2079.5 736.1 947.3 4273.2 827.1 5100.3 2580.1 2815.1 22887.1 8139.5
759758f 1685 336.5 356.3 1778.1 881.8 978.1 4330.7 775.8 5106.5 2031.2 2299.7 19183.7 5289.7
397542F 1679.24 240.7 298.9 1809.2 1114 1132.9 4595.6 861.1 5456.7 2197.9 2218.2 21567.1 7185.3
876846F 2199.14 330.9 330.9 2279.3 797.1 797.1 4535.5 794.5 5330 2355.6 2355.6 17771 6196.6
098560d 2446.22 648.6 542.5 6864.7 1831.4 1622.7 11510 1056 12566 2747.2 2886.7 25106.3 8153.2
001831g 1342.05 122.2 119.7 861.2 246.8 289.1 1639 643.4 2282.4 1383.4 1508.8 14146.7 4422.7
382773d 2900.65 287.4 354.7 1711.3 1031.6 985.4 4370.3 826.7 5197 2784.8 2913.1 21984.5 8463.6
719059f 2450 655.1 645.5 6744.8 1724.6 1633.6 11403.5 953.5 12357 3214.3 3297.2 26695.1 8437.8
DEXA
Hospital # lean R leg lean subtotal Lean Head Lean Total
lean+BMC L 
arm
lean+BMC 
R arm
lean+BMC 
trunk
lean+BMC L 
leg
lean+BMC 
R leg
Lean+BMC 
subtotal
lean+BMC 
head
Lean+BMC 
Total
166100d 8253.1 46603.4 2903.8 49507.1 3312.2 3371.4 24246.4 8891.9 8741.2 48563.1 3376.8 519399
931954d 8193.6 43904.8 3239.3 47144.1 3645 3204.7 23506.1 7509.7 8692.8 46558.3 3774.8 50333.1
947997A 6386.6 37515.7 3121 40636.7 3020.5 2648.5 20973.4 6169.8 6692.7 39504.9 3636.3 43141.2
435662c 4809.4 35242.1 3081.5 38323.6 4175.4 3686.8 21339.3 3045.9 5100.9 37348.4 3594.6 40943
148454b 8145.7 46544.8 2942 49486.9 3828.6 3116.2 25693.3 8242.8 8573.2 49454.2 3477.6 52931.8
344992b 6626.2 37449 3013.6 40462.6 3000.8 2630.7 20440.9 6631.1 7042.4 39746 3568.9 43314.8
769058B 7512.8 41862.1 3145.9 45007.9 3297.3 2949.5 23476.1 6766.6 7894.4 44383.9 3713.8 48097.7
692890d 7418.7 39866 2837.9 42703.9 2836.1 2551.5 21626.7 7049.1 7784.9 41848.3 3267.9 45116.2
842477b 8450.4 42195.6 3577.7 45773.3 3302.6 2854.6 22290.5 7447.9 8819.7 44715.3 4353.4 49068.8
146789c 8939.6 46656.9 3294.4 49951.3 3809 2995.8 25219.5 8325.4 9432.3 49782 3937.6 53719.6
041577f 9186.7 49019.4 3141.8 52161.2 3405.2 3173.1 26407.4 8764.5 9722.2 51472.3 3610.9 55083.2
078857f 9918.4 53150.3 3571.8 56722 4039.8 3340.9 29025.9 8919.7 10377.8 55704.1 4046.7 59750.9
169529f 7299.1 41019.2 3096.5 44115.6 2563.1 2729.3 22012.6 7687.1 7665.3 42657.4 3556.4 46213.8
178799f 9717.4 50907.9 3509.5 54417.4 3921.9 3331.4 27814.8 8911.8 10193.4 54173.3 4022.3 58195.6
040471f 9202.5 53003.6 3684.7 56688.2 4611.7 3946 30368.2 8211.5 9767.1 56904.4 4390.6 61295
969312c 6626.4 36252.3 2810.6 39063 2260.7 2553.5 18873.4 6962.4 6907.6 37557.6 3194 40751.6
267415f 6341 39475.5 2884.8 42360.3 2664.4 2386.3 22102.2 7187.7 6699.5 41040 3298.7 44338.7
620928f 9084.4 55866 3471.1 59337.1 4209.9 3983.8 30551.3 9766.5 9614 58125.5 4127.4 62252.9
491172F 7875.3 48641.9 2859.8 51501.7 2370 2513.8 29269 8082.6 8336.7 50572.2 3359.9 53932.1
608754f 7688.5 44601.6 3459.4 48061.1 3034.1 3313.9 23907.3 7917.3 8075.8 46248.3 3951.2 50199.5
405664f 9065.8 52445.6 3220.9 57150.5 3286.7 3190 25546.2 10115.2 11885.5 55345.8 4010.6 63510.4
197387d 9724.5 48727.9 3332.6 52060.5 3083.9 3189 24721.8 9597 10298.9 50890.6 3973.6 54864.2
245968d 11242.6 58681.9 3301.1 61983 3263.7 3630.8 30198.3 12276.3 11855 61224.1 3880.3 65104.4
325123d 10351.2 54470.3 3652.3 58122.5 3405.3 3671.7 27839.4 10997.8 10955.2 56869.3 4243.3 61112.6
081488d 8517.7 46305.6 3187.6 49493.2 3108.8 3288.1 23736.9 9170.1 8980.7 48284.8 3805 52089.8
DEXA
402049d 11345.8 52230.5 3205.9 51390.1 3275.6 3300.1 24450.8 10016.8 9235.4 51145.5 3980.8 62256.7
191320d 8362.5 48081.9 3051.3 51133.2 3317.8 3333.1 25736.2 8773.7 8815.1 49976 3647.8 53623.8
199071d 7181 40544.2 2624.2 43168.3 2636.3 2823.1 21600.8 7801.7 7618 42480 3145 45624.9
076597d 7058.3 39285.2 2689.6 41974.8 2443.4 2712.2 20737.3 7572.2 7451.9 40917 3268.5 44185.5
365772d 7843.6 42956.7 3063.3 46020 2400.4 2542.6 23224 8169.9 8235.8 44572.6 3495.4 48068
926741c 6252 36166.4 2772.1 38938.5 2109.4 2272.7 20177 6609.4 6651.9 37820.5 3306.8 41127.3
489555f 7812.5 42617.9 2990.8 45608.7 2702.4 2813.6 22637 8084.9 8295.7 44533.7 3590.9 48124.6
663426f 6110.2 39032.9 3187.8 42220.8 2709.5 2734.9 21603.8 6980.9 6452.6 40481.7 3774.1 44255.8
526332d 7190.4 37655.5 3210 40865.5 2394.3 2336 19922 7148.9 7598 39399.2 3766.9 43166.1
711816f 6612.9 39941.3 3023.6 42964.8 2329.1 2469.9 22531.3 7242.6 7004.3 41577.2 3662.9 45240.1
306232f 7247.4 39959.7 2915.7 42875.4 2552.9 3040.5 20841.2 7498.6 7643.2 41576.4 3477.6 45054
514231d 8531.3 47504.9 2656.1 50161.1 3002.2 3059.8 25365.1 8960.5 8994.4 49382 3110.1 52492.1
783803F 6880.3 35751.9 2727.3 38479.2 2294.1 2709.4 17527.7 7338.1 7245.7 37114.9 3123.3 40238.2
656674f 8150.6 45995.3 3022.1 49017.4 2699.4 2904.1 25124.6 8525.2 8572.6 47826 3552.8 51378.8
805508f 6686.6 36501.7 2696.8 39198.5 2284.3 2496.1 19534.9 6557.5 7014.8 37887.7 3059.4 40947.1
783692f 9993.2 52848.7 3369.7 56218.4 3288.5 3613.9 27219.1 10053.6 10418.6 54593.7 3875.4 58469.2
853457d 9701.5 50057.1 3222.7 53279.9 3028.8 3260.6 26033 9488.3 10179.4 51990.2 3663 55653.3
642111f 8306.5 44728.3 2868.1 47596.4 2759.2 3021 23529.5 8636 8807 46752.7 3358.1 50110.8
759758f 5071.7 33876 2683.1 36559.1 2461.5 2446.3 19533.4 5572.5 5378.4 35092.2 3151.8 38243.9
397542F 7428.3 40596.8 2994.5 43591.3 2326.9 2342 21942.9 7491.8 7723.2 41826.7 3443.8 45270.6
876846F 6196.6 34875.2 2717.3 37592.5 2522.6 2522.6 18252.3 6547 6547 36391.5 3400.1 39791.7
098560d 7836.2 46729.6 3089.8 49819.3 2926.2 3091.7 25824.3 8573.6 8240.8 48656.6 3609 52265.6
001831g 4704.9 26166.4 2222.7 28389.2 1480.1 1614.5 14397.6 4656.5 4961.2 27109.8 2621.5 29731.2
382773d 8708.8 44854.9 2848.4 47703.3 3000.7 3147.3 22644 9052.4 9299.1 47143.6 3460.4 50603.9
719059f 8683 50327.4 3290.9 53618.3 3385.8 3476.1 27286.4 8876.1 9125.1 52149.4 3918.5 56068
DEXA
Hospital # total mass L arm
total mass R 
arm
total mass 
trunk
total mass 
Lleg
total mass R 
leg
total mass 
subtotal
total mass 
head
total mass 
Total %fat L arm %fat R arm %fat trunk %fat L leg %fat R leg
166100d 3597.4 3613.1 26369 9930.2 9795.8 53305.5 4214.6 57520.1 7.9 6.7 8 10.5 10.8
931954d 3933.9 3499.3 25675.2 8825.7 10240.9 52174.9 4708.2 56883.1 7.3 8.4 8.4 14.9 15.1
947997A 3636 3382.9 25966.8 8603.7 9199.9 50789.3 4536.8 55326 16.9 21.7 19.2 28.3 27.3
435662c 4757.1 4290 27167.8 6328 8751.9 51294.8 4482.6 55777.4 12.2 14.1 21.5 51.9 41.7
148454b 4337 3610.3 32116.3 10797.4 10797.4 61868.1 4327.1 66195.1 11.7 13.7 20 23.7 22.1
344992b 3322.7 2985.4 23426.2 8018.8 8387.9 46140.9 4439.6 50580.6 9.7 11.9 12.7 17.3 16
769058B 3713.8 3361.4 27730.4 8645 9807.4 53258.1 4624 57882.1 11.2 12.3 15.3 21.7 19.5
692890d 3172.8 2831.8 23816.9 8596 9337.3 47754.8 4082.7 51837.5 10.6 9.9 9.2 18 16.6
842477b 3711.2 3275.8 25211.7 10000.6 11633.5 53832.8 5383.2 59246 11 12.9 11.6 25.5 24.2
146789c 4141.9 3386.2 27753.8 9939.1 11247.1 56468.2 4888 61356.2 8 11.5 9.1 16.2 16.1
041577f 4560.8 4447.4 37407.1 11977.5 13160.1 71552.8 4533.3 76086.1 25.3 28.7 29.4 26.8 26.1
078857f 4578.4 3818.5 36272.7 10414.6 12210.5 67294.7 5090.2 72384.9 11.8 12.5 20 14.4 15
169529f 3555.3 3615 34254.7 10942.9 10799.7 63167.6 4619.5 67787.1 27.9 24.5 35.7 29.8 29
178799f 4645.7 4080.8 35779.9 12074.2 13683.4 70264 5031.7 75295.8 15.6 18.4 22.3 26.2 25.5
040471f 5255.2 4792.3 37650.6 10453.9 12082.1 70234.2 5479.5 75713.6 12.2 17.7 19.3 21.5 19.2
969312c 3257.5 3667.9 30800.9 10958.8 10824.1 59509.2 4162.5 63671.7 30.6 30.4 38.7 36.5 36.2
267415f 3760.1 3357.3 34621.1 10732.2 10193.5 62664.2 4293 66957.2 29.1 28.9 36.2 33 34.3
620928f 5257 5285 41251.5 12561.5 12085.5 76440.5 5398.1 81838.6 19.9 24.6 25.9 22.3 20.5
491172F 3121.4 3386.2 40330.5 10906.3 11218.4 68962.8 4191.1 73153.9 24.1 25.8 27.4 25.9 25.7
608754f 4023.9 4367 32229.9 10553.3 10860 62034.2 4969.8 67004 24.6 24.1 25.8 25 25.6
405664f 3876.5 4100.75 29905.2 14203.7 12239.9 55850.6 5000.7 76652.8 13.7 11.5 12.9 19.8 18.5
197387d 3402.9 3548.6 27249.4 11749.8 12389.3 58340.1 4938.8 63278.9 9.4 10.1 9.3 18.3 16.9
245968d 3929.1 4428.4 36499.7 15672.1 15258.1 75787.5 4836.1 80623.6 16.9 18 17.3 21.7 22.3
325123d 3953.4 4230.7 32558 13024.3 13390.9 67157.4 5283.2 72440.6 13.9 13.2 14.5 15.6 18.2
081488d 3570.2 3763.6 26966.5 11100.5 11125.7 56526.5 4727.2 61253.8 12.9 12.6 12 17.4 19.3
DEXA
402049d 3885.5 4190.9 30154.3 11002.8 12345.8 59905.4 5100.9 69879.7 13.7 12.9 14 17.8 19.1
191320d 4168.4 4210.8 32581.9 11389.9 11553.5 63904.2 4535.9 68440.1 20.4 20.8 21 23 23.7
199071d 2975.3 3131.8 23728.5 8723.4 8721 47280 3907 51186.9 11.4 9.9 9 10.6 12.6
076597d 2878.5 3123.5 23261.6 9018.6 8966.6 47248.7 4051.3 51300 15.1 13.2 10.9 16 16.9
365772d 2750.4 2879.1 26963 10223.1 10270.2 53085.8 4373.6 57459.4 12.7 11.7 13.9 20.1 19.8
926741c 2473.5 2728.2 23575.3 7824.1 7993.9 44595.1 4108.1 48703.1 14.7 16.7 14.4 15.5 16.8
489555f 3188.3 3353.3 27194.2 9454.6 9804.1 52994.4 4461.2 57455.6 15.2 16.1 16.8 14.5 15.4
663426f 2995.6 3039.7 23432.6 7815.9 7407.7 44691.5 4695.1 49386.6 9.6 10 7.8 10.7 12.9
526332d 2988.3 3042.6 25562.5 9858.4 10385.7 51837.6 4695.5 56533 19.9 23.2 22.1 27.5 26.8
711816f 2850.7 3065.2 25634.1 8433.4 8261.1 48244.6 4542.5 52787.1 18.3 19.4 12.1 14.1 15.2
306232f 2871.1 3382.1 23558 8786.7 9009.8 47607.8 4319.2 51927 11.1 10.1 11.5 14.7 15.2
514231d 3937.9 3990.4 32112.8 10978.5 11377.8 62397.4 3879 66276.5 23.8 23.3 21 18.4 20.9
783803F 2654.1 3135 19621.7 8323.6 8116 41850.4 3907.7 45758.1 13.6 13.6 10.7 11.8 10.7
656674f 3250.2 3434.2 28964.7 10190.3 10475.6 56315 4427.4 60742.4 16.9 15.4 13.3 16.3 18.2
805508f 2926.5 3117.3 22364 8162.8 8741.1 45311.7 3835.2 49146.9 21.9 19.9 12.7 19.7 19.7
783692f 4082.9 4539.7 32628.2 12622.1 13126 66998.9 4847.7 71846.6 19.5 20.4 16.6 20.3 20.6
853457d 4053.7 4312.9 32107.6 12704.5 13519.9 66698.6 4590.9 71289.4 25.3 24.4 18.9 25.3 24.7
642111f 2988.7 3301.7 25608.9 9372.1 9754.3 51025.8 4185.3 55211.1 7.7 8.5 8.1 7.9 9.7
759758f 2498 2802.6 21311.5 6454.3 6356.5 39422.9 3927.6 43350.5 13.5 12.7 8.3 13.7 15.4
397542F 2567.6 2640.9 23752 8605.8 8856 46422.4 4305 50727.3 9.4 11.3 7.6 12.9 12.8
876846F 2853.5 2853.5 20531.6 7344.1 7344.1 40927 4194.6 45121.6 11.6 11.6 11.1 10.9 10.9
098560d 3574.8 3634.3 32689 10405 9863.5 60166.6 4664.9 64851.5 18.1 14.9 21 17.6 16.5
001831g 1602.2 1734.2 15258.8 4903.3 5250.3 28748.8 3264.8 32013.6 7.6 6.9 5.6 5 5.5
382773d 3288.1 3502 24355.2 10084 10284.5 51513.9 4287.1 55801 8.7 10.1 7 10.2 9.6
719059f 4040.8 4121.6 34031.2 10600.6 10758.7 63553 4872 68425 16.2 15.7 19.8 16.3 15.2
DEXA
Hospital # %fat subtotal %fat head %fat Total
166100d 8.9 19.9 9.7
931954d 10.8 19.8 11.5
947997A 22.2 19.8 22
435662c 27.2 19.8 26.6
148454b 20.1 19.6 20
344992b 13.9 19.6 14.4
769058B 16.7 19.7 16.9
692890d 12.4 20 13
842477b 16.9 19.1 17.1
146789c 11.8 19.4 12.4
041577f 28.1 20.3 27.6
078857f 17.2 20.5 17.5
169529f 32.5 23 31.8
178799f 22.9 20.1 22.7
040471f 19 19.9 19
969312c 36.9 23.3 36
267415f 34.5 23.2 33.8
620928f 24 23.5 23.9
491172F 26.7 19.8 26.3
608754f 25.4 20.5 25.1
405664f 17.9 19.4 16.8
197387d 12.8 19.5 13.3
245968d 19.2 19.8 19.2
325123d 15.3 19.7 15.6
081488d 14.6 19.5 15
DEXA
402049d 16.4 19.9 15.9
191320d 21.8 19.6 21.6
199071d 10.2 19.5 10.9
076597d 13.4 19.3 13.9
365772d 16 20.1 16.3
926741c 15.2 19.5 15.6
489555f 16 19.5 16.2
663426f 9.4 19.6 10.4
526332d 24 19.8 23.6
711816f 13.8 19.4 14.3
306232f 12.7 19.5 13.2
514231d 20.9 19.8 20.8
783803F 11.3 20.1 12.01
656674f 15.1 19.8 15.4
805508f 16.4 20.2 16.7
783692f 18.5 20.1 18.6
853457d 22.1 20.2 21.9
642111f 8.4 19.8 9.2
759758f 11 19.8 11.8
397542F 9.9 20 10.8
876846F 11.1 18.9 11.8
098560d 19.1 22.6 19.4
001831g 5.7 19.7 7.1
382773d 8.5 19.3 9.3
719059f 17.9 19.6 18.1
INDIRECT CALORIEMETRY
Lean type 1 DM subjects
Name Hospital # Date REE (Kcal/day) REE (Kcal/day)
1 Ramanan 166100d 9/12/2012 2564 2565
2 Rajeshkumar 931954d 2144 2145
4 Jevanandan 947997A 1899 1900
5 Johnson Clement 435662c 1791 1792
6 Udayakumar 148454b 1549 1550
7 Kishore 344992b 1995 1996
8 Gokul 769058B 2144 2145
9 Murali R 842477b 1717 1718
10 Gowtham 146789c 1988 1989
Obese type 2 DM subjects
1 Murali B 041577f 9/13/2012 1717 1718
2 Munnu Sbramanium 078857f 9/13/2012 2105 2106
3 Mohd Jaffer 169529f 9/3/2012 1731 1732
4 Prabhu 178799f 1875 1876
5 Yuvraj 040471f 9/14/2012 1699 1700
6 Nicholas 969312c 11/1/2012 1752 1753
7 Gajendran 267415f done 1794 1795
8 Siva kumar V.N 620928f 28/10/2013 2074 2075
9 vaideeswaran D 491172F done 1688 1689
10 Karthikeyan B 608754f 1947 1948
Lean non DM subjects
1 Sankar P 405664f
2 Ramesh C 197387d 2722 2723
3 Paneer selvam 245968d 2200 2201
4 TG Ramkumar 325123d 14/11/2013 2355 2356
5 Rajesh Kumar 081488d 1750 1751
6 Vinodh kumar 402049d done 1319 1320
7 Satish kumar 191320d 18/01/2014 1683 1684
8 Prem kumar 199071d 1606 1607
9 vivekanandan 076597d 1568 1569
10 vinod m 365772d 1652 1653
INDIRECT CALORIEMETRY
FCPD
1 Srinivasan 926741c 26/08/2013 1212 1213
2 Raj kumar patra 489555f 1875 1876
3 Sadhan bashik 663426f 1349 1350
4 Ahmed basha 526332d 18/10/2013 2580 2581
5 Sanjib roy 711816f 18/11/2013 1519 1520
6 Koushik ghosh 306232f 18/11/2013 1660 1661
7 Rajesh 514231d 1656 1657
8 Uttam maiti 656674f 24/02/2014 1387 1388
9 Polas bag 783803F 11/02/2014 2893 2894
10 panchan mahato 80508f 27/02/2014 1762 1763
11
 
Hassan 783692f 07/03/2014 1661 1662
12 Arun kumar 853457d 21/04/2014 2043 2044
13 Ramesh rai 642111f 27/05/2014 1689 1690
14 Sankar 759758f 16/10/2014 1255 1256
15 Elumalai 397542F 20/11/2014 2598 2599
16 Sk.MD Belal 876846F 2120 2121
17 Kumar 098560d 7/31/2012 2172 2173
18 Manaranjan Bag 001831g 1850 1851
19 Prabhakaran 382773d 10/21/2014 1963 1964
20 Nantu das 719059f 9/12/2014 1935 1936
GLUCAGON
Lean type 1 DM subjects Glucagon
Name Hospital # 0 15 30 45 60 90 120 150 180
1 Ramanan 166100d 48.8 49.6 50.3 54.5 69.9 78.8 67.7 62 50.9
2 Rajeshkumar 931954d 50.8 52.2 49.2 59.8 65.5 82.3 80.4 71.2 63.4
3 Jeevanandan 947997A 53.2 55.5 56 58.9 55.5 72.6 63.3 67.7 70.8
4 Johnson Clement 435662c 64.5 61.9 68.8 74.5 90.3 95.5 83.6 87.8 75.6
5 Udayakumar 148454b 39.6 42.2 49.8 52.1 68.3 77.4 81.6 72.3 59.8
6 Kishore 344992b 54.1 58.8 59.9 61 66.4 72.2 78.6 65.3 59.9
7 Gokul 769058B 52.2 50.9 48.4 60.2 76.5 84.3 73.1 63 63.1
8 Singarvela 692890d 65.9 71.8 68.8 70.9 83.3 77.7 78.6 68.8 66.6
9 Murali R 842477b 56.2 62.2 64.2 68.3 83.9 90.6 81.5 70.1 58.9
10 Gowtham 146789c 46.8 49.1 48.3 50.9 70.2 92.8 88.8 74.8 76.6
 
Obese type 2 DM subjects Glucagon
Name Hospital # 0 15 30 45 60 90 120 150 180
1 Murali B 041577f 212.7 202.8 200.9 216.5 248.8 312.5 299.8 300.2 286.5
2 Munnu Subramanium 078857f 289.8 280.9 300.7 296.5 322.5 367.6 399.8 350.6 373.8
3 Mohammed jaffer 169529f 209.9 276.5 288.8 312.2 376.6 388.8 365.5 390.2 381.2
4 Prabhu 178799f 230.7 218.7 228.8 230.9 289.6 300.8 323.5 317.5 310.8
5 Yuvraj 040471f 175.8 182.7 211 288.9 350.8 352.5 332.7 342.8 312.89
6 Nicholas 969312c 156.5 118.8 128.8 142.2 177.9 166.8 170.8 170.6 179.4
7 Gajendran 267415f 166 212.7 276.6 278.8 315.5 333.8 301.8 299.8 311.9
8 Siva kumar V.N 620928f 201.6 230.5 232.7 229.8 267.6 288.7 285.5 273.3 261.8
9 vaideeswaran D 491172F 144.2 140.3 149.6 176.6 180.9 209.9 198.8 188.5 162.3
10 Karthikeyan B 608754f 135.9 135.1 116 100.5 97.7 146.6 108.8 133.7 117.6
Lean non DM subjects Glucagon
Name Hospital # 0 15 30 45 60 90 120 150 180
1 Sankar P 405664f 59.6 59.1 60.2 58.7 53.2 49.3 42.1 40.8 34.6
2 Ramesh C 197387d 38.7 41.3 40.9 36.6 42.2 39.1 35.6 34.4 29.8
3 Paneer selvam 245968d 67.1 66.2 65.3 64.3 56.5 52.2 53.8 55.9 49.1
4 TG Ramkumar 325123d 52.2 51.4 55.3 54.4 50.9 44.7 40.3 34.2 38.9
5 Rajesh Kumar 081488d 76.2 78.8 73.3 72.8 71.9 63.3 59.3 59.5 52.8
6 Vinodh kumar 402049d 35.8 35.3 36.3 41.2 34.4 33.2 28.7 29.2 28.3
7 Satish kumar 191320d 45.4 48.2 60 59.2 51.3 42.2 40.8 40.1 36.3
8 Prem kumar 199071d 30.1 29.6 33.2 32.2 31.8 25.1 22.2 27.8 23.3
9 Vivekanandan 076597d 43.8 43.5 44.1 44.8 41.2 39.8 45.5 50.4 40.1
10 Vinod M 365772d 60,.8 62.1 61.3 58.1 54.9 53.2 48.7 43.3 43.2
GLUCAGON
FCPD Glucagon
Name Hospital # 0 15 30 45 60 90 120 150 180
1 Srinivasan 926741c 127.3 122.2 130.8 154.3 182.6 230.8 216.7 197.7 204.2
2 Raj kumar patra 489555f 77.5 107.6 117.6 132.2 129.6 142.2 140.8 129.9 119.8
3 Sadhan bashik 663426f 178.3 227.8 217.9 220.6 350.6 342.8 313.5 293.8 301.1
4 Ahmed basha 526332d 112.4 94.3 117.8 151.7 156.7 141.7 107.5 99.7 100.4
5 Sanjib roy 711816f 89.2 145.7 148.8 142.2 202.3 218.5 199.9 180.6 189
6 Koushik ghosh 306232f 162.5 259.5 196.3 255.4 283.7 288.6 212.5 185.5 200.1
7 Rajesh 514231d 87.2 72.9 80.5 94.6 99.7 101 83.6 88.9 96.5
8 Polas bag 783803F 165.4 173.2 184.3 199 190.5 201.5 194.3 212.6 212.7
9 Uttam Maiti 656674f 115.3 127.3 115.3 139.9 122.4 118.8 133.2 129.7 124.1
10 Panchanan Mahato 805508f 121.5 132 128.8 136.5 141.2 140.7 132.2 140.3 144.4
11 M.P.Muhammed Hassan 783692f 75.5 91.4 62.3 75.6 85.1 72.8 82.8 41.6 76.8
12 Arun kumar 853457d 100.1 112.2 88.9 99.9 154.8 172.6 188.6 162.2 148.6
13 Ramesh rai 642111f 92.3 120.9 130.9 144.4 142.2 196.3 188.6 212.4 199.9
14 Sankar 759758f 155.5 158.8 189.9 167.6 177.6 187.6 190.8 183.2 173
15 Elumalai 397542F 78.8 66.2 65.8 74.8 79.2 100.9 89.9 91.3 83.8
16 Sk.MD Belal 876846F 68.8 69.9 68.9 72.2 78.6 65.7 69.4 72.2 63.2
17 Kumar 098560d 117.6 108.7 104.4 116.5 89.9 92.2 78.5 77.8 83.4
18 Manaranjan 001831g 160.5 155.7 167.7 162.2 178.8 189.1 183.3 184.4 177.2
19 Prabhakaran 382773d 80.9 81.8 90.8 92.3 112.5 110.6 98.9 100.7 101,.2
20 Nantu Das 138850F 133.8 150 144.2 149.6 216.7 189.8 199.8 185.6 201.7
EGP+RD
abbrevaitions EGP endogenous glucose production
Rd Rate of disapperance of glucose
Lean type 1 DM subjects
Name Hospital # EGP AV RD AV EGP AV RD AV
1 Ramanan 166100d -0.271 3.76 -2.55 10.08
2 Rajeshkumar 931954d 0.488 4.87 -1.12 9.52
3 Jeevanandan 947997A 0.765 2.57 1.122 7.13
4 Johnson Clement 435662c 0.57 3.24 -0.34 6.76
5 Udayakumar 148454b -0.304 4.15 -0.854 7.35
6 Kishore 344992b 0.677 5.54 -0.422 10.6
7 Gokul 769058B 0.902 2.83 -0.9145 7.944
8 Singarvela 692890d 1.241 4.18 -0.555 8.98
9 Murali R 842477b 0.651 4.18 -0.853 7.36
10 Gowtham 146789c -0.812 4.11 -1.47825 8.816
Obese type 2 DM subjects
Name Hospital # EGP AV RD AV EGP AV RD AV
1 Murali B 041577f 0.822 1.97 -0.46 4.35
2 Munnu Subramanium 078857f 0.824 2.61 -0.082 3.71
3 Mohammed jaffer 169529f -0.952 1.04 -2.381 1.3
4 Prabhu 178799f 0.762 2.1 0.192 2.66
5 Yuvraj 040471f 0.196 4.27 1.179 7.48
6 Nicholas 969312c 0.94 2.97 -0.04 5.65
7 Gajendran 267415f 0.784 2.86 0.186 4.12
8 Siva kumar V.N 620928f 0.57 2.27 -0.09 1.97
9 vaideeswaran D 491172F 0.17 1.82 -0.35 2.56
10 Karthikeyan B 608754f 0.65 3.91 0.04 5.08
Lean non DM subjects
Name Hospital # EGP AV RD AV EGP AV RD AV
1 Sankar P 405664f -0.2 9.25 -2.34 15.47
2 Ramesh C 197387d -0.18 7.35 -2.28 12.25
3 Paneer selvam 245968d -0.15 4.63 -1.23 7.2
4 TG Ramkumar 325123d 0.05 5.52 -0.84 9.4
LOW INSULIN PHASE HIGH INSULIN PHASE
LOW INSULIN PHASE HIGH INSULIN PHASE
LOW INSULIN PHASE HIGH INSULIN PHASE
EGP+RD
5 Rajesh Kumar 081488d -1.69 6.61 -3.44 16.31
6 Vinodh kumar 402049d -2.61 7.12 -3.53 11.11
7 Satish kumar 191320d -0.68 7.74 -0.93 9.57
8 Prem kumar 199071d -1.05 6.9 -1.34 9.78
9 Vivekanandan 076597d 0.13 3.25 -1.97 7.99
10 Vinod M 365772d -1.04 7.07 -1.22 11.47
FCPD
Name Hospital # EGP AV RD AV EGP AV RD AV
1 Srinivasan 926741c -0.41 3.9 0.04 6.46
2 Raj kumar patra 489555f -0.19 4.69 -1.57 8.77
3 Sadhan bashik 663426f -0.13 4.59 -0.34 6.08
4 Ahmed basha 526332d 0.24 5.53 -0.75 9.93
5 Sanjib roy 711816f 0.55 4.61 0.06 7.7
6 Koushik ghosh 306232f 0.59 4.24 -0.55 8.18
7 Rajesh 514231d 0.02 5.51 -0.42 8.69
8 Polas bag 783803F 0.29 4.02 -1.3 6.23
9 Uttam Maiti 656674f 0.39 5.07 -0.36 9.23
10 Panchanan Mahato 805508f 0.35 8.75 -0.22 10.27
11 M.P.Muhammed Hassan 783692f 0.66 4.32 -0.72 6.59
12 Arun kumar 853457d 0.66 3.38 -0.98 8.45
13 Ramesh rai 642111f 1.16 2.77 0.5 2.91
14 Sankar 759758f 0.9 5.7 -0.47 11.23
15 Elumalai 397542F -0.13 9.17 -0.87 11.33
16 Sk.MD Belal 876846F 0.35 4.86 0.06 9.75
17 Kumar 098560d 0.09 4.47 -0.08 5.67
18 Manaranjan Bag 001831g 0.11 4.95 -0.45 9.25
19 Prabhakaran 382773d 0.15 7.54 -0.33 9.57
20 Nantu Das 0.1 4.98 -0.32 9.15
